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Abstract 
NEIL3 is the largest of three homologs of the bacterial Nei protein in mammalian cells. 
It has been shown to have DNA glycosylase activity in vitro, excising oxidised purine 
and pyrimidine bases from both single- and double-stranded DNA. Additionally, NEIL3 
has recently been shown to release oxidised bases from telomeric regions of DNA. 
While NEIL3 shows a restricted expression pattern in normal human cells, previous 
studies have shown that NEIL3 is highly expressed in various cancer cell lines when 
compared with normal counterparts. Furthermore, high expression levels of NEIL3 
were associated with development of metastases in patients with primary malignant 
melanoma. However, no one has looked at the expression of NEIL3 in paediatric cancer 
cells, or attempted to correlate the expression of NEIL3 with proteins involved in 
telomere length maintenance. Therefore, the aim of this project was to determine the 
gene expression levels of NEIL3 in paediatric cancer cell lines and to determine any 
association between the levels of NEIL3 expression and the presence or absence of 
telomerase in these cells. Gene expression of NEIL3, hTERT and POT1 was measured 
by qRT-PCR in two cell lines of acute lymphoblastic leukaemia (ALL; steroid sensitive 
and steroid resistant cells), osteosarcoma, hepatoblastoma and medulloblastoma 
tumours. An initial assessment of whether the levels of NEIL3 expression are indicative 
of the response of paediatric tumours to sensitivity to DNA damaging agents was also 
carried out using the hepatoblastoma and the ALL cells. The results confirmed that 
NEIL3 was highly expressed in all cell lines tested and that the relative levels of NEIL3 
and telomerase mRNA was significantly higher in steroid resistant ALL cells than in the 
steroid sensitive ALL cells. However, there was no correlation between the expression 
of NEIL3 and the presence or absence of telomerase. ALL and hepatoblastoma cells 
were sensitive to cisplatin, doxorubicin and tert-butyl hydroperoxide (t-BHP), as a 
decrease in cell growth was observed at each concentration of the compounds tested. 
Results also indicate that following treatment with t-BHP, growth of the steroid 
sensitive ALL cells was significantly more inhibited than that of the resistant ALL cell 
line. Therefore, NEIL3 could be a resistance factor to cancer chemotherapy in paediatric 
cancer cells and may be a novel target for the treatment of paediatric cancers. 
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Chapter 1: Introduction 
1.1 Cancer                                                                                            
Cancer is a disease where cells begin to multiply rapidly and uncontrollably. All 
eukaryotic cells have a control centre, the nucleus where the chromosomes, which are 
composed of the genetic material, DNA, are located. Healthy cells control their growth 
through the complex interaction of the products of positive (proto-oncogenes) and 
negative (tumour suppressor genes) growth signals and any significant changes 
affecting the function of these signals allows the cells to continue growing and form a 
mass of malignant cells; these changes are called mutations. A multifactorial causation 
is behind the pathogenesis of these mutations. It is thought that a combination of genetic 
and environmental factors is responsible for the aetiology of cancer (Cancer Research 
UK, 2014).                     
Despite the breakthrough in the management of many cancers, the mortality rate is still 
high and some types of cancers exhibit resistance (either intrinsic or acquired) to 
chemotherapy. Thus, there remains an urgent quest for novel treatments and new 
therapeutic targets, especially for paediatric cancers where there is a high incidence of 
subsequent malignant neoplasms (Chen et al, 2014; Armenian et al, 2015). 
 
1.1.1 Childhood cancer                                                                                
Leukaemia together with lymphoma, is the most frequent occurring cancer in children, 
while brain and spinal cord tumours are the commonest solid tumours in this age group 
(Figure 1.1). According to the latest estimated figures, which were collated by Cancer 
Research UK, between 2009-2011, an average of 1,574 children annually in the UK was 
diagnosed with cancer. While, about 252 children per year died from cancer in 2009-
2011 in the UK. However, the 5- year survival rate in the UK was around 82% in 2006-
2010 (Figure 1.2) (Cancer Research UK, 2014). 
Integration of the molecular data together with the clinical features plays a significant 
role in identifying the exact classification of tumours and prediction of the prognostic 
factors in children who are suffering from neoplasms (López-Terrada, 2006). 
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Figure 1.1: Percentage of different types of childhood cancer below 14 years of age in 
the UK between 2001and 2010. The vast majority of cases presented were leukaemias 
followed by CNS tumours (Adapted from Cancer Research UK, 2014).   
     
 
                                                            
Figure 1.2: Average cases of paediatric tumour annually in UK among males and 
females, 2006-2008. Leukaemia presented the highest figures in both genders between 
2006 and 2008 (Adapted from Cancer Research UK, 2014). 
 
1.1.2 Leukaemia                                                                                                
The most predominant tumour among the paediatric age group is presented by 
leukaemia, accounting for approximately one third of all childhood malignancy. With 
the advances in the treatment protocol, about 80% of children cases can be cured 
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(Hagag and Nosair, 2015). However, it is predicted that the survival rate in patients with 
leukaemia should continue to increase, owing to a better understanding of the biology of 
the disease leading to more novel and cancer specific molecular targets being identified 
(Pui et al, 2012). 
Leukaemia arises in the bone marrow from progenitor white blood cells (lymphoid blast 
cells or myeloid blast cells). The blast cells increase in number and then invade the 
blood stream. Thus, the function of the healthy cells is affected. Leukaemia is classified 
by oncologists into two main types: lymphoblastic leukaemia and myeloid leukaemia. 
This classification depends on which kind of hematopoietic cell is affected; whether 
from the lymphoid or myeloid lineage (Figure 1.3). Furthermore, each type is 
subdivided into acute or chronic leukaemia. In acute leukaemia, the cells divide rapidly 
in a short time, whereas in chronic leukaemia, the leukaemic cells divide more slowly 
over a longer period (Faderl et al, 2003; Shah and Kumar, 2013). 
 
           
Figure 1.3: Differentiation of the hematopoietic cells from stem cells. A lymphoid stem cell 
differentiates into a lymphoid blast, which further differentiates to T-lymphocyte and B-
lymphocyte (Adapted from Cancer Research UK, 2014).                                                       
 
1.1.2.1 Acute lymphoblastic leukaemia  
Acute lymphoblastic leukaemia (ALL) is a tumour of lymphoid stem cells, usually 
affecting children between 2 to 5 years of age (Pui et al, 2008). Based on the type of 
clonal cell differentiation, it is divided into T-cell ALL and B-cell ALL. However, B 
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lymphocyte ALL accounts about 85% of childhood ALL (Garza-Veloz et al, 2015). 
ALL patients commonly present with symptoms such as fever, generalized weakness, 
joint pain and bleeding (Onciu, 2009). About 80% of leukaemic children are diagnosed 
with ALL (Bekker-Méndez et al, 2014) and it accounts for approximately 30% of the 
total paediatric cancers (Samuels et al, 2014).  
High white blood cells number, metastasis through the central nervous system at the 
diagnosis, enlarged liver and spleen, alterations in the chromosomes, absence of the 
expression of CD10, failure to induce the remission after starting the therapy, the 
presence of lymphoid and myeloid antigens and infant age groups; all are bad 
prognostic factors in ALL (Pui and Evans, 1999). 
It has been estimated that the 5 year survival rates in leukaemic children is around 80%. 
To push the survival rate further, it is essential to understand the pathogenesis of 
leukaemia and therefore to analyse the molecular basis of ALL (including chromosomal 
abnormalities and the pattern of gene expression) (Pui et al, 2011).   
The aetiology of ALL is related to environmental, socioeconomic, infectious and 
hereditary factors. However, Epstein Barr virus and human immunodeficiency virus are 
linked to the development of mature B-cell ALL. In comparison with the general 
population, children with Down syndrome (trisomy 21) have an increased risk of 
developing ALL by 20 times. Furthermore, ALL is associated with other genetic 
disorders e.g. Klinfter syndrome, Fanconi anemia and ataxia telangiectasia. ALL in the 
second twin of both dizygotic and monozygotic twins occurs at a higher percentage than 
would be expected in the general population (Faderl et al, 2003). 
 
1.1.2.1 (i) The molecular genetic aspects of acute lymphoblastic leukaemia  
Over 75% of ALL cases have genotype mutations, which are identified via standard 
genome analysis (Pui et al, 2008). However, with the advantage of high-resolution 
genome-wide techniques, many new oncogenic abnormalities have been recognized 
(Pui et al, 2011). All leukaemic children can be categorised into subgroups with regard 
to the patterns of specific gene expression (Figure 1.4). In addition, cooperative 
oncogenic lesions are required in the pathogenesis of ALL and they were considered to 
have a role in drug responsiveness. Mullighan et al (2007) identified that deletion, 
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amplification, point mutation and structural rearrangement (which affects the genes 
regulating B lymphocyte differentiation) were implicated in the development of 40% of 
B-progenitor ALL cells. 
 
                                                             
Figure 1.4: The estimated percentage of genetic abnormalities in acute lymphoblastic 
leukaemia. Hyperdiploidy of more than 50 chromosomes and ETV6-RUNX1 t(12;21) 
account for the commonest cytogenetic aberrations in ALL patients (Pui et al, 2011).   
 
According to the immunophenotypic features and cytogenetic-molecular markers, ALL 
has been classified into subtypes, which correlate with the prognosis (Faderl et al, 
2003). In terms of immunophenotyping, ALL is divided into precursor-B cells (includes 
pre-pre-B ALL (pro-B ALL), common ALL (cALL), pre-B ALL), mature-B-cells and 
T-lineage ALL. However, the most presenting subtype among leukaemic children is 
cALL which is detected in 50% of Philadelphia positive ALL (Ph-positive ALL) and it 
carries with it a dismal prognosis (Faderl et al, 2003).  
Based on the analysis of cytogenetic-molecular abnormalities, ALL can be caused by 
chromosomal translocations, chromosomal hyperploidies and alteration in the 
expression of transcription factors (Pui et al, 2004). Approximately 3% of ALL 
paediatrics possess Philadelphia (Ph) chromosome in which the ABL1 oncogene on 
chromosome 9 is reciprocally translocated to a breakpoint cluster region (BCR) on 
chromosome 22 t(9;22) (q34;q11) (Faderl et al,1999). The Ph chromosome was the first 
cytogenetic aberration identified that linked to ALL and chronic myeloid leukaemia 
17 
 
(CML). The isoform  p210BCR-ABL is related to CML, while the isoform p190BCR-ABL 
presents in Ph-positive ALL. BCR-ABL1generates an activated tyrosine kinase, and 
ALL patients with BCR-ABL1 rearrangement have more blast cells than Ph-negative 
ALL at diagnosis (Preti et al, 1994).     
Interestingly, the prognosis for BCR-ABL1-positive ALL patients is worse than for 
CML, suggesting that an additional factor is implicated in the progression of ALL 
(Mullighan et al, 2008). Mullighan et al (2008) identified a deletion on 7p12 of IKZF1 
(it was deleted in 83.7% of ph+ ALL but not in CML), which is responsible for coding 
the lymphoid transcription factor IKAROS, and appears to have a role in making the 
outcome of the Ph-positive ALL poor compared with CML (Iacobucci et al, 2009). 
Then Mullighan et al (2009) established that about 10% of BCR-ABL1-negative ALL 
have mutations in Janus kinases (JAK1, JAK2 and JAK3), and furthermore these 
mutations were combined with deletion of IKZF1. The authors suggested a great effort 
should be made to identify a therapeutic agent that targets JAK mutated ALL. 
Furthermore, Garza-Veloz et al (2015) recognized that overexpression of FLT3 and 
DEFA1 genes in B-ALL are poor prognostic factors, and they are associated with high 
mortality rate.  
On the other hand, T-cell ALL is branched into numerous subsets according to genes 
alterations namely: HOX11L2, LYL1 plus LMO2, TAL1 plus LMO1 or LMO2, 
HOX11, and MLL-ENL. It was recognized that HOX11L2 is linked to an unfavorable 
prognosis, while HOX11 is associated with a better survival rate (Meijerink et al, 2009). 
Additionally, the presence of rearrangement of the mixed-lineage leukaemia (MLL) 
gene at chromosomal band 11q23 in T-ALL cell lines is correlated with poor prognosis. 
A histone methyltransferase is encoded by the MLL gene, which has a vital role in 
development of ALL via regulating the expression of HOX genes. The MLL locus can 
be affected by translocations, deletions, inversions, gene amplifications and internal 
duplications. Translocation abnormalities include t(4;11) (q21;q23), t(11;19) (q23;p13) 
and t(9;11) (p22;q23), however the former is the most common (Hilden et al, 2006; 
Beesley et al, 2010).  
In spite of the high cure rate in children with ALL is high, some subgroups with 
chromosomal abnormalities need a combination of cytotoxic therapeutics and 
radiotherapy. However, allogeneic bone marrow transplant is required for the resistant 
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cases (Stanulla and Schrappe, 2009). The duration of the therapy in ALL after the 
induction phase can last up to 3 years (Samuels et al, 2014).  
 
1.1.2.1 (ii) The effect of glucocorticoids on acute lymphoblastic leukaemia  
In addition to the previously mentioned treatment for ALL, glucocorticoidal steroids 
(GCs) have been used by physicians as main antileukaemic regimen owing to their 
ability to induce apoptosis (programmed cell death) in lymphoid tumours. Nevertheless, 
in some occasions GCs cannot promote their apoptotic action on leukaemic cells when 
glucocorticoids face a cellular resistance. Dexamethasone (DEX) and prednisolone 
(PRED) are the most commonly used synthetic glucocorticoids in the treatment of ALL 
(Kaspers et al, 1994). Bindreither et al (2014) studied the mechanism of both steroids in 
ALL and the authors concluded that DEX and PRED regulate the same genes in 
childhood ALL and the disparity in the treatment efficacy of DEX and PRED was 
related to the difference in the pharmacokinetics and the pharmacodynamics of these 
agents. 
GCs belong to steroid hormones, which exert their biological action via binding with 
the glucocorticoid receptor (GR). NR3C1 gene is responsible for encoding GR and the 
gene is located on chromosome 5 (5q31) (Bindreither et al, 2014). There are two GR-
protein isoforms namely GR-α and GR-β. GR-α is strongly linked to steroid sensitivity 
while GR-β is linked to steroid insensitivity (Shah and Kumar, 2013).   
Mutations in the transcription factor that regulates NR3C1 expression could explain the 
mechanism of the emergent resistance in ALL (Ploner et al, 2005). Glucocorticoid 
insensitivity occurs as one of two types: primary GCs resistance (present in about 10%-
30% of leukaemic patients and this type of patients do not respond to the anti-lymphotic 
effect of GCs) or secondary GCs resistance (patients with this type of resistance, 
initially show response to the growth-inhibiting effect of GCs then after time GCs fail to 
induce blast cell arrest) (Kaspers et al, 1994). 
Several studies have been carried out on lymphoid cells, aimed at identifying the genes 
that are responsible for regulation the intracellular function of steroids. However, 
experiments have been conducted on two subclones of lymphoblastic cell lines termed 
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CEM-7-14 (prototypical GR sensitive) and CEM-1-15 (prototypical GR resistant) which 
were obtained from a child with T-ALL cells, treated with DEX (Medh et al, 2003). 
Schmidt et al (2006) reported that, FKBP5/FKBP51and DDIT4/Dig-2 are upregulated 
in CEM-1-15 after induction the DEX. While, Beach et al (2011) identified E4BP4 is 
overexpressed in CEM-7-14 following initiating the treatment with DEX but not in 
CEM-1-15. Additionally the authors explained the mechanism of how E4BP4 displays 
DEX-evoked apoptosis in ALL and stated that the function is carried out through Bim 
upregulation. Moreover, Beesley et al (2010) reported that RNAi knockdown of MLL 
mRNA in T-ALL led the lymphoid cells to develop resistance to DEX and gamma 
radiation. 
 
1.1.3 Central nervous system tumours                                                
Central nervous system (CNS) tumours are neoplasms of glial tissue involving the brain 
and the spinal cord, they are the second most common paediatric oncological diseases, 
presenting in more than a quarter of childhood cancers (Kheirollahi et al, 2015). 
Globally around 200,000 people are affected each year by brain cancer. According to 
the clinical behaviour, brain tumours can be benign or malignant. Additionally, CNS 
tumours are classified into primary tumours (those originate in the brain) and secondary 
tumours (those begin in other organs then metastasize to the central nerve system) 
(Kheirollahi et al, 2015).  
Primary brain cancer is less common than secondary cancer; usually the sources of the 
secondary brain tumours are breast tumour, cancer of colon, lung tumour, kidney 
tumour or melanoma. The presentation of brain tumours may include headaches, 
vomiting, convulsion, and difficulty in speech, abnormal gait, sensory deficit, hearing 
and vision problems (Barrow Neurological Institute, 2013).   
Depending on which cells are being affected, brain tumours are subdivided into 
astrocytoma (tumours arise from astrocytes); these neoplasms present around 43% of 
brain tumours and the majority of them are benign. Embryonal tumours account the 
second most common CNS tumours, about 73% of this subgroup is accounted for 
medulloblastomas and the remaining CNS tumours are presented by ependymoma 
(Cancer Research UK, 2014). 
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1.1.3.1 Medulloblastoma  
Medulloblastoma (MB) was identified in 1925 by Harvey Cushing and his associate 
Percival Bailey (Li et al, 2013). Eighty percent of MB patients are diagnosed at the age 
of 15. MB follows the primitive neuroectodermal tumours (PNETs) and it is the most 
presenting nervous system malignancy in the paediatric age group. The primary 
originates in the cerebellar vermis and 10% of childhood neoplasm mortality is caused 
by these tumour cells. These poorly differentiated embryonal neuroepithelial tumours 
arise from the infratentorial site in the posterior fossa. (Santhana Kumar et al, 2015).  
These malignant cells are highly aggressive owing to their ability to spread through the 
leptomeningeal space and 30% of cases do not respond to treatment (Wang et al, 2014). 
Although many patients with meduloblastoma have improved following treatments, 
which include surgery, chemotherapy and radiation, those who received radiotherapy 
suffer from the side effects of radiation such as secondary neoplasms and 
neurocognitive impairments (Jakacki et al, 2005; Mulhern et al, 2005). Thus, to lower 
the neurotoxicity caused by radiation, the planned management is to start with a 
prolonged course of chemotherapy, as the cytotoxic agents are effective in controlling 
the proliferation of the malignant cells in MB and to omit the radiotherapy except for 
relapsed patients (Duffner et al, 1993). 
According to the histopatholigical features, MB is classified into five subgroups: classic 
medulloblstoma, nodular (desmoplastic), medulloblastoma with extensive nodularity, 
anaplastic and large cell medullobstoma (Taylor et al, 2012). 
 
1.1.3.1 (i) The molecular genetic aspects of medulloblastoma 
Owing to advances in genome wide expression profiles, many genetic alterations are 
being discovered in medulloblastoma. However, mutations affecting the molecular 
pathways which control the proliferation of neural progenitor cells termed Wingless 
(WNT) and Sonic Hedgehog (SHH) pathways are the cornerstone in the oncogenesis of 
MB and numerous genes are linked to these pathways (Thompson et al, 2006).  
The most common molecular abnormalities related to MB are the loss the short arm of 
chromosome 17 and the loss the long arm of chromosome 9 (Koch et al, 2001). About 
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10% of medulloblastomas are associated with mutations of the PTCH gene, which is 
located on chromosome 9q22.3. The encoded proteins of PTCH gene are believed to be 
receptors in the SHH pathway (Dong et al, 2000).  
It was noticed that mutations in the adenomatous polyposis coli (APC) gene are 
associated with MB. However, many components in the WNT/SHH pathway are 
encoded via APC gene. Furthermore, APC protein has an important role in the 
regulation of β-catenine level in which it activates the degradation of cytoplasmic β-
catenine, thereby leading to cellular growth inhibition. Additionally, mutations in 
CTNNB1 (which is a part of β-catenine) and deletion of AXIN1 were detected in 
around 20% of MB and they were linked to inappropriate activation of the WNT signal 
transduction pathway. Thus, AXIN1 acts as a tumour repressor gene in MB. It was 
found that AXIN1 mutations were linked to desmoplastic and classic types of MB 
(Dahmen et al, 2001).  
Su et al (2006) identified that MB is often associated with overexpression of both the 
repressor of neuronal differentiation/neuron-restrictive silencer factor (REST/NRSF) 
and the MYC gene. The MYC family is composed of MYCn and c-MYC. These 
transcription factors have important functions, including regulation the cell 
proliferation, apoptosis and stem cell differentiation via encoding a nuclear 
phosphoprotein. Moreover, MYC proteins create heterodimers with Max, both of them 
contain Helix-loop-helix and leucine zipper protein. MYC/Max heterodimers bind to 
particular sequences on the DNA of target genes and regulate the transcription of these 
genes through inhibition or induction processes. However, high levels of MYC mRNA 
in MB are correlated with poor outcome (Grotzer et al, 2001; Swartling et al, 2012). 
Eberhart et al (2002) concluded that chromosomal losses are more frequent in anaplastic 
MB compared with other histological subtypes and that is a link between MYC gene 
amplification and loss of chromosome 17p. In addition, Kenney et al (2003) identified 
that MYCn is implicated in dysregulation of the SHH pathway and MB development. 
Nevertheless, c-MYC alone is not sufficient to generate MB. 
REST/NRSF is a transcription repressor factor that controls the function of many 
neuronal genes through binding with a conserved 23 bp motif, namely repressor element 
(RE1). High levels of REST mRNA in neuronal cells suppress the transcription of 
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numerous neuronal differentiation genes and arrest these cells at a step before complete 
differentiation, which leads to MB neoplasm formation (Fuller et al, 2005).   
Lawinger et al (2000) carried out transient transfection experiments and the authors 
designed a recombinant transcription factor (REST-VP16) by substituting the repressor 
domains of REST with the activation domain of the adenovirus (VP16) protein. The 
expression of REST-VP16 in MB cells was able to oppose the repression effects of 
endogenous REST on neuronal promoters, activate the cell death pathways. In addition, 
the authors confirmed that injection of REST-VP16 in medulloblastoma cells, which 
were grown in nude mice leads to inhibition of their growth. Thus, REST could be a 
novel target gene for MB therapy.   
 
1.1.4 Bone tumours                                                                                        
The majority of childhood bone tumours are benign tumours. However, these benign 
cells are often asymptomatic and diagnosed accidentally during trauma or through 
evaluation the child for another presenting illness. Benign bone tumours are sub-
classified into non-ossifying fibroma (mainly affects the metaphysis), desmoid fibroma 
(occurs commonly in the posterior medial condyle of the femur), osteochondroma (it 
has a unique sign on an X-ray which is obvious by the continuity of the cortex with the 
normal bone) fibrous dysplasia and chondroma (Vanel et al, 2009).  
Malignant bone tumours are divided into osteosarcoma, Ewing sarcoma, 
chondrosarcoma and spindle cell sarcoma. The most common presenting symptoms in 
bone neoplasms are bone pain, which becomes severe during the night and swelling. 
(He et al, 2014). 
 
1.1.4.1 Osteosarcoma                                                                      
Osteosarcoma (OS) is the most frequent malignant tumour of bone that arises from 
primitive bone forming cells, termed mesenchymal cells, which produce osteoid and 
immature bone. Twenty percent of bone paediatric bone neoplasms are caused by these 
malignant osteoblast cells, affecting mainly teenagers. Therefore, OS is linked to the 
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growth spurt, the metaphysis growth plates of the long bones such as the distal femur, 
proximal tibia, and proximal humerus are the target sites (Richardson, 2014).  
According to the histological features, OS is divided into chondroblastic OS and 
fibroblastic OS (He et al, 2014). Despite adjuvant chemotherapy, radiotherapy and 
surgery, osteogenic sarcoma still carries a poor prognosis due to their early metastasis 
(Bai et al, 2015). Most of OS tumours metastasize to the lung. More than 30% of OS 
patients suffer from pulmonary metastasis during the five years from the diagnosis. 
Therefore, more attention needs to be paid to understand the pathophysiology and the 
molecular pathways of lung metastasis in OS (Khanna et al, 2001).  
 
1.1.4.1 (i) The molecular genetic aspects of osteosarcoma  
It has been recognized that OS is associated with a high rate of drug resistance. Studies 
conducted to explain the mechanism of OS-induced drug resistance identified that high 
level of Bcl-2 mRNA (B-cell lymphoma 2) is correlated with developing tumour 
resistance to chemotherapeutics (Ye et al, 1998). Bcl-2 is an oncogenic protein as it has 
an anti-apoptotic role (Reed, 1997). Ferrari et al (2004) reported that OS cells, which 
exhibit high levels of Bcl-2 are high grade tumour cells and tend to induce early 
pulmonary metastasis. Similarly, Zhao et al (2009) confirmed that knockdown of Bcl-2 
leads to an increased the effect of doxorubicin on OS. Therefore, the authors suggested 
that Bcl-2 could be used as a target in the treatment of OS.  
Germ line mutations in retinoblastoma and p53 genes have been established to be 
related to increase the incidence of OS in the tumour suppressor genes (He et al, 2014). 
Moreover, Wong et al (2007) confirmed that OS cells, which express high levels of 
mutated p53 and p53-R273H are at a high risk of developing drug resistance.    
Hattinger et al (2003) examined the Saos-2 cell line (human OS cell line; which is 
methotrexate resistant) to identify the chromosomal abnormalities related to the 
development of chemotherapy resistance in OS. The authors stated that gain of 8q22-
qter and MYC (8q24.12-q24.13) along with low expression level of RFC (reduced 
folate carrier that allows the methotrexate to enter the cell through the cell membrane) 
gene is correlated with Saos-2 resistant cells. Therefore, RFC could be used to predict 
the chemosensitivity to methotrexate in OS (Ifergan et al, 2003). Notably, four altered 
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RFC proteins known as Leu291Pro, Ser46Asn, Ser4Pro and Gly259Trp are implicated 
in methotrexate OS resistance (Flintoff et al, 2004). Guo et al (1999) noticed that high 
levels of DHFR (dihydrofolate reductase) mRNA are linked to pulmonary metastatsis in 
OS.   
Upregulation of glutathione S-transferase P1 (GST P1) is associated with poor outcome 
in OS patients (Uozaki et al, 1997) GST P1 is a phase II detoxification enzyme that 
belongs to cytosolic GSTs, which have a major role in deactivation of many antitumour 
compounds (Uozaki et al, 1997). Moreover, Huang et al (2007) conducted RNAi 
knockdown of GST P1 on HOS cell lines (human osteogenic OS cell lines) and these 
cells were exposed to either cisplatin or doxorubicin. The authors concluded that 
suppression of GST P1 enhances the effect of these chemotherapeutic agents on OS 
cells, induces severe DNA damage and apoptotic cell death. In another study, Zhang et 
al (2012) found that OS patients with GST P1 Val/Val genotype have a shorter survival 
rate than those with GST P1 lle/lle genotype. Therefore, the authors suggested that 
polymorphisms of GST P1 gene could have a predictive value to identify the prognostic 
criteria in OS patients who received antineoplastic drugs.  
To tackle GST P1-induced resistance in OS, an in vitro experiment evaluated the 
influences of NBDHEX [6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol], which acts 
as an GST P1 inhibitor, on the Saos-2 cell line. This study confirmed that NBDHEX 
could be applied to OS patients who show high level of GST P1 together with the 
chemotherapeutic drugs (Pasello et al, 2008). 
A study carried out by Wang et al (2004) reported that overexpression of AP-
endonuclease 1 (APE1) was associated with high mortality rate in OS individuals. In 
addition, the authors silenced APE1in OS cell lines via siRNA and that led to increased 
sensitivity of OS cells to γ-radiation, oxidizing and alkylating DNA damaging agents.   
A further study revealed that a low level of ERCC4 mRNA (which is involved in 
nucleotide excision repair) in OS is linked to a high rate of chemotherapeutic resistance 
(Nathrath et al, 2001). 
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1.1.5 Hepatic tumours                                                                               
Slightly more than 1% of childhood tumours are hepatic tumours. Unfortunately, the 
vast majority of these neoplasms are malignant (about 60%), while the remaining 40% 
are benign. Patients usually complain of abdominal distension, malaise, abdominal 
discomfort and constipation. According to their histopathologycal character, malignant 
liver tumours are divided into hepatoblastoma, hepatocellular carcinoma, sarcoma, germ 
cell tumours and rhabdoid tumours. On the other hand, benign liver tumours include 
vascular tumours, hamartomas, adenomas, and focal nodular hyperplasia (Litten and 
Tomlinson, 2008). 
 
1.1.5.1 Hepatoblastoma       
Hepatoblastoma (HB) arises from hepatic primordium embryonic cells and was firstly 
recognized by Walter in 1896; at that time, it was termed paediatric hepatocellular 
carcinoma (Heywood et al, 2002). HB is the most common presenting tumour among 
children with liver neoplasms and is more frequent in boys than girls. Furthermore, HB 
follows an aggressive course with early metastasis through the lymphatic and blood 
vessels (Perilongo et al, 2012). The initial 3 years of life is the average age of 
presentation and in the last 30 years, the incidence of HB has increased significantly 
(Czauderna et al, 2014).  
It has been suggested that the HB cells start to develop during the antenatal period as 
these stem liver malignant cells commonly occur in preterm neonates rather than in term 
neonates. The right hepatic lobe is the frequent affected part in the liver. In addition, HB 
has four main types, (each type has different cells) epithelial, mixed, small cell 
undifferentiated (has the worst prognosis), pure foetal (has the best prognosis) (Figure 
1.5) (Litten et al, 2008).                                                         
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Figure1.5: Percentage of the histological types of hepatoblastoma. Epithelial-Mixed 
embryonal and foetal type accounts the largest numbers (Adapted from Litten et al, 
2008).      
 
1.1.5.1 (i) The molecular genetic aspects of hepatoblastoma 
Healthy cells possess a balance between the level of ROS and endogenous antioxidants 
enzymes, during liver damage; ROS activate hepatic stellate cells (which are 
responsible for synthesis of the extracellular matrix that is important for cellular growth 
and differentiation). However, chronic activation of hepatic stellate cells has been 
linked with enhancement of division of liver cells and the development of hepatic 
tumours. On the other hand, profound exposure to ROS resulted in cell death (Marra et 
al, 2011). 
Different molecular alterations have been linked to the pathogenesis of HB. Through the 
analysis of different histological types of hepatoblastoma, López-Terrada et al (2006) 
found that mutations of the beta-catenin gene occur in more than 90% of HB tumours. 
Βeta-catenin is an important gene in the Wnt pathway, which controls tumourgenesis 
(Sakanaka et al, 2000). Moreover, hepatoblastoma is correlated with some genetic 
diseases such as familiar adenomatosis polypi and Beckwith-Weidemann syndrome 
(Herzog et al, 2000). 
Cuevas et al (2007) conducted a study on the HepG2 cell line (human HB cell line) to 
identify the factors that affect the growth of HB. The authors concluded that the 
proliferation of HepG2 is stimulated via insulin receptor substrate-4 (IRS-4). IRS-4 
27 
 
exerts its action through phosphatidylinositol 3-kinase and protein kinase B (Akt) 
pathways. In addition, HB is associated with overexpression of IRS-4 (Xia et al, 2014).  
Dong et al (2014) reported that, lncRNAs (long non-coding RNAs) have a major role in 
the development of HB. Eukaryotic cells contain thousands of lncRNAs, they are longer 
than 200 nucleotides in length and regulate gene expression (Dinger et al, 2009; Ponting 
et al, 2009). Additionally, alterations in the level of expression of lncRNAs have been 
linked to the progression of several tumours (Ge et al, 2013; Sun et al, 2013).                                                   
 
 1.2 DNA Damage                                                                                               
DNA contains the genetic information for achieving the appropriate growth, 
performance and breeding of living creatures (de Boer and Hoeijmakers, 2000). 
However, the biological stability of DNA in vivo is influenced by factors such as 
oxidation, hydrolysis and methylation (Lindahl, 1993).     
A variety of innate responses to radiation and other oncogenic agents are exhibited by 
mammalian cells. Indeed the activation of oncogenes or deactivation of tumour 
suppressor genes was noticed to be responsible for the presentation of numerous 
neoplasms. In the majority of patients, mutation in a chromosome at a specific site is the 
commencement point in liberating cells from the dormant situation to the direction of 
uncontrolled cell proliferation. The connection between damaged DNA and 
carcinogenic activity indicates ineffectiveness in at least one of the pathways of DNA 
repair and is strongly implicated in carcinogenesis (Athas et al, 1991).  
 
1.2.1 Aetiology of damaged DNA                                                                          
DNA in cells is frequently damaged by different genotoxins. The stability and the 
composition of DNA sequences might be disturbed endogenously by various replication 
errors and cellular metabolites or exogenously by radiation (such as UV-light and X-
rays), oxygen radicals, alkylating agents, polycyclic aromatic hydrocarbons and 
chemotherapy drugs (Goode et al, 2002).  
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Different DNA damaging agents produce different DNA lesions; however, single-strand 
DNA breaks are caused by X-rays, oxygen radicals and indirectly by alkylating agents. 
In particular, the products of respiratory metabolism in mammalian cells release reactive 
oxygen species (ROS) (Figure 1.6), which lead to oxidative damage in the DNA 
molecule. Deamination and depurination are frequent hydrolysis reactions that occur 
due to intrinsic insults affecting the nucleotide; uracil is produced via deamination of 
cystine while depurination generates a non-coding abasic site. Bulky chemical adducts 
are induced by UV-light and polycyclic aromatic hydrocarbons. Double-strand DNA 
breaks occur because of X-rays and interstrand cross-links through the action of some 
genotoxic drugs, such as cisplatin (de Boer and Hoeijmakers, 2000). 
     
Figure 1.6: The influence of reactive oxygen species (ROS) on mammalian cells. (A) A 
normal cell has the ability to repair the damaged mitochondrial DNA (mtDNA) and 
nuclear DNA (nDNA) caused by ROS. (B) Aging cells lack the ability repair the 
oxidative DNA damage to nuclear and mitochondrial DNA, which ends in cell growth 
arrest (Adapted from Yakes and Van Houten, 1997).    
 
Oxidative DNA base damage (Figure 1.7) are mutagenic such as thymine glycol (Tg) 
produced by oxidation of thymine, 8-oxo-7,8-dihydroguanine (8-oxoG) produced by 
oxidation of guanine and 5-hydroxyuracil (5-OH-U) produced by oxidation of cytosine. 
These lesions lead to genomic instability either, as a result of blocking DNA 
polymerases or through base mispairing. Therefore, DNA base lesions should be 
repaired to maintain the stability of the genomic DNA (Brooks et al, 2013). 
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Figure 1.7: The most common oxidative DNA base damage. The figure illustrates 
different types of oxidative DNA base lesions (Brooks et al, 2012). 
 
1.2.2 Reactive oxygen species                                                             
Reactive oxygen species (ROS) are free radical species that have a crucial role in all 
fields of biology as they are signalling molecules in living organisms involved in 
apoptosis (programmed cell death) and combat foreign organisms through oxidizing the 
cell components for instance: lipid, protein and DNA. It has been estimated that 1-3% 
of oxygen utilized by oxidative phosphorylation generate ROS through reduction of 
oxygen to water; this reaction involves adding electrons in four steps, which can lead to 
the production of superoxide anion (O2
-), hydrogen peroxide (H2O2) and the hydroxyl 
free radical (OH.). ROS are generated from the electron transport chain (ETC) that 
occurs in the mitochondria of the mammalian cells (Figure 1.8) (Sullivan and Chandel, 
2014). 
                                                                       
Figure 1.8: ROS production pathway. Mammalian cells utilise oxygen in aerobic 
respiration to perform many vital functions. These processes lead to unstable reactive 
molecules. Superoxide (O2
-) is produced by adding an electron to an oxygen molecule, 
and then by the effect of superoxide dismutase (SOD), two molecules of superoxide are 
converted to hydrogen peroxide (H2O2). H2O2 is reduced to H2O by glutathione 
peroxidases (GPXs), catalase and peroxiredoxins (PRXs). Hydroxyl radical (OH.) is 
generated through the Fenton reaction on H2O2 (Adapted from Sullivan and Chandel, 
2014).  
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ROS are also produced from macrophages and neutrophils during the inflammatory 
response against bacterial and viral infection. Moreover, exogenous reagents such as 
chemical substances, for example 4-nitroquinoline-1-oxide and ionizing radiation 
produce ROS (Figure 1.9) causing  harmful effects in cells in the form of oxidative 
DNA lesions, abasic sites, and DNA strand break. ROS-induced base damage has been 
implicated in the pathogenesis of several diseases such as cancer, rheumatoid arthritis, 
arrhythmia, neurodegenerative disorder and aging. In comparison with other organs, the 
brain is more susceptible to the deleterious effect of ROS owing to it possessing low 
levels of antioxidant enzymes and high amount of unsaturated fatty acids, which are 
implicated in lipid peroxidation. To tackle all these hazards and conserve the cells from 
mutation, organisms have several DNA repair pathways (Nishioka et al, 1999; 
Quintanilla et al, 2012).  
Exogenous antioxidants are another natural defence mechanism that acts against the 
effects of ROS. This mechanism is offered by fruit, vegetables and certain herbs, which 
have antioxidants in the form of vitamin C, vitamin E and carotenoids. Previous studies 
conducted on this mechanism concluded that consuming a diet rich in vegetables and 
fruit correlated with a lowered risk of developing cancer (Collins, 1999).      
  
                                                                                
Figure 1.9: The pathogenesis of tumour formation. Several oncogenic pathways have 
been linked to cancer development, through generation of ROS, from the electron 
transport chain in mitochondria, to hypoxia, chemical substances, mutations affecting 
the mitochondrial DNA and loss of tumour inhibitors (Adapted from Sullivain et al, 
2014). 
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1.3 Types of DNA repair mechanisms                                                                              
DNA repair includes a number of sophisticated systems that play significant role in 
preventing the transcription, DNA replication of the damaged nucleotides. There are 
five methods, each one deals with particular sort of DNA damage: direct reversal repair, 
base excision repair (BER), nucleotide excision repair (NER), mismatch repair (MMR) 
and double-strand break (DSB) repair (Figure 1.10) (Goode et al, 2002; Hakem, 2008). 
 
                                                                                                              
Figure 1.10: DNA repair mechanisms. The figure illustrates four DNA repair pathways: 
base excision repair, which repair the damaged DNA caused by X-ray, ROS and 
alkylating agents, while mismatch repair is responsible for repairing DNA replication 
errors. On the other hand, nucleotide excision repair DNA damage induced by UV-light 
and polycyclic aromatic hydrocarbons. Additionally, double-strand break repair repairs 
the DSB induced by ionizing radiation (Adapted from Goode et al, 2002).      
 
1.3.1 Direct reversal   
Unlike other DNA repair pathways, direct reversal is a simple process that does not 
need the excision of the altered bases. Direct reversal repairs alkylated DNA lesions 
such as O6-alkylguanine. O6-alkylguanine is repaired in Escherichia coli by the Ogt and 
Ada proteins, while it is repaired in mammalian cells by O6-methylguanine-DNA 
methyltransferase (MGMT). Moreover, 1-methyladenine (1meA) and 3-methylcytosine 
(3meC) are other damaged bases induced by alkylating agents, which are repaired in E. 
coli by AlkB and by the ALB homologs, ABH2 and ABH3 in vertebrate cells (Hakem, 
2008). 
32 
 
1.3.2 Nucleotide excision repair                                                                          
Nucleotide excision repair (NER) has evolved to eliminate helix distorting DNA 
adducts and pyrimidine dimers caused by environmental agents such as UV light and 
certain chemical carcinogens. Several molecular studies conducted on NER illustrated 
that genetic abnormality in NER is associated with some rare genetic diseases such as 
xeroderma pigmentosum (XP). Patients with XP have a 2,000-fold risk of developing 
skin cancer compared to the rest of the population (Benhamou and Sarasin, 2000).  
The NER mechanism is composed of four processes: First, via a complex of linked 
proteins, e.g. XPC and XPA, the damage is detected, and then the affected DNA 
segment is covered by the TFIIH complex. The next step involves making two incisions 
and removing a DNA portion (approximately 25-30 nucleotides), which is carried out 
by the ERCC1, XPF complex and XPE. The fourth step includes DNA polymerization 
by a DNA polymerase and ligation by DNA ligase (Goode et al, 2002). 
 
1.3.3 Double-strand break repair  
There are two mechanisms that mediate DSB repair: homologous recombination (HR) 
and non-homologous end-joining (NHEJ). In yeast and prokaryotes, DSBs are repaired 
by HR, while in mammalian cells over 90% of DSBs are repaired by NHEJ (Hakem, 
2008).  
In NHEJ, the two broken DNA termini are ligated without need for a homologous DNA 
sequence. HR is complicated mechanism, as it requires several proteins to search for the 
homologous DNA template and to carry out DNA strand invasion. However, after 
resection, the DNA ends of the recently uncovered 3´-single-stranded tails invade into 
the double helical DNA to achieve an error free repair of the DSB (Goode et al, 2002). 
Mutations in the BRCA1, BRCA2 and XRCC3 genes (which have a role in the HR 
pathway) are associated with cancer of the ovary, breast and other tumours 
(Venkitaraman, 2002).  
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1.3.4 Mismatch repair  
Mismatch repair (MMR) has a fundamental role in protecting the cells against DNA 
replication mistakes as a result of DNA polymerase errors. Impaired MMR genes 
(MLH1, MSH2, PMS2, and MSH6) lead to instability of short bases repeats 
(microsatellite instability) which have been linked to hereditary nonpolyposis colorectal 
cancer. MMR starts by detecting mismatch in the newly synthesized strand, and then the 
following steps are incision, excision, polymerization and ligation (Aquilina and 
Bignami, 2001).                                                                                             
                                                                                                                                                                                 
1.3.5 Base excision repair  
The mechanism of base excision repair (BER) was first described by Lindahl (1974). 
BER releases alkylated and oxidized bases and repairs apurinic/apyrimidinic (AP) sites 
and DNA single-strand breaks. Mammalian cells use highly conserved enzymes named 
DNA glycosylases, to identify and remove chemically modified bases from DNA 
(Krokan et al, 2000).  
DNA glycosylaese are divided into two major groups according to the type of DNA 
binding motif: Helix-hairpin-helix (HhH) or Helix 2 turn Helix (H2TH). OGG1, MutY 
and Nth have HhH structure, while MutM (Fpg), Nei and NEIL family follow H2TH 
group. However, all members in H2TH family have zinc finger motif except NEIL1, 
which has zincless finger motif (Liu et al, 2013). 
OGG1 conserve the cells from the influences of 8-oxoG. 8-oxoG is the most oxidized 
purine, it implicates in tumour pathogenesis as this compound bind with A and C 
resulting in G: C → T: A transversions (Morland et al, 2002). 
DNA glycosylases initiate BER by excision of the damaged base through splitting the 
N-glycosidic bond between the target base and the DNA sugar-phosphate backbone 
(deoxyribose) resulting in release of the nitrogenous base and creating an AP site. 
Moreover, certain DNA glycosylases are bifunctional and cause a break of the  
phosphodiester backbone 3' to the abasic site through their AP lyase activity that results 
in blocking the 3'-side of the AP site with 3'-phosphounsaturated aldehyde (3'-
PUA) or 3'-phosphate (3'-PO4), while the 5'-end has a phosphate (5'-PO4) residue. This 
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characteristic activity is a unique feature of oxidized base-specific DNA glycosylases. 
On the contrary, in monofunctional glycosylases the intact AP site is cleaved by an AP-
endonuclease (APE) generating 3'-hydroxy (3'-OH) and 5'-deoxyribose phosphate (5'-
dRP) termini. The basic disparity between both enzymes is related to the nucleophile 
compound, in that the activated water molecule is being used by APE dependent DNA 
glycosylases as the active site nucleophile, while an amine or N-terminal proline or 
valine is used by AP lyases as the nucleophile in attacking the sugar C1 (Lu et al, 2001). 
Following incision of the phosphodiester backbone, BER can be either short patch or 
long patch. In short patch repair, replacement of one nucleotide is carried out, in which 
DNA polymerase (Pol) uses the remaining DNA strand, as a template in DNA 
synthesis then DNA ligase III, XRCC1 are responsible for the ligation step. While, long 
patch repair involves gap filling of about 2-8 nucleotides, which requires DNA 
polymerase δ/ε, proliferating cell nuclear antigen (PCNA), replication factor C (RF-C), 
replication protein A (RP-A), flap structure-specific endonuclease 1 (FEN1) and DNA 
ligase I (Figure 1.11) (Nakanishi et al, 2007).   
                                                                                          
Figure 1.11: Base excision repair mechanism. (A) Bifunctional DNA glycosylases, in 
which their action is mainly carried out via internal AP lyase residue. (B) 
Monofunctional DNA glycosylases, in which the action is achieved by AP 
endonuclease. Both A and B illustrate short patch repair, in which filling the gap with 
single nucleotide is achieved via DNA Pol β, DNA ligase III and XRCC1.(C) Long 
patch repair, in which the BER conducted with replacement of several nucleotides via 
DNA Pol δ/ε, PCNA, RF-C, RP-A, FEN1, DNA ligase I (Adapted from Krokan et al, 
2000).                                                                                                                                                                                                                                                                 
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1.4 Oxidized base-specific DNA glycosylases in euokaryotic cells                                                                        
Oxidative stress generated from hydrogen peroxide, superoxide and hydroxyl radicals 
have been implicated as a cause of mutagenic base lesions affecting purines and 
pyrimidines. It has been estimated that the genomic DNA in each cell is liable to 104-
105 lesions each day (Lindahl, 1993). 
The pathway of BER was initially determined in E. coli, and further experiments 
revealed that the mechanism occurs in mammalian cells as well. Therefore, DNA 
glycosylases are expressed in both prokaryotic and eukaryotic cells. Although, for each 
type of DNA glycosylase there is a preferred kind of base damage and sometimes the 
substrate specificity overlaps. These enzymes are small proteins, approximately 30-50 
kDa (Krokan et al, 2000; Hegde et al, 2008). 
DNA glycosylases specific for oxidized bases in Homo sapiens are bifunctional by 
virtue of an AP lyase activity and are classified into two major families named Nth 
family and Fpg (MutM)/Nei (Endonuclease VIII) family. NTH1 and OGG1 are 
included in the Nth family, while NEIL1, NEIL2 and NEIL3 are members of the 
Fpg/Nei family. Depending on the elimination reactions at AP site, Nth family uses β-
elimination activities and leaves 3'-PUA at the DNA strand break. In comparison, the 
NEIL family with the exception of NEIL3 utilizes a elimination reaction and 
liberates 3'-PO4 termini at the strand break (Figure 1.12) (Hegde et al, 2008; Edmonds 
and Parsons, 2014). 
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Figure 1.12: Bifunctional DNA glycosylases with β-elimination reaction and 
elimination reaction. NEIL1and NEIL2 use elimination reaction at AP site, 
while NEIL3, OGG1 and NTH1 use β-elimination reaction. DNA synthesis is carried 
out by DNA polymerase β and DNA ligation via DNA ligase (Adapted from Liu et al, 
2013). 
 
1.5 NEIL family          
NEIL family is Nei-like protein in vertebrate genome (Hazra et al, 2002). The genes for 
NEIL1, NEIL2 and NEIL3 are located on chromosomes 15, 8 and 4 in human cells 
respectively (Takao et al, 2002).       
 
1.5.1 NEIL1            
 NEIL1 (endonuclease VIII-like I) is a 44 kDa protein. According to the catalytic 
activity there is a considerable similarity between NEIL1 and both Nei and Fpg. 
However, NEIL1 is closer to Nei than Fpg in that, 8-oxoG-C pair-containing DNA or 
oligos are poor substrates for NEIL1. Nevertheless, NEIL1 and Fpg have similar 
excisional activity as both prefer ring-opened purines such as the 
formamidopyrimidines FapyA (4,6-diamino-5-formamidopyrimidine) and FapyG (2,6-
diamino-4-hydroxy-5-formamidopyrimidine). Additionally, NEIL1 has the ability to 
excise 8-oxoG, Tg and 5-OH-U. It was concluded that NEIL1 takes part in replication-
associated repair of the oxidized bases as its expression level rises sharply by about 
37 
 
seven-fold in S-phase compared with that in G0/G1. NEIL1 utilises the N-terminal 
proline amino acid at position 2 (Pro2) as the nucleophile, while the C-terminal end has 
the nuclear localization signal (NLS), which is essential for nuclear translocation (Takao 
et al, 2002; Yamomoto et al, 2014).  
Unlike NEIL2 and NEIL3, which have zinc finger motifs, NEIL1 has a characteristic 
feature by lacking the loop that carries the zinc residue, thus NEIL1 exerts its DNA 
glycosylase activity through a zincless finger. However, the zinc finger motif is also 
absent in other members of the Fpg family namely Arabidopsis thaliana Fpg and 
Candida albicans Fpg (Doublie et al, 2004).       
In addition, the role of NEIL1 in repairing the damaged genome was demonstrated by 
knocking down the level of NEIL1 in embryonic stem cell lines through RNAi. The 
results showed that the cells become highly sensitive to the effect of low dose of gamma 
radiation (Rosenquist et al, 2003). 
It was confirmed that NEIL1 is involved in humoral immunity as a study was conducted 
on NEIL1 showed that NEIL1 is highly expressed in germinal centre (GC) B cells. 
However, when mouse NEIL1 (Mmu NEIL1) was deleted, the frequency of 
immunoglobulin gene hypermutation was lowered and the clonal expansion and the 
responses of GC B cells against T cell-dependent antigen decreased (Mori et al, 2009).  
 
1.5.2 NEIL2                                                                                                    
NEIL2 (endonuclease VIII-like II), a 37 kDa protein, is expressed in testes and 
voluntary muscles whereas the level of NEIL1 mRNA is highly expressed in liver, 
pancreas and thymus. In contrast to that, the expression of NEIL1 decreases 
dramatically in muscles and testes. The previous variations conclude that, the function 
of NEIL1 is complementary to NEIL2 (Hazra et al, 2002).      
Furthermore, there are some similarities between NEIL1 and NEIL2, in that both have 
N-terminal Pro2 to fulfil their roles as DNA glycosylases. Additionally, NEIL2 and 
NEIL1 are mainly located in the nucleus. Nonetheless, the protein level of NEIL2 is not 
regulated during the cell cycle. Notably, NEIL2 has a strong repair tendency toward the 
lesions that are produced via oxidation of cytosine (C), and its preferred substrate is 5-
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OH-U. However, NEIL2 has a marginal activity to 5-hydroxycytosine (5-OH-C) and 
5,6-dihydrouracil and it has unmeasured activity to 8-oxoG, 2-hydroxyadenine, 
hypoxanthine and xanthine (Hazra et al, 2002).  
Several studies conducted on the influence of ROS-induced DNA damage reveal that 
the products of oxidized cytosine are the most common mutagens leading to GC → AT 
transitions; the C → T transition is the most frequent base replacement affecting the 
genomic DNA. This was explained by the following: initially cytosine oxidation leads 
to cytosine glycol (Cg). Due to the instability of Cg, it is either dehydrated to 5-OH-C 
or deaminated to uracil glycol (Ug). The third compound is 5-OH-U is formed by either 
removing the amine group from 5-OH-C or removing the water from Ug (Figure 1.13). 
These uracil derivatives are mispaired with adenine during DNA replication (Kreutzer 
and Essigmann, 1998). 
 
                                                                                                                               
Figure 1.13:  Cytosine oxidation. Exposure of cytosine to ROS generates an unstable 
cytosine glycol (Cg) product. Further reactions that include dehydration and 
deamination will lead to three pre-mutagenic lesions namely: 5-hydroxycytosine (5-OH-
C), uracil glycol (Ug) and 5-hydroxyuracil (5-OH-U) (Adapted from Kreutzer and 
Essigmann, 1998). 
 
1.5.3 NEIL3                                                                                       
NEIL3 (endonuclease VIII-like III) is a 68 kDa protein. Recently, NEIL3 has been 
discovered as a third mammalian oxidative base pair DNA glycolysase that homologous 
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to the E. coli DNA glycolysases Fpg and Nei. The hNEIL3 (human NEIL3) gene is 
situated on chromosome 4q34.3 and is encoded via the plus strand. In addition, the 
hNEIL3 locus is flanked by two genes namely AGA gene (aspartylglucosaminidase) 
which is situated on the telomeric end and another gene located on the centromeric side 
termed VEGFC gene (vascular endothelial growth factor c). Nevertheless, both genes 
are encoded via the minus strand. The NEIL3 gene has 10 exons and consists of 1818 
bp in the coding sequences, which gives the full length of hNEIL3 protein of 605 amino 
acids (Liu et al, 2013).  
NEIL3 is mainly present in the cell nuclei (Torisu et al, 2005). It has been observed that 
there is a significant increase in the protein level of hNEIL3 in G2 phase and the Ras 
dependent ERK-MAP kinase pathway has been implicated in the enhancement of the 
transcription of hNEIL3 in early S phase. There are several transcription factors 
affecting the level of gene expression, in a manner that they increase or decrease the 
level of NEIL3 mRNA for instance, the E2F family, which consists of eight factors that 
adhere with the target promoters, thus control their expression. Members of E2Fs family 
also bind with DP1or DP2 and create active DNA binding heterodimers. Additionally, 
they bind with pocket protein group such as retionbalstoma (RP) tumour suppressor, 
p107 and p130. DREAM complex consists of E2F4, DP1, RB p130 and MuvB core 
complex. However, the DREAM complex possesses an important role in suppression 
the expression of NEIL3 mainly in G0 dormant cells (Neurauter et al, 2012).  
 
1.5.3.1 Analysis of the structure of NEIL3 and its DNA glycosylase activity 
Regarding the protein structure, hNEIL3 has a unique long C terminal domain that 
contains a Ranbp-like zinc finger motif and tandem GRF zinc finger motifs in addition 
to the H2TH motif (Figure 1.14). Moreover, NEIL3 has an N-terminal valine amino 
acid at position 2 (Val2) instead of the usual Pro2 residue. Thus, NEIL3 uses this amino 
acid to form a transient catalytic Schiff base. The valine nucleophilie is also a 
characteristic feature of another DNA glycosylase named MvNei2 (Acanthamoeba 
polyphaga mimivirus) (Liu et al, 2010). 
The preferred substrates for NEIL3 are hydantoin lesions such as spiroiminodihydantoin 
(Sp) and guanidinohydantoin (Gh) in both single-strand DNA (ssDNA) and double-
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strand DNA (dsDNA). However, NEIL3 has no excisional activity to ward 8-oxoG. 
Nonetheless, NEIL3 has a unique feature, in that it is the only repair enzyme that 
excises Sp and Gh in ssDNA. Also it was found that Neil3 exerts some excisional 
activity toward 5-OH-C and 5-OH-U in ssDNA. On the other hand, there is no activity 
shown by NEIL3 on 5-OH-C and 5-OH-U in dsDNA. Compared with NEIL1 and 
NEIL2, which both have a robust lyase activity, NEIL3 has very weak lyase 
activity forming 3'-PUA at the DNA strand break (Liu et al, 2013).  
Additionally, several experiments were carried out on Mmu NEIL3 (mouse NEIL3, Mus 
musculus) concluded that NEIL3 is responsible for releasing the mutagenic FapyG base 
lesion. Indeed there is overlapping in the activity toward the specific substrates between 
hNEIL3, Nth1, NEIL2 and NEIL1 (Liu et al, 2013).       
 
                                     
Figure 1.14: Structural comparison between NEIL3, NEIL2, NEIL1, E. coli nei and E. 
coli Fpg. E. coli nei, E. coli Fpg and NEIL2 have an Fpg/Nei family zinc finger motif, 
H2TH motif and conserved N-terminal Pro2 residue, while NEIL1 possesses additional 
features such as a zincless finger motif. On the other hand, NEIL3 has a GRF zinc 
finger motif and a RANbp-like zinc finger motif at C-terminus, H2TH motif and 
conserved N-terminal Val2 amino acid instead of Pro2 terminus (Liu et al, 2013).  
 
Mmu NEIL3 has been characterized through crystal structure analysis of two domains, 
which form the catalytic core and resembles Fpg glycosylases (Liu et al, 2013). The N-
terminal domain consists of two layers of helices, while the C-terminal domain forms a 
stalk of α-helicies, the H2TH motif form two of them and the zinc finger motif are 
placed after H2TH motif. Between the N-terminal domain and C-terminal domain, there 
is a fissure with positive charges that create an electrostatic attraction toward DNA. The 
catalytic task of Mmu NEIL3 is carried out via the Val2, which is located in the fissure. 
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In addition, the 8-oxoG capping ring, which harbours the 8-oxoG in prokaryotic Fpg 
proteins is very small in NEIL3, thus this enzyme is unable to trap the 8-oxoG in the 
binding place. Furthermore, the absence of two void-filling residues in Mmu NEIL3, 
which are responsible for stabilisation of the complementary DNA strand after 
removing the base damage, along with the presence of the negative charge residues, 
which prevent the NEIL3 from binding with the opposite DNA strand. However, all 
these features explain the high excision activity of NEIL3 toward ssDNA (Takao et al, 
2009; Liu et al, 2013).  
 
1.5.3.2 The role of NEIL3 in rapidly dividing cells 
It has been suggested that NEIL3 has a major role in repairing the damaged bases in 
rapidly dividing cells, as the level of NEIL3 is highly expressed during the 
embryogenesis phase in brain regions containing many stem cells. In addition, the level 
of hNEIL3 mRNA was examined in 18 different tumour tissues and healthy tissues. The 
result showed that there was a significant increase in the level of NEIL3in tumour cells 
except testes and pancreas compared with the normal cells (Figure 1.15) (Hildrestrand 
et al, 2009).  
Despite all the previous research and the achieved results on NEIL3, its biological role 
remains an enigma because of issues related to purification of the protein. However, a 
great effort is needed to illustrate the task of NEIL3 in mammalian cells and the purpose 
of being a unique component of eukaryotes (Hildrestrand et al, 2009).  
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Figure 1.15: The relative level of NEIL3 mRNA in different tumours and healthy 
organs. q-RT-PCR was carried out on cDNA obtained from different human cell lines. 
The relative expression of NEIL3 mRNA was calculated via normalization with β-actin. 
The selected cell lines were A: Adrenal gland, B: Breast, Ce: Cervix, Co: Colon, En: 
Endometrium, Oe: Oesophagus, K: Kidney, Li: Liver, Lu: Lung, Ly: Lymph nodes, Ov: 
Ovary, Pa: Pancreases, Pr: Prostate, S: Stomach, Te: Testis, Th: Thyroid gland, Ur: 
Urinary Bladder, Ut: Uterus (Adapted from Hildrestrand et al, 2009). 
 
Interestingly, high expression levels of NEIL3 and other DNA repair proteins has been 
correlated with the development of metastasis and high mortality rates in patients with 
primary malignant melanoma (Kauffmann et al, 2008). Thus, it has been suggested that 
high levels of DNA repair genes might explain the resistance of melanoma to 
chemotherapy and radiotherapy (Kauffmann et al, 2008). 
 
1.5.3.3 The role of NEIL3 in replication-associated repair 
There is a strong suggestion that NEIL3 has a specific role in repair the replicating 
1genome due to alignment of the NEIL3 sequence with proliferating cell nuclear 
antigen (PCNA) binding proteins and replication protein A binding proteins. 
Replication protein A is a single-strand DNA binding protein, which is required during 
DNA metabolism (Morland, 2002), while PCNA is a ring-shaped protein that surrounds 
the DNA and enhances the processivity of DNA synthesis by binding the catalytic 
subunit of the replicative DNA polymerase with the DNA template. PCNA has 
additional tasks in the nucleus as it deals with remodeling the chromatin structure and it 
is a cofactor for DNA polymerase ε, which explains the function of the PCNA in DNA 
repair. Moreover, PCNA exerts its role in genome replication through stimulation DNA 
polymerase δ (Kelman, 1997).  
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1.5.3.4 The immunological role of NEIL3 
Since Mmu NEIL3 is highly expressed in spleen, lymph nodes, thymus, B cells and 
bone marrow along with a marginal decline in the numbers of mouse white blood cells 
after NEIL3 knockout, it has been suggested that NEIL3 has a function in the immune 
system (Torisu et al, 2005; Hildrestrand et al, 2009).  
Furthermore, several DNA glycosylases are involved in promoting the mutated 
immunoglobulin genes. A good example of this is uracil DNA glycosylase (UDG) 
which recognizes the mismatched base pairs (dU: dG) in the immunoglobulin genes 
during B cell differentiation by class switch recombination (CSR) and somatic hyper 
mutation (SHM). dU: dG damages are produced via deamination of deoxycytidine (dC) 
residues in the single-strand DNA which leads to antibody gene diversification. 
However, UDG initiates the switch recombination through cleaving the strand at abasic 
sites by using the AP-endonuclease (Rada et al, 2004; Dominguez and Shaknovich, 
2014).  
 
1.5.3.5 NEIL3 and human immunodeficiency virus type 1 (HIV-1)   
HIV-1 is an RNA virus that belongs to the retrovirus family. Due to the fact that the 
length of the HIV-1 genome is about 9.8 kb and it is responsible for encoding only 15 
proteins, HIV uses host proteins to complete all the steps of its reproductive cycle. 
These steps include entrance of the nucleoprotein core of the virus into the host cell, 
followed by reverse transcription phase then the viral double-stranded DNA is imported 
into the cell nucleus and integrated into the target chromosomes. After that, the provirus 
is transcribed into viral mRNA and translated into viral proteins then the assembled new 
viral particles are released to the cytoplasm (Goff, 2007; Lama and Planelles, 2007).     
Although there have been major advances in antiretroviral therapy, many patients are 
still suffering from drug resistance. It was estimated that about 35.3 million people are 
infected globally by HIV-1. As the current antiretroviral agents block the viral enzymes, 
which include viral protease, reverse transcriptase and integrase, mutation emerges in 
these enzymes that can make the HIV-1 therapeutics ineffective. For that reason, there 
is a need for novel antiretroviral drugs that target the host proteins (Asamitsu et al, 
2015).  
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To illustrate the cellular factors that are linked to HIV-1 replication, Zhou et al (2008) 
carried out genome-wide small interference RNA (siRNA) experiment on HeLa P4/R5 
cells. These cells were transfected with siRNA and after 24 h they were infected with 
HIV-1 and the DNA was isolated. siRNA is a technique used to identify the biological 
role of specific genes by applying small double-strand RNA (sdRNA) to the cytoplasm 
of the cell which results in silencing the expression of the target gene (Elbashir et al, 
2001). About 311 cellular genes were detected in this screen, which influence the 
existence of HIV-1. Of these, 267 genes are not previously recognized. Interestingly, 
NEIL3 was discovered as one of the host cellular cofactors, which are needed for 
integration the HIV-1 cDNA into the host genome. However, this virus host interaction 
is very important for the life cycle of HIV-1 and for its replication as knocking down of 
NEIL3 mRNA led to decrease the HIV infection and hinder its integration to the cell. 
Furthermore, cDNA rescue experiments were conducted in a non-targeted form, which 
confirm the function of the identified host genes (Zhou et al, 2008). 
 
1.6 Telomeres 
The termini of mammalian linear chromosomes are capped with telomeres, which serve 
as one of the biological indicators for aging. Telomeres were first recognized in the 
1930s and consist of nucleoprotein complexes in a form of approximately 9-15 kb 
telomeric repeated 5' TTAGGG 3' sequences and telomeric binding proteins (Wang et 
al, 2015).  
In addition, telomeres end with a conserved structure of about 150 bp 3'G overhanging 
single-strand (Raynaud et al, 2008; Zhou et al, 2015).  Telomeres have vital functions in 
which they hinder uncontrolled cell proliferation and they conserve the subtelomeric 
regions from end to end fusion and the deleterious effects of nucleolytic activities such 
as DNA degradation. Furthermore, the peripheral parts of chromosomes are 
distingushed from double-strand DNA breaks by the structure of the telomeres and 
thereby the genomic integrity is protected (McEachern et al, 2000; Hug and Lingner, 
2006; Degerman et al, 2014). 
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1.6.1 Factors that influence telomere length 
Studies conducted on telomere length have demonstrated the factors, which are 
implicated in loss of telomere repeats. These factors are divided into environmental, 
genetic and cellular factors; telomeres become significantly shortened as a result of the 
cellular factors and this decline in telomere length is enhanced via environmental factors 
(Njajou et al, 2007). 
Owing to the process of DNA replication, which is incapable of entirely replicating the 
telomeric DNA (the activity of DNA polymerases is unidirectional 5'→3'), gradual 
shorting of the telomeres occur. In addition, degenerative activities and nonhomologous 
end-joining of telomeric DNA shorten the telomeres as well. However, short telomeres 
promote replicative senescence or chromosome instability, which ends with generation 
of cancer cells (Andrew et al, 2006). Alter et al (2012) measured the length of the 
telomere by automated multicolour flow fluorescence in situ hybridization in peripheral 
white blood cells subtypes. The authors concluded that short telomere length is linked to 
inherited genetic diseases such as dyskeratosis congenita (inherited bone marrow failure 
syndrome), aplastic anemia and mutation in some genes e.g. TERT. Additionally, the 
authors noticed that the length of telomere reflects the severity of the associated 
diseases and decrease with aging. Moreover, short telomere length is related to 
dementia, atherosclerosis and cardiovascular diseases (Saretzki and Von Zglinicki, 
2002; Andrew et al, 2006).  
In terms of the environmental factors and their effects on telomere length, Valdes et al 
(2005) tested the association between telomeres, body weight and cigarette smoking. 
The authors reported that the length of telomeres in obese females reduced by 240 bp 
when they were compared with telomeres of the normal females and every pack-year 
smoked was equal to 5 bp of telomeres lost. Therefore, oxidative stress is implicated in 
telomere attrition. In addition, Gardner et al. (2005) examined the relation between 
insulin hormone and the length of telomeres in leukocyte cells. The authors stated that 
white blood cells telomere length is inversely correlated with insulin resistance. 
Additionally, poorly controlled type 2 diabetes mellitus and hypertension are linked 
with short leukocyte telomeres (Aviv, 2002; Biron-Shental et al, 2015; D'Mello et al, 
2015). 
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There is a wide disparity in the length of telomeres in human organs and among people. 
Takubo et al (2002) tested the telomere lengths in the human cerebral cortex, 
myocardium, liver, renal cortex and the spleen in relation to the age. The authors 
reported that the telomeres decrease by 29-60 base pair (bp) per year in liver, spleen and 
renal cortex. However, the authors confirmed that the reduction rates of telomere do not 
involve the myocardium and cerebral cortex and the myocardium has the longest 
telomeres, whereas the renal cortex and liver have the shortest telomeres.  
Moreover, Okuda et al (2002) examined telomere length by calculating the mean length 
of the terminal restriction fragments (TRF) in different ages and in both sexes. The 
authors sum up that all intrauterine fetuses have different lengths of telomeres but that 
telomere length in their organs is similar. Then as a result of postnatal circumstances, 
this length was subjected to change. Additionally, comparing both genders, telomere 
lengths are shorter in men than in women, which were explained by the influences of 
estrogen on a female’s telomeres, as it stimulates the degradation of ROS (Aviv et al, 
2002). 
ROS are generated via Fe2+-mediated Fenton reaction and these species enhance 
numerous abnormalities in all cellular components. As oxidative agents prefer G-rich 
sequences, thus telomeres are favored to be altered as they have runs of triplet guanines. 
Furthermore, telomeric DNA has high binding activity to Fe2+ (Rai et al, 2005). 
However, the most common oxidized base lesion in telomeres is 8-oxoG, which is 
repaired by OGG1. 8-oxoG interrupts telomerase, reduces the activity of the binding 
proteins (TRF1 and TRF2) and even the DNA repair mechanism at telomeres is less 
effective compared with non-telomeric DNA as a result of the failure of OGG1 to 
remove 8-oxodG from the 3'-overhang (Rhee et al, 2011).  
 Kawanishi and Oikawa (2004) concluded that oxidative stress accelerates telomere 
shortening through the generation of oxidized guanine in the telomeric DNA. In 
addition, it was confirmed that oxidative stress induces single-strand breaks in telomeric 
DNA (Von Zglinicki et al, 2000; Honda et al, 2001).  
To assess the effect of genetics on telomere length, many studies were carried out. 
Nawrot et al (2004) said that telomere repeat factor (TRF) length is linked to X 
chromosome. Furthermore, another report revealed the pattern of inheritance in 
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telomeres is father-to-offspring (Nordfjäll et al, 2005). In addition, Vasa-Nicotera et al 
(2005) identified the mean TRF length is linked to a locus on chromosome 12. Then 
Andrew et al (2006) measured the mean TRF length via Southern blotting analysis in 
both homozygotic and dizygotic twins; the authors stated that a robust association 
between the telomere length and loci on chromosomes 14q23.2, 10q26.13 and 3p26.1. 
However, recently it has been demonstrated that maternal factors are also implicated in 
telomere length maintenance (Asghar et al, 2015). 
 
1.6.2 Factors regulating telomere homeostasis 
To tackle the issues caused by decreasing the telomere length, vertebrate cells maintain 
the stability of the genomic telomeres with each cell cycle proliferation by many genes, 
including TERT, UP1, Tankyrase, EST1, EST2, EST3, YKU70, SIR4 and RIF2 (Njajou 
et al, 2007). 
Telomeric DNA sequences are bound by six specific chromosomal proteins, collectively 
known as shelterin: telomere repeat factor 1 and 2 (TRF1, TRF2), TRF-1 interacting 
nuclear factor 2 (TIN2), repressor activator protein 1 (Rap1), tripeptidyl peptidase 1 
(TPP1) and protection of telomere protein 1 (POT1) (Raynaud et al, 2008). POT1 binds 
to single-stranded G-rich telomeric sequences and it plays a major role in maintaining 
telomere length. This function was illustrated by loss of the telomeric DNA following 
the deletion of the POT1 gene (Baumann and Cech, 2001).  
Shelterin has numerous roles to prevent the loss of the genomic sequences such as 
controlling the protection of telomeres via telomerase, inhibition of the ATM and ATR 
kinase signaling pathways and avoidance of nonhomologous end fusion (de Lange, 
2005; Palm and de Lange, 2008). Shelterin proteins assist telomeres to exist in a T-loop 
form with 3'-single-stranded overhang invading double-strand telomeric DNA. The 
stability of telomeres is affected by interruption of the T-loop, therefore the 3'-overhang 
will be exposed (Figure 1.16) (Rhee et al, 2011). 
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Figure 1.16: Structure of telomere. (A) Shelterin proteins such as TRF1, TRF2 and 
POT1 help in stabilisation telomere into a structure known as T-loop. T-loop is formed 
by folding back of the 3' G-rich, single-stranded overhang then it invades the double-
strand part of telomeric DNA. (B) During DNA replication, shortens of telomere occur. 
(C) Loss of telomere is recognized by DNA damage response genes such as p53 which 
ends in apoptotic cell death. (D) TERT is the catalytic subunit of telomerase that is 
responsible to maintain the length of telomere in cancer cells (Adapted from Ben-Porath 
and Weinberg, 2004).   
 
 
1.6.3 Telomerase 
Telomerase (telomere terminal transferase) is ribonucleoprotin complex; the activity of 
which was first identified by Greider and Blackburn (1985) in the protozoan 
Tetrahymena (Vaziri et al, 1993). Then the telomere terminal transferase was detected 
in human tumour cells by Morin (1989). The structure of telomerase allows the addition 
de novo of telomeric TTAGGG repeats to overcome the loss of telomere length that 
accompanies each cell division. Subsequently, it was confirmed that telomerase plays a 
very important role in immortal cells such as neoplastic cells and germ line cells (Figure 
1.17) (Aviv et al, 2002). 
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Figure 1.17: The activity of telomerase in different cell types. (A) Normal cells lose 
about 50-100 bp of telomere length with each proliferation cycle. (B) The size of 
telomere in pre-senescent cells is about 8-10 kb. (C) Telomere length decreases 
significantly in senescent cells and its final size is around 5-8 kb. (D) Owing to marked 
shortening in telomere, cells in phase M2 start to express telomerase. (E) Telomere 
length is synthesized by telomerase. (F) Cancer cells immortalized express high levels 
of telomerase (Saldanha et al, 2003).           
 
Telomerase is an RNA-dependent DNA polymerase that is composed of two 
components; an RNA template known as human telomerase RNA component (hTERC) 
which adheres to the 3' overhang of telomeres. This subunit contains 11 nucleotides (5'-
CUAACCCUAAC) complementary to telomeric hexanucleotides sequences. The 
second component of telomerase is human telomerase reverse transcriptase (hTERT) 
and this catalytic subunit synthesizes TTAGGG repeats from hTERC (Newbold, 2002) 
(Figure 1.18). hTERC gene is mapped to chromosome 3q26.3, while hTERT gene is 
localized on chromosome 5p15.33 (Bryce et al, 2000).    
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Figure 1.18: The activity of telomerase on the telomeric termini. The two components 
of telomerase (hTERT and hTERC) act to replace the loss in the telomeric sequences 
(Adapted from Raynaud et al, 2008).                                   
                     
It was found that more than 85% of neoplastic cells express telomerase (telomerase-
positive cells) and the level of telomerase in these cells is higher than in germ cells and 
stem cells. Significantly, most somatic cells do not express telomerase. In addition, the 
activity of telomerase is controlled via hTERT; c-myc, interleukin-6 and insulin-like 
growth factor lead to hTERT upregulation. On the other hand, retinoblastoma protein, 
protein phosphatase 2A (PP2A), cyclin-dependent kinase inhibitor p21 and p53 cause 
hTERT downregulation (Tahtouh et al, 2015).  
Furthermore, the level of hTERT mRNA is strongly correlated with the activity of 
telomerase and induction of this activity induces tumourgenesis (Newbold et al, 2002). 
Recently, telomeric repeat-containing RNA (a long noncoding RNA) which arises from 
subtelomeric sites has been shown to have a vital role in telomerase homeostasis 
(Giardini et al, 2014). 
Approximately 15% of cancer cells are telomerase-independent cells, including soft 
tissue sarcoma, osteosarcoma, some types of brain cancer such as medullobastoma, 
glioblastoma, astrocytoma and oligosarcoma, ovarian carcinoma, breast carcinoma, 
gastric carcinoma, heptoblastoma and adrenocortical carcinoma. Many studies have 
been conducted to identify the mechanism that allows these cells to maintain the length 
of telomeres, as the average telomere length in cancer cells lacking telomerase is 
between 3 kb-59 kb (Morrish et al, 2013). This mechanism was named alternative 
lengthening of telomeres (ALT) and was first recognized by Bryan et al (1995). ALT is 
a homologous recombination-based DNA replication pathway and it is regulated 
through numerous genes, including Rad50, Rad51, MRN complex, SMC5/6, Mus81-
EME1 Top3a, FANCD2 and FANCA (Morrish et al, 2013).  
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Importantly, telomerase-negative cancer cells have a unique feature by possessing C-
overhang structure (cytosine-rich single-stranded 5' telomeric overhang) and this 
structure was identified as having a significant role in the ALT mechanism. Thus, 5'-C-
overhangs could be targeted in the treatment of telomerase-negative neoplastic cells 
(Oganesian and Karlseder, 2011; Školáková et al, 2015). 
 
1.6.4 The association between telomeric proteins and DNA repair mechanisms       
Many DNA repair proteins exert a vital role in maintenance of telomere length 
(Slijepcevic, 2006). The telomeric DNA of mammalian cells possesses repetitive 
noncoding sequences of G-rich oligonucleotides. In vitro experiments, which were done 
under physiological salt conditions, illustrated that; telomeric sequences were folded to 
generate guanine quadruplex (G4) structures (Smith and Feigon, 1992).  
The basic structure of G4 is two or more layers of four guanines. Each layer composed 
of four guanines, which bind together through Hoogstein base pairs. Monovalent cations 
eg Na+ and K+ fix each layer onto the other (Zhou et al, 2013).  
Additionally, G4 telomeric structures were implicated in the loss of the stability of 
telomeres via blocking the action of telomerase. Moreover, they have an essential role 
in the control of DNA replication, transcription and mRNA translation (Lipps and 
Rhodes, 2009).  
Taking all the previous information together, medical intervention should be targeted 
toward telomeric guanine quadruplexes in the treatment of tumours (Neidle and Read, 
2000; Chen et al, 2008). However, many suggestions were raised about the formation of 
G4 in mammalian cells (Biffi et al, 2013). Yang et al (2009) first confirmed the 
existence of G4 structure in human telomeres by designing a novel cyanine dye 
supramolecular assembly. By this means, more than 3.0 x 104 quadruplex sequences in 
the genomic DNA of vertebrates was estimated (Wu and Brosh, 2010).  
Of all the four bases in DNA, guanine is more liable to oxidative damage. Therefore, G4 
is the preferred target for oxidative stress, which is produced via DNA charge transport 
(Coluzzi et al, 2014). Oikawa et al (2001) examined the influence of UVA irradiation 
on telomeric sequences in mammalian cells and reported that 8-oxoG was induced over 
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5 fold more frequently in telomeric DNA than in nontelomeric DNA sequences. This 
led the authors to conclude that UVA radiation leads to loss of the telomere length via 
DNA damage at guanine sequences. Moreover, Szalai et al (2002) stated that the 
activity of telomerase is affected by the deleterious effects of the oxidized guanine. 
Furthermore, shelterin proteins such as TRF1 and TRF2 are disrupted by 8-oxoG 
(Opresko et al, 2005). Further oxidation of 8-oxoG leads to the generation of Gh and Sp 
and it has been shown that Gh and Sp led to blocking of the DNA polymerase at the 
telomeric sequences. Thus, the replication of the telomeric DNA will be discontinued 
(Aller et al, 2010). 
Therefore, repair of telomeric oxidative DNA lesions should be carried out to preserve 
genomic integrity. Zhou et al (2013) investigated the activity of the mammalian 
oxidative DNA glycosylases (NTH1, OGG1, NEIL1, NEIL2 and Mmu NEIL3) on 
telomeric quadruplex guanine; the results showed that Mmu NEIL3 has the ability to 
excise Tg, Gh and Sp from the damaged telomere, while NEIL1 can remove Sp and Gh 
from G4. On one hand, the authors found Tg is a preferred substrate for Mmu NEIL3, 
while on the other, NEIL1 exerts high excisional activity towards Gh in the telomeric 
DNA. Nonetheless, the authors were unable to identify any physical relation between 
NEIL3 and shelterin proteins such as TRF1 and TRF2 in mammalian cancer cell lines 
by co-immunoprecipitation. Moreover, the authors emphasised neither NEIL1, Mmu 
NEIL3 nor OGG1 have the ability to excise 8-oxoG from the telomeric G4. Therefore, 
in comparison with the other parts of chromosomes; telomeric DNA has abundant of 8-
oxoG lesions. Recently, Zhou et al (2015) have confirmed the significant role of both 
NEIL1 and the DNA glycosylase domain of human NEIL3 on removing the oxidized 
base damage from telomeres via BER. Thus, the stability of telomeres will be 
maintained.  
 
1.7 Genotoxic drugs 
Since cytotoxic drugs have been incorporated in the management protocol to treat 
different sorts of tumours, significant improvement in the mortality rate has been 
observed. Nevertheless, there are some issues, which hinder the effectiveness of these 
agents. One of the main issues is drug toxicity as the chemotherapeutic drugs destroy 
both malignant cells and healthy cells. Thus, novel medical interventions should be 
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discovered to target specific markers of tumour cells. In addition, optimization the 
chemotherapeutic doses has an essential role in decreasing the side effects of these 
medications (Pfister et al, 2006; Weidmann et al, 2014).  
Another issue is drug resistance, which could be inherent or acquired, and it occurs 
through many mechanisms; changes in the drug target, loss of the drug activity, decline 
in drug accumulation via elevated drug efflux or reduced drug uptake and avoidance of 
apoptosis. Therefore, further experiments should focus on the molecular pathways of 
drug resistance to design new antitumour compounds, which have high sensitivity and 
specificity (Brabec and Kasparkova, 2005). 
   
1.7.1 Cisplatin 
Platinum-derivative compounds such as cisplatin, carboplatin and oxaliplatin are a 
specific class of chemotherapeutic agents that are widely used by many oncologists to 
treat patients with tumours (Hato et al, 2014).  
Cisplatin was first synthesized in 1845 by Michel Peyrone (de Biasi et al, 2014). Then 
Rosenberg et al (1965) confirmed the inhibitory effect of cisplatin on E. coli cell 
division. Four years later, Rosenberg discovered the antineoplastic activity of cisplatin 
in a mouse model. Subsequently, this result led scientists to test cisplatin on human 
cancer cells. Since that time, cisplatin has become one of the most commonly used 
antitumour drugs (de Biasi et al, 2014). 
Cisplatin [cis-diamminedichloroplatinum (II)] is an inorganic metal-based cytotoxic 
drug, (Figure 1.19) which has been used frequently to treat both children and adult 
neoplasms such as germ cell, lung, testes, ovary, cervix, bladder, head and neck 
tumours. Furthermore, cisplatin can be used as monotherapy or in combination with 
other chemotherapy drugs. Despite the effectiveness of cisplatin in limiting the 
proliferation of cancer cells, numerous adverse effects have been caused by this drug 
e.g. nephrotoxicity, ototoxicity, peripheral neuropathy and bone marrow suppression 
(Shiraishi et al, 2000). 
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Figure 1.19: Chemical structure of cisplatin (Adapted from Pinato et al, 2013). 
 
1.7.1.1 Pharmacokinetic properties of cisplatin                       
Cisplatin has the ability to enter the cells via the following steps: simple passive 
diffusion, active transport mechanisms through a protein gate that binds with Na+ K+-
ATPase pump, H2O phase endocytosis, organic cation transporter (OCT) and copper 
transporters (CTR1/SLC31A1, ATP7A and ATP7B). While cisplatin efflux, is regulated 
by melanosomes, ATP7B dependent vesicles, ATP7A protein and MRP1-5 proteins 
(Hall et al, 2008; Burger et al, 2010; Amable and Fain, 2014). In the cytoplasm of cells; 
through hydrolysis, cisplatin losses the chloride ions and generates reactive mono-aqua 
and di-aqua derivatives. However, these water molecules are positively charged 
electrophiles, which react with nucleophilic sites on DNA (Mandic et al, 2003).  
Detoxification of cisplatin occurs via its conjugation with glutathione by glutathione-S-
transferase (GSTs), thus, patients with low activity of GSTs have a better response to 
cisplatin. On the other hand, these patients may suffer from cisplatin toxicity (Roco et 
al, 2014).       
 
1.7.1.2 Pharmacodynamic properties of cisplatin                       
Cisplatin is an alkylating DNA-damaging agent that inhibits DNA synthesis via a 
mechanism of DNA cross-links. This mechanism leads to the formation of different 
types of cisplatin-DNA adducts including intra- and interstrand cross-links (Roco and 
Cayún, 2014). These adducts occur at the nitrogen in position 7 of guanine (N7) (Pinato 
et al, 2013). 
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Cisplatin-DNA adducts bend and unwind the DNA leading to impairment in the DNA 
repair pathways including nucleotide excision repair, mismatch repair and homologous 
recombinational repair. Finally, the cisplatin modified DNA blocks transcription and 
DNA replication, subsequently ends in cell apoptosis. Moreover, several studies 
conducted on cisplatin-induced cell death revealed that two pathways are implicated in 
cell-cycle arrest, which include the tumour-suppressor protein p53 and the p53-related 
protein p73 (Jordan and Carmo-Fonseca, 2000; Zhang et al, 2010). Although, cisplatin 
is cell cycle-independent, in a few situations it leads to prolongation of G2 phase cell-
cycle arrest (Roco et al, 2014). 
In addition, cisplatin binds with biomolecular targets other than DNA to exert its 
antitumour activity such as proteins and RNA (Mandic et al, 2003). Interestingly, 
cisplatin forms DNA-protein cross-links with sulphur-containing proteins such as 
glutathione and albumin (Wang and Guo, 2007; Pinato et al, 2013). Moreover, it was 
identified that cisplatin has immunogenic effect as it modulates the immune system by 
the following pathways: cisplatin increases the expression of MHC class I, enhances the 
growth of macrophages and T lymphocytes, induces the lytic activity of the cytotoxic 
cells and reduces the immunosuppressive parts of the tumour microenvironment (de 
Biasi and Adusumilli, 2014).          
Zhang et al (2010) examined the cytotoxic effect of cisplatin on the HepG2 cell line 
after abrogation of the XRCC1 gene via transfection of the short hairpin RNAs 
(shRNA). The results showed that inhibition of XRCC1 enhanced the sensitivity of the 
malignant cells to cisplatin. Wu et al (2003) confirmed that knockdown of XPA by 
antisense RNA transfection in human lung cell lines decreases the expression of NER 
and sensitises the malignant cells to cisplatin. 
 
1.7.1.3 Mechanisms of cisplatin resistance 
It has been considered that the cellular resistance to cisplatin is multifactorial, which 
involves limitation in the formation of cisplatin-DNA adducts and prevents apoptosis 
following cisplatin-induced damage by enhancement of DNA repair mechanisms. In 
addition, alterations in the influx cellular transporters of cisplatin such as cMOAT, 
OCT-hSLC22A2, copper transporters and a cis-configuration specific platinum influx 
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transporter have been attributed to decrease the amount of drug accumulation. 
Subsequently, this has led malignant cells to acquire resistance to cisplatin treatment 
(Hall et al, 2008; Burger et al, 2010). Moreover, a high level of cMOAT mRNA (A 
multidrug resistance associated protein that is located on 10q24 chromosome) was 
detected in cisplatin resistant tumour cells (Taniguchi et al, 1996). 
Much research has been carried out to explore the mechanisms of cisplatin resistance in 
tumour cells. Jordan et al (2000) stated that alterations in the mismatch repair pathway 
are associated with cisplatin unresponsiveness. In addition, Ferry et al (2000) reported 
that upregulation of the ERCC1 and XPF genes (NER genes) is related to cisplatin 
resistant cancer cells, while Amable et al (2014) concluded that Gli1 (upstream 
regulator of NER) has an important role in protecting the malignant cells from the DNA 
damaging effects of cisplatin via its effect on c-jun and ERCC1.     
 
1.7.2 tert-butyl hydroperoxide  
Tertiary-butyl-hydroperoxide (t-BHP), is a short chain organic hydroperoxide (simple 
lipophilic alkyl hydroperoxide) that has frequently been used as a model substance to 
illustrate the biological pathways of oxidative stress in many organs such as renal, liver, 
brain and skeletal muscle (Haidara et al, 2008; Tan et al, 2011; Jho et al, 2013). t-BHP 
has been found to have a similar mode of action to lipid hydroperoxides, as it generates 
ROS and produces mitochondrial dysfunction (Cheng et al, 2007). 
                                                                                 
1.7.2.1 Pharmacokinetic properties of tert-butyl hydroperoxide                      
t-BHP is metabolised by two pathways and both of them lead to oxidative damage. The 
first pathway is mediated via cytochrome P450, which generates peroxyl and alkoxyl 
radicals. The second pathway involves the action of glutathione peroxidase, which 
ultimately induces t-butanol and glutathione (γ-L-glutamyl-L-cysteinylglycine, GSH). 
However, GSH is oxidized to glutathione disulphide (GSSG) (Cacciatore et al, 2010; 
Tan et al, 2011; Kučera et al, 2014).  
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1.7.2.2 Pharmacodynamic properties of tert-butyl hydroperoxide     
Several articles have investigated the different mechanisms of how t-BHP causes 
cytotoxic biochemical changes. Schnellmann (1988) examined the mechanism of 
oxidative injury caused by t-BHP in the proximal renal tubules of rabbit stating that t-
BHP exhibits its cytotoxic action via enhancement of lipid peroxidation of 
polyunsaturated fatty acids, which alters the permeability of the cell membrane. In 
addition, Buc-Calderon et al (1991) reported that t-BHP increases the level of 
intracellular calcium ions and reduces the level of cellular GSH (GSH is a powerful 
antioxidant protein); both of them lead to apoptotic cell death (Kang et al, 2011; Choi et 
al, 2015).      
Adams et al (1994) recognized that t-BHP is a neurotoxic agent that exerts its action 
through its major metabolite (tert-butanol) on different sorts of brain cells (astrocyte 
cells, oligodendrocyte cells and endothelial cells) and t-BHP has a major role in 
damaging dopaminergic, GABAergic and cholinergic neurons. Furthermore, Guidarelli 
et al (1997) concluded that t-BHP induces single-strand DNA breaks and it is 
implicated in hydrogen peroxide formation.                                                                                                
Haidara et al (2002) conducted a study on rat liver cells by applying t-BHP to identify 
the pathogenesis of oxidative stress-induced apoptosis based on cytochrome c as an 
apoptotic signal. Finally, the author stated two main conclusions. Firstly, the 
involvement of the cytosolic cytochrome c as it was released from the mitochondrial 
membrane in response to oxidative damage. Secondly, t-BHP induces two types of cell 
death depending on its concentration; a dose less than 0.4 mM is associated with 
apoptosis, while a dose higher than 0.4 mM is associated with necrosis. Furthermore, 
Lin et al (2014) stated that t-BHP is an oxidative stress-inducing drug that causes 
oxidative DNA damage in many cells mainly by alkoxyl and alkyl radicals.  
 
1.7.3 Doxorubicin 
Doxorubicin (DOX), also known as Adriamycin, belongs to the anthracycline group of 
compounds (Figure 1.20). DOX was the first anthracycline compound to be idenitifed 
and was first isolated from the soil bacterium Streptomyces peucetius var. caesius in the 
1970’s (Thorn et al, 2011; Yang et al, 2014).  
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DOX is a highly effective antineoplastic antibiotic, which is commonly used by many 
oncologists to treat different types of tumours including sarcoma, lymphoma, 
leukaemia, bladder, liver, lung, thyroid and breast cancer (O'Brien et al, 2004; Smith et 
al, 2010; Girotti and Minotti, 2013).  
 
                                                                                                           
Figure 1.20: Chemical structure of doxorubicin (Adapted from Kostrzewa-Nowak et al, 
2005).    
 
DOX has significant side effects that limit its pharmacological use, such as cardiac 
contractility dysfunction, which leads to dose-cumulative cardoitoxicity and skeletal 
muscle myopathy. However, it has been identified that DOX-mediated muscle toxicity 
is mainly caused by the emission of mitochondrial ROS and stimulation of the cysteine 
protease calpain. Therefore, a highly selective mitochondrial-targeted anti-oxidant agent 
along with calpain inhibitor should be offered to ameliorate the undesirable effects of 
DOX on both skeletal and cardiac muscles (Min et al, 2015).  
Interestingly, molecular studies conducted to understand the mechanism of DOX-
induced myopathies, revealed that DOX increases the expression of FoxO (forkhead-
box O) gene and that exercise can protect the muscles from DOX toxicity (Kavazis et 
al, 1985). Furthermore, the active metabolite of DOX, doxorubicinol, inhibits the 
calcium pumps of the endoplasmic reticulum, interferes with the regulation of iron and 
subsequently leads to the initiation of ROS-induced cell death. Taken together, iron 
chelator compounds such as dexrazoxane protects the cardiomyocytes from the toxic 
influences of DOX (Thorn et al, 2011). 
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In addition to the previously mentioned DOX-associated side effects, a single dose of 
DOX might lead to hair loss, nausea, vomiting, bone marrow suppression and mucositis 
(O'Brien et al, 2004).    
 
1.7.3.1 Pharmacokinetic properties of doxorubicin  
Recently it has been shown that individual genetic differences can influence the 
pharmacokinetics of DOX. The half-life of DOX presents three phases; between 5 to 10 
min, 0.5 to 3 h and 24 to 36 h. About 74%-76% of DOX is bound to albumin. 
Importantly, DOX is metabolized via liver enzymes then it is excreted through the 
biliary tract and it is reduced via carbonyl reductases and aldoketoreductases to its 
active metabolite doxorubicinol. On the other hand, aglycones, glucuronides and 
sulphates are inactive DOX metabolites (Ryu et al, 2014).     
 
1.7.3.2 Pharmacodynamic properties of doxorubicin                         
Doxorubicin exhibits its anti-cancer activity by blocking the activity of topoisomerase 
II.  Topoisomerase II is an ATP-dependent enzyme, which has two isoforms in 
eukaryotic cells named topoisomerase IIα and topoisomerase IIβ. Interestingly, it has 
been shown that DOX exerts its anti-neoplastic action via topoisomerase IIα, while 
topoisomerase IIβ is responsible for DOX-mediated cardiotoxicity (Zhang et al, 2012; 
Yang et al, 2014). Moreover, topoisomerase IIβ inhibitors conserve the cardiac muscles 
from the toxicity of DOX. The previous literature confirmed the inhibition of 
topoisomerase II by DOX prevents DNA synthesis, RNA transcription and replication 
(Vavrova et al, 2013).  
DOX is a bioreductive agent that induces free radicals through cellular oxidoreductases 
such as NADH dehydrogenase, NADPH cytochrome P450 reductase, xanthine oxidase 
and nitric oxide synthase. However, these oxidoreductases convert DOX to an unstable 
semiquinone radical through a pathway of one-electron reduction then followed by 
reoxidation process with oxygen molecule to quinone that ends with the generation of 
ROS (Kostrzewa-Nowak et al, 2005; Finn et al, 2011) (Figure 1.21). ROS leads to 
protein oxidation, lipid peroxidation and DNA cross-linking (Gewirtz, 1999; 
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Macpherson and Evans, 2009). Recently, it has been shown that DOX generates double-
strand DNA breaks around promoters of active genes (Yang et al, 2015).  
 
                                                                              
Figure 1.21: One-electron redox cycling of doxorubicin. The addition of one-electron 
to quinone moiety in DOX generates semiquinone, which reproduces quinone through 
oxygen reduction to ROS. This cycle is enhanced via NADPH oxidoreductases. 
(Minotti et al, 2004).  
  
The cytotoxic impact of DOX on cancer cells can be promoted through the formation of 
DOX-DNA adducts. DOX has a high tendency to bind to adjacent GC base pairs. 
However, the linkage of DOX to one strand of DNA is stabilized via a covalent bond 
between DOX and guanine, which is based on formaldehyde, while DOX is linked to 
the guanine on the other DNA strand through a hydrogen bond. Importantly, it has been 
identified that DOX-sensitive neoplastic cells have higher levels of formaldehyde than 
DOX-unresponsiveness neoplastic cells. Thus, more DOX-DNA adducts have an 
essential function in increase the responsiveness of tumour cells to DOX (Forrest et al, 
2012; Yang et al, 2014).     
DOX-induced apoptosis is also mediated by increase the release of ceramide. Ceramide 
consists of sphingosine and a fatty acid and is implicated in cellular growth arrest 
(Senchenkov et al, 2001; Kawase et al, 2002). 
Pang et al (2013) identified a novel mechanism that allows anthracycline agents 
independent of topoisomerase II to cause apoptotic cell death; this mechanism has been 
termed histone eviction. DOX, which does not trap topoisomerase II, evicts histone 
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variant H2AX. H2AX has an essential role in the DNA damage signalling pathway. 
Therefore, H2AX eviction is linked to impairment in the genome repair mechanism. 
  
1.7.3.3 Mechanisms of doxorubicin resistance 
Tumour cells are characterized by developing numerous pathways to counteract the 
toxic effect of DOX. However, high level of MDR1 mRNA, which encodes the 
membrane-bound glycoprotein, known as P-glycoprotein has been recognized to be 
related to DOX resistant tumour cells. P-glycoprotein has a high molecular weight of 
170 kDa and it functions as a drug discharge pump; therefore, it decreases the 
accumulating intracellular drug level (Ueda et al, 1987; Senchenkov et al, 2001). Thus, 
to reverse the resistance that arises from alteration in P-glycoprotein, a novel delivery 
method of DOX was designed to treat osteosarcoma resistant tumour cells, namely 
lipid-modified dextran-based polymeric nanoparticals. This new drug delivery mode 
enables co-delivery of DOX and MDR1 siRNA and promises to oppose the effect of P-
glycoprotein induced DOX resistance in cancer cells (Susa et al, 2010). Additionally, 
Akman et al (1990) stated that high levels of glutathione peroxidase mRNA is 
associated with DOX resistance in tumour cells.  
It has been reported that tumour cells which express low levels of topoisomerase II are 
resistant to DOX, whereas neoplastic cells with high levels of topoisomerase II are 
sensitive to DOX. Thus, the activity of topoisomerase II could be used to predict the 
clinical response of malignant cells to topoisomerase II targeted chemotherapeutics 
(Holden, 1997). In addition, the amplification of human epidermal growth factor 
receptor-2 (HER-2/ERBB2) which is close to topoisomerase IIα on chromosome 17 has 
been identified to have an association with DOX-resistant cells (Oakman et al, 2009; 
Thorn et al, 2011). Additionally, Itoh et al (2003) confirmed that low levels of ceramide 
are associated with DOX-insensitive cells. Furthermore, overexpression of GCS 
(glucosylceramide synthase enzyme that is responsible for converting ceramide to 
glucosylceramide) is correlated with loss of response to DOX on tumour cells (Uchida 
et al, 2004).  
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Aims of the project 
Although previous studies have shed light on the biochemical and cellular role of 
NEIL3, particularly in the developing brain (Hildrestrand et al, 2009), the question of 
why its expression is conserved in vertebrate cells has not been answered. In cancer 
cells, high levels of NEIL3 have been determined when compared with normal cells. 
Moreover, recent work has shown that NEIL3 is involved in the excision of hydantoin 
lesions from telomeric and other G-quadruplex regions in DNA. Therefore, it was 
hypothesized that NEIL3 might decrease the sensitivity of paediatric tumour cells to 
certain genotoxic chemotherapeutic compounds. The main purpose of this study was to 
verify the gene expression of NEIL3, hTERT and POT1 in several paediatric cancer cell 
lines of different origin and then to determine any association between the levels of 
NEIL3 expression and the presence or absence of telomerase in these cells. In addition, 
the sensitivity of ALL and hepatoblastoma cells to cisplatin, doxorubicin and tert-butyl 
hydroperoxide (t-BHP) was determined in order to compare the response of these cells 
to the levels of NEIL3 determined. 
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Chapter 2: Materials and Methods  
2.1 Materials  
The materials used in this study include chemicals, kits and primers. All of them are 
illustrated in the following Tables with their catalogue numbers and the suppliers. 
 
2.1.1 Chemicals  
All the chemicals (include reagents, cell culture media, and cytotoxic drugs) required to 
carry out the experiments are listed in Table 2.1 
Table 2.1: List of Chemical substances 
No Name of the chemical substances Supplier company Catalogue 
number 
1 MEM Non-essential Amino Acid 
Solution (100×)  
Sigma-Aldrich, UK M7145-100ML 
2 Dulbecco's Modified Eagle's Medium 
(DMEM)    
Sigma-Aldrich, UK D6429-
6X500ML 
3 RPMI-1640 (SLS) Scientific 
Laboratory Supplies, 
UK  
LZ12-167F24 
4 Lonza McCoy's 5A with glutamine 
and 25mM Hepes (500 ml)  
(SLS) Scientific 
Laboratory Supplies, 
UK  
LZBE12-168F 
5 Foetal bovine serum heat inactivated 
(FBS)   
(SLS) Scientific 
Laboratory Supplies, 
UK  
F9665-50ML  
6 95% Ethanol Fisher, UK E/0600/05 
7 Penicillin/Streptomycin  Labtech LM-A4118/100 
8 Phosphate buffer saline 10X (PBS) Fisher, UK 10214733 
9 Dimethyl sulfoxide hybri-max sterile 
filtered (DMSO) 
(SLS) Scientific 
Laboratory Supplies, 
UK 
D2650-5X5ML 
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10 Trypsin  1X (500 ml) Labtech LM-T1705/500 
11 L- glutamine  1X (100 ml) Labtech XC-T1715/100 
12 Boric acid Fisher, UK BP168-1 
13 Agarose Bioline, UK BIO-41025 
14 Virkon Fisher, UK 005414182 
15 EDTA-sodium-salt Sigma-Aldrich, UK E6760 
16 GelRed Nucleic acid stain Biotinum 41002 
17 Hyperladder I marker, 1 kb Bioline, UK BIO-33026 
18 NaOH Sigma-Aldrich, UK S8045-500G 
19  Phenazine methosulfate ≥90%, 
(PMS) 
Sigma-Aldrich, UK P9625-1G 
20 CellTiter 96AQueous MTS Reagent 
Powder, 250mg (MTS)  
Promega, UK G1112 
21 MTT [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide] 
Sigma-Aldrich, UK M2122-5G 
22 Cisplatin    Sigma-Aldrich, UK C2210000 
23 Doxorubicin hydrochloride 
98.0-102.0% (HPLC)    
Sigma-Aldrich, UK D1515-10MG" 
24 tert-butyl hydroperoxide solution 
70% (w/v) 
Sigma-Aldrich, UK 458139-25ML 
25 NaCl B.P. 0.9% (w/v) Fisher, UK BP358-1 
26 RNase free water.                                                          Fisher, UK BP561-1 
27 Tris base Fisher, UK BP152-1 
28 2-mercaptoethanol (B-ME) Sigma-Aldrich, UK M3148 
29  MyTaq Red Mix, 2X Bioline, UK BIO-25044 
30 Bromophenol blue Sigma-Aldrich, UK 114391-5G 
 
 
2.1.2 Kits and other lab consumables  
All kits and other lab consumables used in the study are shown in Table 2.2                                                   
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Table 2.2: List of kits 
No Name of kit Supplier 
company 
Catalogue 
number 
1 ISOLATE II RNA Mini Kit  Bioline, UK BIO-52072 
2 GoScript Reverse Transcription System  Promega, UK A5000 
3 Sensi Fast SYBR Lo-ROX Kit 500 x 20 µl 
Reactions 
Bioline, UK BIO-94005   
4 8-Strip PCR Caps, Flat (X-Clear)  Starlab, UK I1400-0900 
5 96-Well PCR Plate, Skirted, Low-Profile Starlab, UK E1403-5209 
6 6 well plate standard with lid Greiner bio-one 657102 
7 96 Well Cell Culture Plate Sterile, U-bottom 
with lid 
Greiner bio-one 650180 
8 96 Well Cell Culture Plate Sterile,  
F-bottom with lid 
Greiner bio-one 655180 
  
2.1.3 PCR Primers 
The sequences of primers used to assess the expression of the target genes are shown in 
Table 2.3, all of them were purchased from Eurofins Genomics. 
Table 2.3: Real time PCR primers                                                                                                                                                          
No Real time PCR Primers Sequence 5' to 3' Tm 
1 Gapdh 1014 (Forward) GGTGGTCTCCTCTGACTTCAACA 61.82oC 
2 Gapdh 1140 (Reverse) GTTGCTGTAGCCAAAATCGTTGT 60.55oC 
3 NEIL3 1651 (Forward) CGCCTCTGCATTGTCCGAGT 62.29oC 
4 NEIL3 1798 (Reverse) TGGAACGCTTGCCATGGTTG 61.80oC 
5 TERT 2605 (Forward) GGAGAACAAGCTGTTTGCGG  60oC 
6 TERT 2744 (Reverse) AGCCATACTCAGGGACACCT 59.96oC 
7 POT1 1416 (Forward) GTCGGGGAATCAGGGTCTTG 60.11oC 
8 POT1 1555 (Reverse) AGAGCTTGGAAAGCTGTCGT 59.61oC 
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Table 2.4: Composition of buffers 
Buffer Preparation 
0.5 M EDTA (Ethylene diamine tetra 
acetic acid) 
18.61 g EDTA-sodium-salt was dissolved 
in 70 ml d-H2O, NaOH was added to 
adjust the pH at 8, and then the final 
volume was made at 100 ml by adding d-
H2O. 
5X TBE (Tris/Borate/EDTA) buffer 54 g Tris was added to 27.5 g Boric acid + 
900 ml d-H2O, 20 ml 0.5 M (4.65 g) 
EDTA then the total volume of 1 L was 
achieved by adding d-H2O (pH 8.3) 
TE (Tris/EDTA) buffer 0.1 ml of 1 M Tris-HCl was mixed with 
0.02 ml of 500 mM EDTA, then through 
adding NaOH the pH was adjusted to 8 
Agarose gel loading buffer 25 mg Bromophenol blue was added to 4 
g sucrose and 2.4 ml of 0.5 M EDTA. 
Finally,   d-H2O was added to make a total 
volume of 10 ml. 
 
 
2.2 Methods  
2.2.1 Cell culture 
2.2.1.1 Cell lines 
Two main types of cell lines were chosen to conduct different experiments of this 
research; suspension cells and adherent cells. The suspension cells were two clones of 
human ALL cell lines: CEM-7-14 and CEM-1-15. On the other hand, the adherent cells 
were human medulloblastoma TC-32, human hepatoblastoma HepG2 and two types of 
human osteosarcoma; HOS and Saos-2. The Saos-2 cell line was purchased from 
Sigma-Aldrich, UK (code number: 89050205-1VL), while HepG2 cell line was a kind 
gift from Dr Patricia A Ragazzon, University of Salford. 
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2.2.1.2 Growing and maintaining the suspension cells  
CEM-7-14 and CEM-1-15 cell lines were cultured in complete cell culture medium 
(Table 2.5; RPMI-1640 medium supplemented with 10% foetal bovine serum (FBS), 
1% Penicillin/Streptomycin and 2 mM L- glutamine) and they were maintained in a T75 
flask. These flasks were incubated at 37oC, 5% CO2 and a humidified atmosphere.  
Table 2.5: Composition of the complete cell culture media; RPMI-1640, DMEM 
and McCoy's 5A 
Reagent Suspension cells HOS/TC-32 HepG2 Saos-2 
RPMI-1640  89 ml 89 ml   
DMEM   89 ml  
McCoy's 5A    89 ml 
MEM Non-essential 
Amino Acid 
  10 ml  
FBS 10 ml 10 ml 10 ml 10 ml 
Penicillin/Streptomycin 1 ml 1 ml 1 ml 1 ml 
200 mM L- glutamine 1 ml 1 ml 1 ml 1 ml 
 
 
2.2.1.3 Splitting the suspension cells  
The suspension cells were subcultured every 48-72 h when these cells were 70%-80% 
confluent.  The cells were passaged by transferring them to a sterile 30 ml centrifuge 
tube (universal tube), and centrifuged for 3 min at 2000 rpm. After the centrifugation 
was complete, the supernatant was discarded and the cell pellet was resuspended in 2 ml 
of fresh complete medium. Subsequently, each 1 ml of cell suspension was split in a 
new flask containing 9 ml of complete medium to obtain a total amount of 10 ml and a 
dilution of 1:10. Finally, these flasks were returned to the CO2 incubator.  
 
2.2.1.4 Growing and maintaining the adherent cells  
The TC-32 cell line and HOS cell line were grown in RPMI-1640 medium, while 
Dulbecco's Modified Eagle's Medium (DMEM) was used to grow the HepG2 cells and 
McCoy's 5A medium was used for the Saos-2 cell line. All the previously mentioned 
media were supplemented with 10% FBS, 1% Penicillin/Streptomycin and 2 mM L- 
glutamine as shown in Table 2.4. In addition to that, DMEM medium was supplied with 
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MEM Non-essential amino acid solution. These cells were cultured in their media in a 
T75 flask then kept in a humidified atmosphere in a 5% CO2 incubator at 37
oC. 
 
2.2.1.5 Splitting the adherent cells 
The growth of the cells was observed every 2-3 days and the cells split when they were 
more than 70% confluent. The medium was removed and the cells washed with 8 ml 
PBS followed by swirling the flask for about 2 min. After that, PBS was replaced with 1 
ml trypsin and the flask was incubated at 37oC for 3 min. After this period, the flask was 
tapped to increase the detachment of the cells, which was confirmed under microscopic 
examination. Deactivation of the trypsin was achieved by the addition of 10 ml 
complete medium and the cell suspension was centrifuged for 3 min at 2000 rpm. Cells 
were suspended in 2 ml of medium and 1 ml transferred to a previously prepared flask 
with 9 ml of complete cell culture medium. 
 
2.2.1.6 Freezing the suspension cells and the adherent cells  
The freezing medium was prepared by adding 1.8 ml FBS to 200 µl DMSO.  The cell 
pellets of suspension cells and adherent cells were suspended in 2 ml freezing medium. 
Two aliquots of 1 ml of each cell suspension then added to 2 ml cryovials. After that, 
the cryovial was transferred to -80oC for 24 h, before the final storage in liquid nitrogen 
at -196oC.  
 
2.2.1.7 Thawing the suspension cells and the adherent cells 
Frozen cells in cryovial were taken from the liquid nitrogen and placed in a water bath 
at 37oC for a few minutes. After that, 1 ml of complete medium was added to the cell 
suspension followed by centrifugation at 2000 rpm for 3 min to avoid the cytotoxic 
effect of DMSO on the cells. The supernatant was removed and the cell pellet then 
resuspended in 1 ml of the appropriate complete medium. The cells were then added to 
a T75 flask containing 9 ml of complete medium and incubated at 37oC, 5% CO2 
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2.2.1.8 Cell counting 
Counting of the cells was carried out by taking 500 µl of cell suspension from each 
flask and transferring them into a universal tube. After that, 10 µl of the cell suspension 
was transferred onto a haemocytometer and the cells in the four large squares were 
counted by placing the haemocytometer under the light microscope using the objective 
10X. The average cell number was then calculated.  
 
2.2.1.9 Time course of cell growth 
The growth pattern of the cells was observed for 96 h to determine the best time for the 
preparation of the cell pellet and RNA extraction. Each cell line was set up with 
duplicate flasks containing 2x106 cells/12 ml medium and the cells were counted every 
24 h over a period of 96 h. 
 
2.2.1.10 Preparation of cell pellets for RNA extraction                                                                                   
The time course of cell growth indicated that, all cell lines were in the exponential phase 
of growth at 72 h and therefore this was a suitable time for analysing and comparing 
gene expression. Therefore, each cell line was grown for 72 h in a duplicate flask, which 
was loaded with 2x106 cells in 10 ml of complete medium. On the third day, the number 
of cells in four flasks was calculated to insure the increasing in growth rate of these 
cells. Subsequently the volume of the cell suspension containing 5x106 cells for four 
flasks was calculated and centrifuged to form a cell pellet, 1 ml PBS was added and 
these suspensions transferred to 1.5 ml microcentrifuge tubes. Subsequently, they were 
centrifuged at 1200 xg for 5 minutes to form a pellet. The supernatants were discarded 
and the 1.5 ml microcentrifuge tubes were placed in dry-ice before storage at -80oC 
until used for RNA extraction. 
 
2.2.2 RNA extraction                                                                                         
RNA extraction was carried out from the stored pellets of the different cell lines using 
the ISOLATE II RNA Mini Kit following the manufacturer’s guidelines; 350 µl of 
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Lysis Buffer was added to the cell pellet followed by 3.5 µl B-ME (2-mercaptoethanol) 
and mixing on a vortex. The Isolate II Filter was placed in a 2 ml collection tube and the 
lysate was loaded in it, then it was centrifuged at 11,000 xg for 1 min. The flow -
through was transferred into a 1.5 ml microcentrifuge tube, then 350 µl of 70 % ethanol 
was added and mixed by vortexing (2 x 5 s).  
Pipetting  up and down of the lysate was carried out 3 times before it was transferred to 
a 2 ml collection tube which was placed in an Isolate II RNA Mini Column and 
centrifuged at 11,000 xg for 30 s. After that, the column was put in a new 2 ml 
collection tube and the silica membrane was desalted by adding 350 µl of Membrane 
Desalting Buffer and the membrane was dried through centrifuging at 11,000 xg for 1 
min. 
 DNase I reaction mixture was prepared by adding 10 µl of reconstituted DNase I to 90 
µl Reaction Buffer for DNase I (RDN) and mixing conducted by gently flicking the 
tube. Genomic DNA was digested by adding 95 µl DNase I reaction mixture directly 
onto the centre of the silica membrane and incubated at room temperature for 15 min.  
The silica membrane was then washed several times, first by adding 200 µl of Wash 
Buffer RW1, followed by centrifugation at 11,000 xg for 30 s. The second wash was 
carried out by adding 600 µl Wash Buffer RW2, then it was centrifuged at 11,000 xg for 
30 s, the flow- through was discarded and the column was placed into a new collection 
tube. The last wash was achieved by adding 250 µl wash Buffer RW2 followed by 
centrifugation at 11,000 xg for 2 min and the column was placed into a nuclease free 1.5 
ml collection tube.  
Finally, the RNA was eluted by adding 60 µl RNase -free water directly onto the centre 
of the silica membrane followed by centrifugation at 11,000 xg for 1 min.     
Estimation the concentration of RNA in the extracted samples is an important step 
before proceeding in any molecular experiment, particularly when comparing the gene 
expression levels between different cell lines. Nucleic acids only absorb a light with 260 
nm wavelength. Thus, RNA concentration was measured at 260 nm via a photo-detector 
in the spectrophotometer (Bustin et al, 2009). 
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The concentration and the purity of the extracted RNA were measured at an absorbance 
of 260 nm using a Nanodrop 2000 Spectrophotometer (Thermo scientific) by loading 1 
µl from the final product of RNA on the Nanodrop machine.  
The integrity of the extracted RNA was assessed by using 1% agarose gel 
electrophoresis, which was prepared by mixing 0.5 g agarose with 50 ml 0.5X TBE in a 
100 ml flask then heating the mixture in a microwave oven. After the agarose had 
cooled, 2 µl GelRed was added and all the contents were placed in a gel tray. Five 
microliters from each RNA sample was mixed with 3 µl loading buffer and 3 µl d-H2O 
then 2 µl, 4 µl and 5 µl from this mixture was loaded into the gel along with 6 µl 
Hyperladder I marker (prepared by dissolving 2 µl Hyperladder I and 2 µl loading 
buffer in 2 µl d-H2O). The gel was subjected to electrophoresis at 100 V for 70 min. The 
bands were imaged and recorded by using UV transillumination Gene snap software.    
  
2.2.3 Reverse transcription                                                                               
mRNA in the extracted RNA samples was reverse transcribed into cDNA using the 
GoScript Reverse Transcription System kit (Promega) following the manfacturer’s 
instructions. One microgram of RNA was mixed with 1 µl (0.5 µg) oligo (dT)15 and 
nuclease-free water to make a final volume of 5 µl (Table 2.6) and incubated at 70oC for 
5 min. Immediately, it was placed in ice for 5 min then centrifuged for 10 s and kept in 
ice until the reverse transcription mix was added. The reaction mixture for reverse 
transcription was prepared by mixing 4 µl GoScript 5X reaction buffer with 1.5 µl (1.9 
mM) MgCl2, 1 µl nucleotide mix (0.5 mM each dNTP), 0.5 µl of recombinant RNasin 
ribonuclease inhibitor (20 units), 1 µl GoScript reverse transcriptase and 7 µl nuclease 
free water. The RNA – oligo (dT)15 was added to the reaction mixture to make a final 
volume of 20 µl. This was incubated at 25oC for 5 min to ensure annealing of the oligo 
(dT)15 to the mRNA, followed by 42
oC for 60 min. The reverse transcriptase was 
inactivated by heating the reaction at 70oC for 15 min. 
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Table 2.6: Amount of RNA, oligo (dT)15 and nuclease-free water which were used 
to carry out the reverse transcription experiment 
Cell line Amount of RNA to obtain 1 µg 0.5 µg Oligo 
(dT)15 
nuclease-free water 
CEM-1-15 2.5 µl 1.0 µl 1.5 µl 
CEM-7-14  3 µl 1.0 µl 1 µl 
HOS 3.25 µl 1.0 µl 0.8 µl 
TC-32 1.6 µl 1.0 µl 2.4 µl 
HepG2 1.25 µl  1.0 µl 2.75 µl 
Saoa-2 3.7 µl 1.0 µl 0.3 µl 
 
The obtained cDNA was amplified at targeted gene sequences by using specific primers 
through PCR. 
 
2.2.4 Reverse transcription PCR                                                                                                     
Amplification of cDNA sequences of the target genes (NEIL3, hTERT, POT1 and 
Gapdh) was carried out through reverse transcription PCR. Three different 
concentrations of cDNA template were prepared by diluting 1 µl of cDNA with 4 µl TE 
buffer (1:5), 1 µl cDNA with 9 µl TE (1:10) and one sample was used without dilution. 
The primers were prepared by diluting 1 µl (100 pmol) with 9 µl TE (1:10). Each cDNA 
sample was mixed with 2X MyTaq RedMix, forward primer, reverse primer (Table 2.3 
illustrates the sequences of the primers) and the total reaction was made up to 25 µl by 
adding d-H2O (Table 2.7). Table 2.8 shows the conditions of the PCR reaction.            
Table 2.7: Composition of the PCR reaction 
PCR reaction Amount 
 Template cDNA  1 µl 
2X MyTaq RedMix 12.5 µl 
10 µM Forward primer 0.5 µl 
10 µM Reverse primer 0.5 µl 
d-H2O  10.5 µl 
Total 25 µl 
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Table 2.8: PCR conditions, denaturation, Annealing and Extension were set up for 
30 cycles. 
 
Two microliters from each PCR reaction was mixed with 2 µl loading buffer and 6 µl d-
H2O then10 µl was loaded on a 1.5% agarose gel (prepared by mixing 0.75 g agarose 
with 50 ml 0.5X TBE) along with 10 µl Hyperladder I marker (made by dissolving 1 µl 
Hyperladder I and 2µl loading buffer in 7 µl d-H2O). The gel was subjected to 
electrophoresis at 100 V for 70 min. The bands were imaged and recorded using UV 
transillumination and Gene Snap software. Design of hTERT and POT1 primers was 
achieved through NCBI website (Figures 2.1 and 2.2). 
 
POT1 cDNA: 
 
1  gtcagtattt cgccaaacct ccaggcgcca tcagtgtgtg aaccgttacg cagctggtcc 
61 accgcgggcg gagaacaagc gactatgccc agggatcctg cacgcatgcg tggagctgaa 
121 ccgtcagcgt gcgtgtgacg tcacctgcgc gcccgcctaa actcttccta gggttctttc 
181 tagagtacggcagcaagttg tcagattccc tagttgaatt tgctttggac atcagtgtga 
241 agcagaactg atatgccact tgaattaata aaggaagtca atggggtgcc tgaagttcag 
301 ccgctgagta aattacataa agtagatttc ggatccctac agccaggtta caattatagc 
361 aagaaatata ttcagggaaa actttcactt atctcttctt taacttatcg tggaaataaa 
421 acagctgttt tgcagattgg actacaagga caccattgca gtggctagat ttattgtttt 
481 tttagcttct tcatctacaa gcagagatgg taaaccttgc atatttttga aagcatttga 
541 agacctcaaa tcaactgttt atgtttatgt caaatcttta agagattttt ctacagaatc 
601 aatgtctttggttccagcaa caaattatat atatacaccc ctgaatcaac ttaagggtgg 
661 tacaattgtc aatgtctatg gtgttgtgaa gttctttaag cccccatatc taagcaaagg 
721 aactgattat tgctcagttg taactattgt ggaccagaca aatgtaaaac taacttgcct 
781 gctctttagt ggaaactatg aagcccttcc aataatttat aaaaatggag atattgttcg 
841 ctttcacagg ctgaagattc aagtatataa aaaggagact cagggtatca ccagctctgg 
901 ctttgcatct ttgacgtttg agggaacttt gggagcccct atcatacctc gcacttcaag 
961 caagtatttt aacttcacta ctgaggacca caaaatggta gaagccttac gtgtttgggc 
1021 atctactcat atgtcaccgt cttggacatt actaaaattg tgtgatgttc agccaatgca 
1081 gtattttgac ctgacttgtc agctcttggg caaagcagaa gtggacggag catcatttct 
1141 tctaaaggta tgggatggca ccaggacacc atttccatct tggagagtct taatacaaga 
1201 ccttgttctt gaaggtgatt taagtcacat ccatcggcta caaaatctga caatagacat 
PCR Conditions Temperature  Time  
Pre-denaturation 95oC 1 min 
 Denaturation 95oC 10 s                          30  
Cycles Annealing 60oC  10 s 
Extension 72oC  10 s 
Final extension 72oC 5 min  
Soak while end 4oC Hold 
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1261 tttagtctac gataaccatg ttcatgtggc aagatctctg aaggttggaa gctttcttag 
1321 aatctatagc cttcatacca aacttcaatc aatgaattca gagaatcaga caatgttaag 
1381 tttagagttt catcttcatg gaggtaccag ttacggtcgg ggaatcaggg tcttgccaga 
1441 aagtaactct gatgtggatc aactgaaaaaggatttagaa tctgcaaatt tgacagccaa 
1501 tcagcattca gatgttatct gtcaatcaga acctgacgac agctttccaagctctggatc 
1561 agtatcatta tacgaggtag aaagatgtca acagctatct gctacaatac ttacagatca 
1621 tcagtatttg gagaggacac cactatgtgc cattttgaaa caaaaagctc ctcaacaata 
1681 ccgcatccga gcaaaattga ggtcatataa gcccagaaga ctatttcagt ctgttaaact 
1741 tcattgccct aaatgtcatt tgctgcaaga agttccacat gagggcgatt tggatataat 
1801 ttttcaggat ggtgcaacta aaaccccaga tgtcaagcta caaaatacat cattatatga 
1861 ttcaaaaatc tggaccacta aaaatcaaaa aggacgaaaa gtagcagttc attttgtgaa 
1921 aaataatggt attctcccgc tttcaaatga atgtctactt ttgatagaaggaggtacact 
1981 cagtgaaatt tgcaaactct cgaacaagtt taatagtgta attcctgtga gatctggcca 
2041 cgaagacctg gaacttttgg acctttcagc accatttctt atacaaggaa caatacatca 
2101 ctatggatgt aaacagtgtt ctagtttgag atccatacaa aatctaaatt ccctggttga 
2161 taaaacatcg tggattcctt cttctgtggc agaagcactg ggtattgtac ccctccaata 
2221 tgtgtttgtt atgaccttta cacttgatga tggaacagga gtactagaag cctatctcat 
2281 ggattctgac aaattcttcc agattccagc atcagaagtt ctgatggatg atgaccttca 
2341 gaaaagtgtg gatatgatca tggatatgtt ttgtcctcca ggaataaaaa ttgatgcata 
2401 tccgtggttg gaatgcttca tcaagtcata caatgtcaca aatggaacag ataatcaaat 
2461 ttgctatcag atttttgaca ccacagttgc agaagatgta atctaatatt gccatccaat 
2521 ttagcataca taaaatgttg ccactcacct tccctgtttg agcttctttt cctgacctga 
2581 gttttgtatc agcaatgttg atgatgttag catgggtatg ggattagaaa atgtccttac 
2641 cttaaatctc ttggctttta ctgggtgcaa ggtaaataat ggctatggat tttgttttgc 
2701 tttctgtttt gcttttgtac aaagagacct gcttaaacaa gtactgctga gataagtgtc 
2761 tgatcaagct acagtgtact ttaagtagaa atggcaaagt tgctttgttg gggtgctgat 
2821 actgatgatt ttaggataaa ttcatttctt taaacttgta atacatggtt ttattgcttg 
2881 tttctctcca ggatagtaga gatttctcta tttcacctca acctaataaa agtggtcaga 
2941 tttataatgt taatgactta atattatcct tttctaatag tctcatgtaa aatatgccgc 
3001 tattacaact tacaactaat tgaatgagat gttaacttag taaaatagtt tgatttttac 
3061 ctgacagtgt ttgtcaaatt taaaatcatg aatattcaat tttatacaaa catttatata 
3121 tatatatata gatttgtgta tgttatttgc caaagacaga tataaattac ctggtttaat 
3181 attagtgaag aataaataag tgcacacatt tcaactgttt catttatttg ccctaagttg 
3241 agctgaaaaa tgatatgagg caaagaatcg aaataggtgt ggcaatgcag cagatgttta 
3301 gggctgtcta catcccaggt actgtgctaa gcactaaaca tgtatttgat cctcacagca 
3361 acctattttt ccgataagaa atctgaggct tgattgataa gctgacttga ctaagttcac 
3421 acagtttgta aaagctagag tctgtgcctt aattcacata atctctattc agagcctgta 
3481 ctgttaacca ctcaaggatt ctggaacaga agctaacagt tttctgcaac gagtctttga 
3541 cttaaacatc tgaaataaca ttggaaatag attataagag gagtcagtgt gtttttctat 
3601 agtttcaaaa tacttttaac atcttattgt caaaaagatt ggataactga ctttctttgc 
3661 tcataataac tctaaattct agttcctgag tacattaaca catcttcttt acctaactac 
3721 caatgtcccc catcatcgac ttatcagctt gtttgagaca atgagaaaga ctgattttat 
3781 tttcaagaat atagactctt ggttcaaaac attttcagga aaaatatttt aaaaccctac 
3841 agttgaacag gtgtgtttcc gtgttgatga tgtgctcagg atacaaaggt gaaataaaca 
3901 ttttttctgc cttcaggaag ccctcaatct agaagagtag aggtccaaag gtgccatatg 
3961 ttcacactgt gagcctgcaa gatctccacg ttaacaaagg aaaactcttc ctatgaatct 
4021 tcatgatgat aggccatgtc tcttcttatt tttgttttaa ataaacatcc accttatcat 
 4081 gaaaaaaaaa aaaaa                                                                                                                      
 
Figure 2.1: Human POT1 cDNA. The position of the PCR primers used in this study 
are indicated in red. 
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hTERT cDNA 
 
1 caggcagcgc tgcgtcctgc tgcgcacgtg ggaagccctg gccccggcca cccccgcgat 
61 gccgcgcgct ccccgctgcc gagccgtgcg ctccctgctg cgcagccact accgcgaggt 
121 gctgccgctg gccacgttcg tgcggcgcct ggggccccag ggctggcggc tggtgcagcg 
181 cggggacccg gcggctttcc gcgcgctggt ggcccagtgc ctggtgtgcg tgccctggga 
241 cgcacggccg ccccccgccg ccccctcctt ccgccaggtg tcctgcctga aggagctggt 
301 ggcccgagtg ctgcagaggc tgtgcgagcg cggcgcgaag aacgtgctgg ccttcggctt 
361 cgcgctgctg gacggggccc gcgggggccc ccccgaggcc ttcaccacca gcgtgcgcag 
421 ctacctgccc aacacggtga ccgacgcact gcgggggagc ggggcgtggg ggctgctgct 
481 gcgccgcgtg ggcgacgacg tgctggttca cctgctggca cgctgcgcgc tctttgtgct 
541 ggtggctccc agctgcgcct accaggtgtg cgggccgccg ctgtaccagc tcggcgctgc 
601 cactcaggcc cggcccccgc cacacgctag tggaccccga aggcgtctgg gatgcgaacg 
661 ggcctggaac catagcgtca gggaggccgg ggtccccctg ggcctgccag ccccgggtgc 
721 gaggaggcgc gggggcagtg ccagccgaag tctgccgttg cccaagaggc ccaggcgtgg 
781 cgctgcccct gagccggagc ggacgcccgt tgggcagggg tcctgggccc acccgggcag 
841 gacgcgtgga ccgagtgacc gtggtttctg tgtggtgtca cctgccagac ccgccgaaga 
901 agccacctct ttggagggtg cgctctctgg cacgcgccac tcccacccat ccgtgggccg 
961 ccagcaccac gcgggccccc catccacatc gcggccacca cgtccctggg acacgccttg 
1021 tcccccggtg tacgccgaga ccaagcactt cctctactcc tcaggcgaca aggagcagct 
1081 gcggccctcc ttcctactca gctctctgag gcccagcctg actggcgctc ggaggctcgt 
1141 ggagaccatc tttctgggtt ccaggccctg gatgccaggg actccccgca ggttgccccg 
1201 cctgccccag cgctactggc aaatgcggcc cctgtttctg gagctgcttg ggaaccacgc 
1261 gcagtgcccc tacggggtgc tcctcaagac gcactgcccg ctgcgagctg cggtcacccc 
1321 agcagccggt gtctgtgccc gggagaagcc ccagggctct gtggcggccc ccgaggagga 
1381 ggacacagac ccccgtcgcc tggtgcagct gctccgccag cacagcagcc cctggcaggt 
1441 gtacggcttc gtgcgggcct gcctgcgccg gctggtgccc ccaggcctct ggggctccag 
1501 gcacaacgaa cgccgcttcc tcaggaacac caagaagttc atctccctgg ggaagcatgc 
1561 caagctctcg ctgcaggagc tgacgtggaa gatgagcgtg cgggactgcg cttggctgcg 
1621 caggagccca ggggttggct gtgttccggc cgcagagcac cgtctgcgtg aggagatcct 
1681 ggccaagttc ctgcactggc tgatgagtgt gtacgtcgtc gagctgctca ggtctttctt 
1741 ttatgtcacg gagaccacgt ttcaaaagaa caggctcttt ttctaccgga agagtgtctg 
1801 gagcaagttg caaagcattg gaatcagaca gcacttgaag agggtgcagc tgcgggagct 
1861 gtcggaagca gaggtcaggc agcatcggga agccaggccc gccctgctga cgtccagact 
1921 ccgcttcatc cccaagcctg acgggctgcg gccgattgtg aacatggact acgtcgtggg 
1981 agccagaacg ttccgcagag aaaagagggc cgagcgtctc acctcgaggg tgaaggcact 
2041 gttcagcgtg ctcaactacg agcgggcgcg gcgccccggc ctcctgggcg cctctgtgct 
2101 gggcctggac gatatccaca gggcctggcg caccttcgtg ctgcgtgtgc gggcccagga 
2161 cccgccgcct gagctgtact ttgtcaaggt ggatgtgacg ggcgcgtacg acaccatccc 
2221 ccaggacagg ctcacggagg tcatcgccag catcatcaaa ccccagaaca cgtactgcgt 
2281 gcgtcggtat gccgtggtcc agaaggccgc ccatgggcac gtccgcaagg ccttcaagag 
2341 ccacgtctct accttgacag acctccagcc gtacatgcga cagttcgtgg ctcacctgca 
2401 ggagaccagc ccgctgaggg atgccgtcgt catcgagcagagctcctccc tgaatgaggc 
2461 cagcagtggc ctcttcgacg tcttcctacg cttcatgtgc caccacgccg tgcgcatcag 
2521 gggcaagtcc tacgtccagt gccaggggat cccgcagggc tccatcctct ccacgctgct 
2581 ctgcagcctg tgctacggcg acatggagaa caagctgttt gcggggattc ggcgggacgg 
2641 gctgctcctg cgtttggtgg atgatttctt gttggtgaca cctcacctca cccacgcgaa 
2701 aaccttcctc aggaccctgg tccgaggtgt ccctgagtat ggctgcgtgg tgaacttgcg 
2761 gaagacagtg gtgaacttcc ctgtagaaga cgaggccctg ggtggcacgg cttttgttca 
2821 gatgccggcc cacggcctat tcccctggtg cggcctgctg ctggataccc ggaccctgga 
2881 ggtgcagagc gactactcca gctatgcccg gacctccatc agagccagtc tcaccttcaa 
2941 ccgcggcttc aaggctggga ggaacatgcg tcgcaaactc tttggggtct tgcggctgaa 
3001 gtgtcacagc ctgtttctgg atttgcaggt gaacagcctc cagacggtgt gcaccaacat 
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3061 ctacaagatc ctcctgctgc aggcgtacaggtttcacgca tgtgtgctgc agctcccatt 
3121 tcatcagcaa gtttggaaga accccacatt tttcctgcgc gtcatctctg acacggcctc 
3181 cctctgctac tccatcctga aagccaagaa cgcagggatg tcgctggggg ccaagggcgc 
3241 cgccggccct ctgccctccg aggccgtgca gtggctgtgc caccaagcat tcctgctcaa 
3301 gctgactcga caccgtgtca cctacgtgcc actcctgggg tcactcagga cagcccagac 
3361 gcagctgagt cggaagctcc cggggacgac gctgactgcc ctggaggccg cagccaaccc 
3421 ggcactgccc tcagacttca agaccatcct ggactgatgg ccacccgccc acagccaggc 
3481 cgagagcaga caccagcagc cctgtcacgc cgggctctac gtcccaggga gggaggggcg 
3541 gcccacaccc aggcccgcac cgctgggagt ctgaggcctg agtgagtgtt tggccgaggc 
3601 ctgcatgtcc ggctgaaggc tgagtgtccg gctgaggcct gagcgagtgt ccagccaagg 
3661 gctgagtgtc cagcacacct gccgtcttca cttccccaca ggctggcgct cggctccacc 
3721 ccagggccag cttttcctca ccaggagccc ggcttccact ccccacatag gaatagtcca 
3781 tccccagatt cgccattgtt cacccctcgc cctgccctcc tttgccttcc acccccacca 
3841 tccaggtgga gaccctgaga aggaccctgg gagctctggg aatttggagt gaccaaaggt 
3901 gtgccctgta cacaggcgag gaccctgcac ctggatgggg gtccctgtgg gtcaaattgg 
3961 ggggaggtgc tgtgggagta aaatactgaa tatatgagtt tttcagtttt gaaaaaaa 
 
Figure 2.2: Human TERT cDNA. The position of the PCR primers used in this study 
are indicated in red. 
 
2.2.5 Quantitative real time PCR (qRT-PCR)   
In this study, qRT-PCR was conducted to quantify the expression of the target genes 
(which include NEIL3, hTERT, POT1 and Gapdh) on cDNA from different paediatric 
cell lines using the Sensi Fast SYBR Lo-ROX Kit (Bioline) according to the 
manufacturer’s instructions. The reference gene for normalisation was Gapdh and 
melting curves were used to confirm the specificity of the PCR primers. 
Each 5 µl of cDNA from the reverse transcription reaction (20 µl) was mixed with 45 µl 
of  TE to obtain a final volume of 50 µl and then a standard curve was obtained by a 10-
fold serial dilution which was made as follows: 100%, 10%, 1%, 0.1% and 0%  cDNA 
by the following steps:                                                                                                                                        
10%: 8 µl from 100% of cDNA sample was added to 72 µl RNase free water.                                                                             
1%:  8 µl from 10% was added to 72 µl RNase free water.                                                       
0.1%: 8 µl from 1% was added to 72 µl RNase free water.                                                                
0%: 72 µl RNase free water.                                                                       
Triplicate aliquots of 5 µl cDNA template were then added to the wells of a 96-well 
reaction plate as detailed in Table 2.9. The PCR primers were prepared by diluting 1 µl 
(100 pmol) with 9 µl TE to give a final concentration of 10 pmol/ µl. For each PCR 
reaction mix, 18.5 µl forward primer, 18.5 µl reverse primer, 230 µl 2x SensiFast SYBR 
Lo-ROX (containing SYBR Green I dye and dNTPs) and 78 µl RNase free water were 
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mixed in a 1.5 ml microcentrifuge tube and then 15 µl was distributed in each well as 
appropriate (see Table 2.10). Negative control wells have forward primer, reverse 
primer, 2x SensiFast SYBR Lo-ROX and RNase free water. The qRT-PCR was 
prepared in triplicate in a 96-well plate and the wells were loaded as revealed in Table 
2.10. 
Table 2.9: Loading of the 10-fold serially diluted cDNA in triplicate in a 96-well 
plate 
100% 10% 1% 0.1% 0% 
B1,B6,B11, 
C4,C9,D2, 
D7,D12,E5, 
E10,F3,F8          
B2,B7,B12, 
C5,C10,D3, 
D8,E1,E6, 
E11,F4,F9 
 
 
B3,B8,C1, 
C6,C11,D4, 
D9,E2,E7, 
E12,F5,F10 
B4,B9,C2, 
C7,C12,D5, 
D10,E3,E8, 
F1,F6,F11 
B5,B10,C3, 
C8,D1,D6, 
D11,E4,E9, 
F2,F7,F12 
                                                                                                                                                                          
Table 2.10: Loading of a 96-well plate 
Primer Sample Standard Negative Control 
TERT A1,A2,A3 B1,B2,B3,B4,B5 
C9,C10,C11,C12,D1 
E5,E6,E7,E8,E9 
G1,G2,G3 
POT1 A4,A5,A6 B6,B7,B8,B9,B10 
D2,D3,D4,D5,D6 
E10,E11,E12,F1,F2 
G4,G5,G6 
NEIL3 A7,A8,A9 B11,B12,C1,C2,C3 
D7,D8,D9,D10,D11 
F3,F4,F5,F6,F7 
G7,G8,G9 
Gapdh A10,A11,A12 C4,C5,C6,C7,C8 
D12,E1,E2,E3,E4 
F8,F9,F10,F11,F12 
G10,G11,G12 
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Two-step cycling was used for the PCR reaction and the conditions are given in Table 
2.11 
Table 2.11: qRT-RCR conditions 
Cycles  Temperature Time PCR phase 
1 95oC 2 min Denaturation 
40 95oC 5 s Denaturation 
60oC 30 s Annealing/ 
Extention 
Melting curve from 72oC to 90oC, reading every 1oC, hold at 30 s. 
Analysis of the results was conducted through MJ Optocon Monitor version 3.1 
software and the relative expression of the target gene in each cell line was calculated 
via normalization of its mRNA quantitative values with the values of Gapdh using the 
following equation:                                                                                                                                                  
Relative mRNA level of the target gene =   Numerical value of target gene expression 
                                                                    Numerical value of Gapdh expression 
 
2.2.6 Cytotoxicity assays 
Two experiments; MTS assay and MTT assay were conducted to analyse the cell 
proliferation in presence of the cytotoxic drugs: cisplatin, doxorubicin and tert-butyl 
hydroperoxide.   
 
2.2.6.1 MTS assay (cell Titer 96 AQueousNon-Radioactive Cell Proliferation) 
This tetrazolium dye; [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethonyphenol)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt] in the presence of an electron coupling reagent 
(phenazinemethosulfate; PMS) is characterized by its ability to be reduced via NAD or 
NADP dependent dehydrogenase enzymes to a water-soluble formazan. Therefore, 
there is no need to wash the cells or extracting the dye after adding (Buttke et al, 1993; 
Dunigan et al, 1995). The MTS assay was conducted on the suspension cells CEM-7-14 
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and CEM-1-15 to determine the concentration of a drug required to inhibit the growth 
by 50% (IC50). The preparation was carried out as detailed in Table 2.12. 
Table 2.12: Preparation of MTS solution    
Reagent Composition 
MTS  21 ml PBS+ 0.042 g 
PMS 5 ml PBS + 0.0046 g 
Finally 3 ml MTS was added to 150 µl PMS. 
The drugs examined by this assay were: cisplatin, doxorubicin and tert-butyl 
hydroperoxide. Each well of a U-shaped 96-well plate was loaded with 2000 cells in 
100 µl of RPMI complete medium. Seven, 2-fold serially diluted drug solutions were 
prepared as follows: 
Eight, 1.5 ml microcentrifuge tubes were labelled from 1 to 8. Tube number 8 was the 
control (it does not have drug). Two millilitres of complete medium was put into tube 1, 
while 1 ml of medium was put into the remaining tubes. The desired amount of the drug 
was added to tube 1 as detailed in Table 2.13 and mixed. Then, 1 ml from this tube was 
taken and mixed with the medium in tube 2.This step was repeated for the remainder of 
the tubes until tube 7. Then triplicate aliquots of 100 µl were added to the wells of a 96-
well plate as shown in Table 2.14. Finally, the 96-well plate was incubated for 72 h at 
37°C in a humidified, 5% CO2 atmosphere. After this incubation period, 40 µl of 
combined MTS / PMS solution was added to each well and incubated again for 3 h at 
37°C in a humidified, 5% CO2 atmosphere. Finally, the absorbance at 490nm was 
recorded using Multiscan Ascent/Thermo lab system ELISA reader and Ascent 
software. Then MTT template was used to analyze the results obtained. 
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Table 2.13: Drug preparation 
Drug Drug preparation The amount of drug which 
was added to tube 1 
Final Drug 
Concentration 
(i.e.2x) 
Cisplatin 1 mg + 1 ml NaCl 0.9% 
(w/v) (3.3 mM) 
30 µl (3.3 mM) + 1970 µl 
medium 
50 µM    
Doxorubicin 17.2 ml PBS added to 10 
mg  (1 mM), then  10 µl 
+ 990 µl PBS (10 µM) 
40 µl (10 µM) + 1960 µl 
medium 
200 nM 
tert-Butyl 
hydroperoxide 
solution 70% 
(w/v) 
10 µl (7.77 M) + 67.7 µl 
d-H2O = 1 M, then 10 µl 
(1 M) + 990 µl de-H2O = 
10 mM 
100 µl (10 mM) + 1900 µl 
medium 
500 µM 
 
Table 2.14: Loading of the 96-well plate       
Row of the 96-well plate         Tube contains the drug 
Row A Tube 8 
Row B Tube 7 
Row C Tube 6 
Row D Tube 5 
Row E                                                                         Tube 4
Row F Tube 3 
Row G Tube 2 
Row H Tube 1 
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2.2.6.1 MTT assay 
MTT assay is a colorimetric test, used to assess the cells viability to cytotoxic 
compounds via using Tetrazolium salt (MTT solution); 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide. This yellow water soluble reagent is metabolized in 
the dividing cells by mitochondrial succinate dehydrogenase to a purple water insoluble 
formazan, which accumulates in the cells and is dissolved by adding DMSO. Through a 
microplate reader, the absorbance of the produced formazan is measured at 570 nm 
(Figure 2.3) (Talorete et al, 2006; Massignan et al, 2011).   
                                                                                               
 
 
Figure 2.3: Reaction of thiazolyl blue tetrazolium blue with mitochondrial succinate 
dehydrogenase. 
 
This method was carried out on adherent cells; HepG2 cell line. A density of 2 x 103 
cells was plated in each well of a flat-shaped 96-well plate containing 100 µl of 
complete DMEM medium and incubated in a humidified atmosphere in 5% CO2 at 37
oC 
for 24 h. After the incubation period was completed, the cells were treated with one of 
the cytotoxic drugs; cisplatin, doxorubicin or tert-butyl hydroperoxide (Table 2.12) and 
the plates prepared as described for the MTS assay. Then the plate was incubated at 
37oC, 5% CO2 with a humidified atmosphere for 72 h. On third day of incubation, 50 µl 
of MTT reagent (made by dissolving 3 mg of MTT in 1 ml PBS) was added to each 
3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium 
bromide, yellow in color  
Y 
YE 
Formazan, purple in color  
Mitochondrial 
succinate 
dehydrogenase 
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well of the 96-well plate. Again, the plate was incubated in 5% CO2 at 37
oC in a 
humidified atmosphere for 3 h.  
The supernatant was aspirated and 200 µl DMSO was added to each well. After that, the 
difference in the optical density between the sample absorption wavelength (570 nm) 
and the reference wavelength (650 nm) was calculated through Ascent software and 
Multiscan Ascent/Thermo lab system ELISA reader. Then MTT template was used to 
analyze the data obtained.  
 
2.2.7 qRT-PCR on treated HepG2 cells 
The HepG2 cell line was used as a model to evaluate the influence of oxidative stress on 
NEIL3, hTERT and POT1 by qRT-PCR. 5 x10 4 cells were seeded per well in 2 ml of 
complete DMEM medium in a 6-well plate, which was then incubated for 24 h at 37°C 
in a humidified, 5% CO2 atmosphere. After 24 h, the cells were treated with, 2.5 µM or 
5 µM of tert-butyl hydroperoxide solution (prepared as described below) and incubated 
for 72 h at 37°C in a humidified, 5% CO2 atmosphere. 
After 72 h, the cells were trypsinised, counted and pellets prepared for RNA extraction. 
Following the extraction of RNA, reverse transcription PCR was carried out. Triplicate 
aliquots of 5 µl cDNA template HepG2 were used to run qRT-PCR reaction with 
NEIL3, hTERT and POT1 using the Sensi Fast SYBR Lo-ROX Kit. The reference gene 
was Gapdh and the fluorescent dye was SYBR Green I.         
 
2.2.7.1 Preparation of 2.5 µM and 5 µM tert-butyl hydroperoxide solution  
Ten microliters of the 70% (w/v) stock solution of tert-butyl hydroperoxide solution 
was added to 66.7 µl of d-H2O to produce a 1 M solution then 10 µl of the 1 M solution 
was added to 990 µl of d-H2O to produce a 10 mM solution. Finally, 10 µl of the 10 
mM solution was added to 990 µl of DMEM medium to produce a 100 µM solution. 
For 2.5 µM, 200 µl of the 100 µM stock solution was mixed with 3.8 ml of cell culture 
medium and 2 ml transferred to each of two wells. While 5 µM was prepared by mixing 
400 µl of the 100 µM stock solution with 3.6 ml of cell culture medium and 2 ml 
transferred to each of two wells. The 6-well plate was loaded as showed in Table 2.15. 
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Table 2.15: Loading of the 6-well plate 
Row Content 
Row A Control 
Row B 2.5 µM drug concentration 
Row C 5 µM drug concentration 
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Chapter 3: Results 
Statistical analysis of data was carried out by ANOVA and t-test. Results were 
expressed by average and standard deviation. In addition, the relation between different 
parameters were assessed by P value. P < 0.05 was considered as statistical 
significance. 
 
3.1 Identification of the exponential growth phase of each cell line 
The cell growth curve is divided into three phases; lag, exponential and stationary 
phase. During the lag phase, the cells adjust to the new environmental conditions before 
starting to grow in the exponential phase. Here, cellular proliferation increases 
significantly in relation to time in the exponential phase, while the stationary phase is 
characterized by inert cell division and this phase has a mixed of dying and living cells 
as all the nutrients have been consumed by the growing cells. Therefore, the target 
growth phase for conducting the gene expression analyses is the exponential phase 
(Rolfe et al, 2012). 
The growth of the CEM-1-15, CEM-7-14, HOS, Saos2, TC-32 and HepG2 cell lines 
was examined for 96 h and plotted against time in a line graph (Figures 3.1 to 3.4). 
 
    
Figure 3.1: Growth curve of ALL cells over a period of 96 h. (A) Each flask represents 
CEM-1-15 cells. (B) Each flask represents CEM-7-14 cells. 2 x106 cells were used as a 
total cell number per flask. Cell counting was carried out every 24 h for a period of 96 
h.  
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Figure 3.2: Growth curve of osteosarcoma cell lines over a period of 96 h. (A) Each 
flask represents HOS cells. (B) Each flask represents Saos-2 cells.  2 x106 cells were 
used as a total cell number per flask. Cell counting was carried out every 24 h for a 
period of 96 h.  
 
 
 
                                          
Figure 3.3: Growth curve of hepatoblastoma cells over a period of 96 h. Each flask 
represents HepG2 cells. 2 x106 cells were used as a total cell number per flask. Cell 
counting was carried out every 24 h for a period of 96 h.  
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Figure 3.4: Growth curve of medulloblastoma cells over a period of 96 h. Each flask 
represents Tc-32 cells. 2 x106 cells were used as a total cell number per flask. Cell 
counting was carried out every 24 h for a period of 96 h.  
 
The results showed that the growth pattern for CEM-1-15 cell line remained in a plateau 
phase in the first 24 h as the cell number of this cell line is constant (Figure 3.1). After 
this period, the cells show a robust activity of cellular proliferation with a doubling time 
of 24 h. On the other hand, CEM-7-14, Saos2, HOS, HepG2 and TC-32 cell lines 
displayed a faster growth rate entering the exponential growth with a doubling time in 
the initial 24 h (Figures 3.1 to 3.4). 
 
3.2 RNA extraction from the cancer cell lines  
Total RNA was extracted from the different cell lines using ISOLATE II RNA Mini Kit 
(Section 2.2.2). The concentration of the extracted RNA was determined by 
spectrophotometry using a Nanodrop 2000. As well as the OD260, the 260/280 ratio was 
determined to check the level of protein contamination and the 260/230 ratio was 
determined to assess the carryover of organic materials during RNA extraction (Table 
3.1).  
The purified RNA was then subjected to 1% agarose gel electrophoresis to check for 
degradation of the RNA by visualising the two principal rRNA species; 28 S and 18 S 
(Figures 3.5 to 3.8).  
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Table 3.1: The concentration and the purity of RNA 
Cell lines Concentration 260/280 260/230 
CEM-1-15 400 ng/µl 2.07 2.09 
CEM-7-14 327 ng/µl 2.07                                                                                    2.1
HOS  308 ng/µl 2.04                                                                                     2.07
TC-32 621 ng/µl 2.19 2.2 
HEPG-2 800 ng/µl 2.02 2.04 
Saos-2 267 ng/µl 2.07 2.1 
   
Comparing the RNA concentration in six different cell lines, HepG2 cells have the 
highest RNA concentration. On the other hand, Saos-2 cells have the lowest 
concentration. In terms of RNA purity, TC-32 cells have the maximum 260/230 ratio of 
RNA purity, while the 260/230 ratio of RNA purity is lowest in HepG2 (Table 3.1). 
 
                                
Figure 3.5: Agarose gel electrophoresis of extracted total RNA from the ALL cell lines.                                                                                                                                     
(A) CEM-1-15 cell line. (B) CEM-7-14 cell line. Lane H contains Hyperladder I, while 
sample 1, 2 and 3 are shown in lanes 1, 2 and 3 respectively. 5 µl from each RNA 
sample was mixed with 3 µl loading buffer and the final volume of 11 µl was achieved 
via adding d-H2O then 2 µl, 4 µl and 5 µl were loaded as sample 1, 2 and 3 respectively 
in 1 % agarose gel along with 6 µl Hyperladder I. 
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Figure 3.6: Agarose gel electrophoresis of extracted total RNA from the osteosarcoma 
cell lines. (A) HOS cell line. (B) Saos2 cell line. Lane H contains Hyperladder I, while 
sample 1, 2 and 3 are shown in lanes 1, 2 and 3 respectively. 5 µl from each RNA 
sample was mixed with 3 µl loading buffer and the final volume of 11 µl was achieved 
via adding d-H2O then 2 µl, 4 µl and 5 µl were loaded as sample 1, 2 and 3 respectively 
in 1 % agarose gel along with 6 µl Hyperladder I. 
 
                                                                                                                                                                         
                                                                        
Figure 3.7: Agarose gel electrophoresis of extracted total RNA from the 
medulloblastoma cell lines (TC-32 cells). Lane H contains Hyperladder I, while sample 
1, 2 and 3 are shown in lanes 1, 2 and 3 respectively. 5 µl from each RNA sample was 
mixed with 3 µl loading buffer and the final volume of 11 µl was achieved via adding d-
H2O then 2 µl, 4 µl and 5 µl were loaded as sample 1, 2 and 3 respectively in 1 % 
agarose gel along with 6 µl Hyperladder I. 
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Figure 3.8: Agarose gel electrophoresis of extracted total RNA from the 
hepatoblastoma cell lines (HepG2). Lane H contains Hyperladder I, while sample 1, 2 
and 3 are shown in lanes 1, 2 and 3 respectively. 5 µl from each RNA sample was 
mixed with 3 µl loading buffer and the final volume of 11 µl was achieved via adding d-
H2O then 2 µl, 4 µl and 5 µl were loaded as sample 1, 2 and 3 respectively in 1 % 
agarose gel along with 6 µl Hyperladder I. 
 
 
The results reveal the thickness of 28 S in all cell lines is almost twice larger than that in 
18 S. In addition, there is no genomic DNA contamination and all RNA samples show 
very little degradation (Figures 3.5 to 3.8). 
 
3.3 Specificity of the PCR primers 
It is common for PCR primers to amplify more than one target DNA sequence due to 
incorrect annealing temperature or just binding to non-specific DNA sequences. 
Therefore, a careful assessment of primer specificity is necessary and is a mandatory 
step before conducting any qRT-PCR. 
To test the specificity of Gapdh, NEIL3, hTERT and POT1 primers, a 1.5% agarose gel 
was loaded with PCR products amplified from cDNA from CEM-1-15 cells (Figure 
3.9), Saos-2 and HepG2 cell lines (Figure 3.10).  
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Figure 3.9: Agarose gel electrophoresis with Gapdh, NEIL3, hTERT and POT1 on 
cDNA template from CEM-1-15 cells. (A) cDNA in PCR reaction with Gapdh primers. 
(B) cDNA in PCR reaction with NEIL3 primers. (C) cDNA in PCR reaction with 
hTERT primers (D) cDNA in PCR reaction with POT1 primers. Lane H represents 
Hyperladder I, while lanes 1, 2 and 3 contain sample 1, 2 and 3 respectively. Sample 1, 
2 and 3 represents three different concentrations of cDNA CEM-1-15 cells, 100 %, 1:5 
and 1:10 respectively. 
 
A 
B 
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Figure 3.10: Agarose gel with PCR primers on cDNA from HepG2 and cDNA Saos-2 
cell lines. (A) PCR products with cDNA template of HepG2 cell line as the template 
material. (B) PCR products with cDNA template of Saos-2cells as the template 
material. Lane H represents Hyperladder I, while lanes 1, 2, 3and 4 contain Gapdh, 
NEIL3, hTERT and POT1respectively. 
 
The results confirm that, the primers for Gapdh, NEIL3, hTERT and POT1 amplify a 
single band of 127 bp, 148 bp, 140 bp and 140 bp respectively in cDNA of CEM-1-15 
cell line (Figure 3.9). Thus, these primers are successfully suitable for qRT-PCR to 
quantify the expression of the target genes. Importantly, PCR on cDNA from the Saos-2 
cells confirms the hypothesis; Saos-2 cells does not express telomerase gene compared 
with HepG2 cells. As revealed by Figure 3.10 (A) and (B) the absence of amplifying 
cDNA fragments with hTERT on Saos-2 cells. 
 
3.4 Quantification of gene expression by qRT-PCR 
qRT-PCR, the fluorescent based technique commonly used in molecular medicine and 
in biotechnology to measure the level of the mRNA of target genes in biological 
samples through the usage of fluorescent dye such as SYBR Green I. In each 
amplification cycle, the fluorescent signal, which reflects the accumulation of the PCR 
product is detected (Cikos et al, 2007). 
In qRT-PCR appropriate normalisation is required to sort out the experimental errors 
arising from RNA extraction and cDNA generation. Gapdh (glyceraldehyde-3-
phosphate dehydrogenase) is identified as a reference gene as it is assumed that its 
A B 
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expression level is constant in the cells. The level of the target gene mRNA is 
normalised to the reference gene and it is quantified relative to the reference gene. 
Therefore, the measurement of the gene expression is a numerical value, which allows 
studying the patterns of gene expression between different cell lines. Importantly, each 
run of qRT-PCR has a standard curve, which was generated through serial dilution of 
cDNA (Bustin, 2002). 
There are several methods to analyse the obtained fluorescent data from qRT-PCR in 
order to obtain the relative measurement of mRNA target gene. Most of these are 
analyse the data from the exponential phase of the PCR amplification. The most 
predominant analytic way is the threshold-based method in which threshold cycle (Ct) 
represents the number of the amplification cycles required for reaching the threshold 
fluorescence. The amplification curve is a graph of the fluorescent PCR product against 
the number of the amplification cycle and the threshold fluorescence represents a point 
in the amplification curve that has the similar amounts of PCR product in each 
amplification cycle (Cikos et al, 2007). Subsequently, analysis of the linear regression 
(correlation coefficient,  r2) is calculated by plotting the log concentration versus the Ct. 
However, the validity of r2 should be more than 0.99 (Peirson et al, 2003). 
The mRNA level of Gapdh, NEIL3, hTERT and POT1 was assessed in CEM-1-15, 
CEM-7-14, HOS, Saos2, TC-32 and HepG2 cell lines by qRT-PCR. Using Gapdh and 
the CEM-1-15 cell line as an example for each primer pair (Figure 3.11), the standards 
were made from 10-fold serial dilutions of the cDNA and the standard curve was 
applied to optimise the threshold cycle (Figure 3.11 A). The Ct was adjusted where the 
Log10 quantity against the Ct cycle became linear. At the same time, r
2 was set at a value 
higher than 0.97 as revealed in Figure 3.9 B. In addition, the melting curve was assessed 
carefully to ensure that a single sharp peak was obtained, which represented a single 
PCR product (Figure 3.11 C). 
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Figure 3.11: Analysis of the result for Gapdh expression in CEM-1-15 cells.                                                                            
Each coloured line represents a single PCR reaction with serial dilution of cDNA.                                            
(A) Amplification curve shows 10-fold serial dilution of cDNA. Ct was set on the graph 
at a point where the Ct cycle and the log quantity became linear. In this example, the 
sample reaches the Ct value at 13 cycles. (B) The linear regression curve (the standard 
curve for use with Gapdh) represents the relation between the Ct cycle and the log 
quantity and r2 showing a value of 0.995. (C) Melting curve with single sharp peak. 
 
Following the expression of the target gene was determined in every of the six cell 
lines. The raw data is presented in the appendix (Figures 5.1 to 5.6) and the normalised 
data is shown in Figures 3.12 to 3.18. 
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Figure 3.12: Quantification of the expression level of NEIL3, hTERT and POT1 in 
ALL cell lines by qRT-PCR. (A) The expression levels of the target genes in the CEM-
1-15 cell line with the data expressed relative to Gapdh. (B) The expression levels of the 
target genes in the CEM-7-14 cell line with the data expressed relative to Gapdh. The 
results are presented as averages of two independent experiments, which were 
performed in triplicate and the standard deviation of these experiments is illustrated as 
error bars. 
 
                 
Figure 3.13: Quantification of the expression level of NEIL3, hTERT and POT1 in 
osteosarcoma cell lines by qRT-PCR. (A) The expression levels of the target genes in 
the HOS cell line with the data expressed relative to Gapdh. (B) The expression levels 
of the target genes in the Saos-2 cell line with the data expressed relative to Gapdh. The 
results are presented as averages of two independent experiments, which, were 
performed in triplicate, and the standard deviation of these experiments is illustrated as 
error bars. 
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Figure 3.14: Quantification of the expression level of NEIL3, hTERT and POT1 in 
medulloblastoma cell line by qRT-PCR. The expression levels of the target genes in the 
TC-32 cell line with the data expressed relative to Gapdh. The results are presented as 
averages of two independent experiments, which were performed in triplicate and the 
standard deviation of these experiments is illustrated as error bars. 
 
 
                                            
Figure 3.15: Quantification of the expression level of NEIL3, hTERT and POT1 in 
hepatoblastoma cell line by qRT-PCR. The expression levels of the target genes in the 
HepG2cell line with the data expressed relative to Gapdh. The results are presented as 
averages of two independent experiments, which were performed in triplicate and the 
standard deviation of these experiments is illustrated as error bars. 
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Figure 3.16: The relative level of NEIL3 mRNA in different cell lines. The relative 
expression of NEIL3 mRNA was calculated via normalization with Gapdh. Data are 
representative averages of two independent PCR reactions carried out in triplicate. Error 
bars represent standard deviation. 
 
Figure 3.17: The relative level of hTERT mRNA in different cell lines. The relative 
expression of hTERT mRNA was calculated via normalization with Gapdh. Data are 
representative averages of two independent PCR reactions carried out in triplicate. Error 
bars represent standard deviation. 
 
Figure 3.18: The relative level of POT1 mRNA in different cell lines. The relative 
expression of POT1 mRNA was calculated via normalization with Gapdh. Data are 
representative averages of two independent PCR reactions carried out in triplicate. Error 
bars represent standard deviation. 
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Analysis of the qRT-PCR data in ALL cells showed, the relative expression level of 
NEIL3 gene was significantly higher than that of hTERT (P < 0.01) and of POT1 (P < 
0.01) in the CEM-1-15 cell line. However, there was no significant correlation between 
the relative expression of NEIL3, hTERT and POT1 in CEM-7-14 cell line. 
Interestingly, the relative level of NEIL3 mRNA in CEM-1-15 cells was significantly 
higher than that in CEM-7-14 cells (P < 0.01). Furthermore, the increase in the relative 
expression level of hTERT in CEM-1-15 cells when compared to CEM-7-14 cells was 
also highly significant (P < 0.01). However, there was no significant change in the 
relative level of POT1 mRNA between both cell lines (Figures 3.12 and 3. 16 to 3.18).  
Studying the expression of the target genes in osteosarcoma cell lines revealed that the 
relative expression level of NEIL3 gene was significantly higher (P < 0.01) than that of 
POT1 in HOS cell line. While, in Saos-2 cells the relative level of POT1 mRNA was 
significantly (P < 0.01) higher than that of NEIL3. In addition, NEIL3 expression in 
HOS cells was significantly increased over that seen in Saos-2 cells (P < 0.01). On the 
other hand, HOS cells have a significantly lower relative level of POT1 mRNA 
compared with Saos-2 cells (P < 0.01) (Figure 3.13, 3.16 and 3.18).  
In TC-32 and HepG2 cell lines, NEIL3 was again highly expressed, significantly more 
than POT1 in both cell lines (P < 0.01). Moreover, the relative expression of NEIL3 
was much higher than that of hTERT in HepG2 cells (P < 0.01) (Figures 3.14 and 3.15).  
These experiments also confirm that, HOS, Saos-2 and TC-32 cells do not express the 
hTERT gene (Figure 3.17). The data indicate that, there is no correlation between the 
expression of NEIL3 and the presence or absence of hTERT. Importantly, NEIL3 
mRNA was expressed in all the cell lines tested.   
 
3.5 Determination the cell growth inhibitory effect of genotoxic agents using the    
MTS assay  
CEM-1-15 and CEM-7-14 cell lines were treated with cisplatin, doxorubicin and tert-
butyl hydroperoxide for 72 h. Then the cell growth was examined using the MTS assay 
(Figures 3.19 to 3.21).  
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Figure 3.19: Growth curves for ALL cell lines treated with cisplatin for 72 h.                                              
(A) The percent survival of CEM-1-15 and CEM-7-14 cells after treatment with 0-25 
µM cisplatin. (B) The IC50 value of CEM-1-15 cells to cisplatin is 4.18 µM, while the 
IC50 value of CEM-7-14 cells to cisplatin is 2.67 µM. Data are representative averages 
of two independent experiments carried out in triplicate. Error bars represent standard 
deviation.  
 
 
            
Figure 3.20: Growth curves for ALL cell lines treated with doxorubicin for 72 h.                                                          
(A) The percent survival of CEM-1-15 and CEM-7-14 cells after treatment with 0-100 
nM doxorubicin. (B) The IC50 value of CEM-1-15 cells to doxorubicin is 2.5 nM, while 
the IC50 value of CEM-7-14 cells to doxorubicin is 3.04 nM. Data are representative 
averages of two independent experiments carried out in triplicate. Error bars represent 
standard deviation.  
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Figure 3.21: Growth curves for ALL cell lines treated with t-BHP for 72 h.                                                      
(A) The percent survival of CEM-1-15 and CEM-7-14 cells after treatment with 0-250 
µM t-BHP. (B) The IC50 value of CEM-1-15 cells to t-BHP is 18.35 µM, while the IC50 
value of CEM-7-14 cells to t-BHP is 2.92 µM. Data are representative averages of two 
independent experiments carried out in triplicate. Error bars represent standard 
deviation.  
                                                       
The growth of both CEM-1-15 and CEM-7-14 cells was inhibited at every 
concentration of cisplatin examined (Figure 3.19). Although no significant differences 
was observed between the cell lines, the IC50 for CEM-7-14 cells was lower (2.67 µM) 
than that of the CEM-1-15 cells (4.18 µM).     
Similarly, with increasing concentration of doxorubicin, a substantial decrease in the 
growth of ALL cells was observed. At only one concentration (1.56 nM), CEM-1-15 
cells showed greater inhibition of growth than CEM-7-14 cells (P < 0.05).Therefore, the 
value of IC50 in CEM-1-15 cells treated with doxorubicin is 2.5 nM and the value of 
IC50 in CEM-7-14 cells treated with doxorubicin is 3.04 nM (Figure 3.20). 
Interestingly, treatment with t-BHP elicited a marked difference in response between the 
CEM-1-15 and CEM-7-14 cells. Growth of the CEM-7-14 cell line was significantly (P 
< 0.01) more inhibited following treatment with t-BHP, an IC50 of 2.92 µM, compared 
with an IC50 of 18.35 µM for the CEM-1-15 cells (Figure 3.21). 
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3.6 Determination the cell growth inhibitory effect of genotoxic agents using the  
MTT assay  
In order to examine the effect of a non-toxic dose of t-BHP on the expression of NEIL3, 
TERT and POT1, the sensitivity of HepG2 cells to this agent and, as controls, cisplatin 
and doxorubicin was examined using the MTT assay (Figure 3.22).  
 
 
      
                                            
Figure 3.22: Growth curves for HepG2 cell line. (A) The percent of HepG2 survival 
cells after treatment with 0-25 µM cisplatin, IC50= 3.65 µM. (B) The percent of HepG2 
survival cells after treatment with 0-100 nM doxorubicin, IC50= 7.13 nM. (C) The 
percent of HepG2 survival cells after treatment with 0-250 µM t-BHP, IC50= 14.55 µM. 
Data are representative averages of two independent experiments carried out in 
triplicate. Error bars represent standard deviation.  
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As shown in Figure 3.22, HepG2 cells were sensitive to cisplatin, doxorubicin and          
t-BHP as a decline in cell growth was observed at each concentrations of the 
compounds tested. A 50% reduction in the cells growth was obtained with 3.65 µM 
cisplatin, 7.13 nM doxorubicin and 14.55 µM t-BHP.  
 
3.7 Estimation of the effect of tert-butyl hydroperoxide on HepG2 cells on target 
gene expression by qRT-PCR  
To examine the influence of oxidative stress on the expression levels of Gapdh, NEIL3, 
hTERT and POT1 genes in hepatoblastoma cells, the HepG2 cells were treated with 2.5 
µM or 5 µM t-BHP for 72 h, then RNA extracted and reverse transcription PCR was 
carried out. The levels of mRNA target genes were measured via qRT-PCR. The raw 
data is presented in the appendix (Figures 5.7 to 5.9) and the normalised data with the 
reference gene is shown in Figure 3.23. 
      
 
                    
Figure 3.23: Measurement of the level of mRNA NEIL3, hTERT and POT1 on cDNA 
of hepatoblastoma cells treated with t-BHP using qRT-PCR. The first three columns 
represent the control samples, which illustrates the levels of target gene expression in 
the HepG2 cells relative to Gapdh. The second three columns represent HepG2 cells 
treated with 2.5 µM t-BHP, while the third set of columns represent HepG2 cells treated 
with 5 µM t-BHP. Data are representative averages of two independent PCR reactions 
carried out in triplicate. Error bars represent standard deviation.  
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Compared with non-treated HepG2 cells, the relative expression of NEIL3 decreased 
significantly following 5 µM t-BHP treatment (P < 0.01), however the relative level of 
NEIL3 mRNA did not change significantly following treatment with 2.5 µM t-BHP. In 
addition, the relative level of hTERT mRNA increased significantly (P < 0.01) after 
treatment with 2.5 µM and 5 µM t-BHP. On the other hand, the relative level of POT1 
mRNA appears to increase significantly (P < 0.01) following 2.5 µM t-BHP, but was 
reduced significantly (P < 0.01) compared with control levels following 5 µM t-BHP 
treatment (Figure 3.23). 
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Chapter 4: Discussion 
In this thesis, I set out first to determine the gene expression of NEIL3 in a number of 
different paediatric cancer cell lines. Secondly, I was interested to discover if there was 
any correlation between the high levels of expression of NEIL3 previously reported in 
cancer cells and tumours (Hildrestrand et al, 2009) with the gene expression of 
telomerase and POT1, a component of the shelterin proteins that surround the telomere. 
Telomerase is known to be expressed in 85% of human tumours (Tahtouh et al, 2015) 
and is an important for cell immortality, one of Hanahan and Weinberg’s Hallmarks of 
Cancer (Hanahan and Weinberg, 2011) while NEIL3 has recently been shown to act on 
telomeric regions of DNA (Zhou et al, 2015). Finally, I wanted to determine the effect 
of different genotoxic compounds on the growth of selected cancer cell lines, 
particularly the two ALL lines, but also the heptoblastoma cells, which could more 
easily be used for future RNAi knockdown studies. 
 
4.1 The significant role of NEIL3 
While the biological role of NEIL3 has yet to be fully determined, it is known that the 
N-terminal domains can function as a DNA glycosylase (Liu et al, 2013). Recently, it 
has been shown that NEIL3 may be involved in the repair of telomeric and other G-
quadruplex regions in DNA, such as those found in the promoters of certain oncogenes 
(Zhou et al, 2015). 
Hildrestrand et al (2009) confirmed that NEIL3 was highly expressed in sixteen 
different cancer tissues compared with normal counterparts (Figure 1.16) and the 
analysis carried out in this work confirmed that NEIL3 was highly expressed in all of 
the paediatric cancer cell lines tested, with the highest levels of NEIL3 mRNA detected 
in the HOS and HepG2 cell lines. 
When comparing the two ALL cell lines, the expression of NEIL3 in the glucocorticoid 
resistant CEM-1-15 cells was significantly higher than that in GC sensitive CEM-7-14 
cells (P < 0.01). In a microarray analysis, Kauffmann et al (2008) found that NEIL3 
was the most over-expressed DNA repair gene in metastatic melanoma tumours when 
compared to primary melanoma tumours where no metastisis had been observed. Thus, 
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a high level of NEIL3 mRNA was correlated with a high risk of metastasis and low 
survival rates in patients with primary malignant melanoma. The authors also 
speculated that the general increase in DNA repair protein expression, including NEIL3, 
in metastaic melanoma could be the cause of their resistance to genotoxic 
chemotherapeutic agents and radiotherapy. The results described in this project confirm 
that NEIL3 is highly expressed in the paediatric cancer cell lines tested and that a higher 
expression level is correlated with resistance to oxidative stress (Figure 3.21 & Section 
4.2).  
While, NEIL3 is the largest of the five mammalian DNA glycosylases involved in 
removing oxidative base damage (Hegde et al, 2008; Liu et al, 2013), the exact cellular 
function of its unique protein structure still needs to be determined. It has two GRF zinc 
finger motifs and a RANbp-like zinc finger motif at the C-terminus and an N-terminal 
Val2 amino acid instead of Pro2 (Liu et al, 2013). Therefore, further studies should be 
conducted to determine the biological role of these distinct components, as they could 
be involved with decreasing the sensitivity of paediatric malignant cells to chemo- and 
radio- therapeutic agents.  
Approximately 15% of tumours lack telomerase activity, which include some of 
sarcomas, brain tumours and certain types of epithelial-derived tumours; however, they 
can still maintain the length of the telomeric DNA by ALT (Tahtouh et al, 2015). The 
results of this study confirmed that osteosarcoma (HOS and Saos-2 cell lines) and 
medulloblastoma tumours do not express telomerase (Figure 3.17). Furthermore, the 
results show that there was no correlation between the expression of NEIL3 and the 
presence or absence of telomerase (Figures 3.12 to 3.17). POT1, along with TRF1 and 
TRF2, are part of the shelterin complex that protects the telomeric ends of 
chromosomes. Zhou et al (2013) reported that they were unable to detect any physical 
correlation between NEIL3 protein and TRF1 or TRF2 using co-immunoprecipitation in 
HeLa or HEK293 cells, or to colocalise NEIL3 and POT1. The results of this study 
indicate that the expression of NEIL3 and POT1 do not appear to be linked (Figures 
3.12 – 3.15). 
Artandi et al (2002) stated that high levels of telomerase mRNA was associated with 
tumourgenesis. Thus, hindering telomere maintenance in tumour cells could be targeted 
in treatment of neoplasms (Henson et al, 2002; Morrish et al, 2013). In this work the 
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results showed that the relative level of telomerase mRNA was significantly higher in 
steroid resistant ALL cells (CEM-C1-15) than in the steroid sensitive ALL cells (CEM-
C7-14) (P < 0.01) (Figure 3.12). Kauffmann et al (2008) concluded that high levels of 
the genes responsible for telomere maintenance was correlated with spreading of 
metastases in patients with melanoma and increased the resistance of these neoplastic 
cells to chemo- and radiotherapy. Thus, the results reported here confirm that higher 
levels of telomerase expression was observed in the GC resistant ALL cell line relative 
to Gapdh, the expression of which was also higher in the GC resistant cell line. 
 
4.2 The effect of oxidative stress on steroid sensitive and steroid resistant acute 
lymphoblastic leukaemia    
t-BHP is commonly used to illustrate the biological effects of oxidative stress in cells 
(Haidara et al, 2008; Tan et al, 2011; Jho et al, 2013). It has been shown that the action 
of t-BHP is similar to lipid hydroperoxides, which lead to the formation of ROS (Cheng 
et al, 2007). Calderon et al (1991) stated that t-BHP leads to elevation in the level of 
intracellular calcium ions and decreases the level of cellular GSH. Moreover, Lin et al 
(2014) reported that t-BHP is an oxidative stress-inducing compound that exerts 
oxidative genomic damage in many cells mainly by its metabolites; alkoxyl and alkyl 
radicals.  
ALL is the most common paediatric cancer that arises from lymphoid progenitor cells. 
GCs are widely used in the treatment protocol of ALL patients. However, some ALL 
cells develop resistance to GCs, as evidenced by CEM-1-15 cells, while CEM-7-14 
cells are steroid sensitive cells (Chen et al, 2012). In addition, Cole et al (2015) 
confirmed that oxidative stress leads to poor neurocognitive outcome in ALL patients 
who received cytotoxic drugs. 
Here, the effect of oxidative stress on the growth of ALL cells was assessed; CEM-1-15 
and CEM-7-14 cell lines were exposed to various concentrations of t-BHP for 72 h.  
Interestingly, the results showed that the growth of the GC insensitive CEM-1-15 cell 
line was also significantly (P < 0.01) more resistant to t-BHP (IC50 of 18.35 µM) than 
the GC sensitive CEM-7-14 cells (IC50 of 2.92 µM) (Figure 3.21). Therefore, these 
results confirm the finding of Rasool et al (2015) who reported that an increased level 
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of ROS has been linked with the development of ALL and, furthermore, that it was 
correlated with emerging chemotherapeutic-resistant ALL cells. Additionally, Beesley 
et al (2010) concluded that ALL cells might develop resistance to DEX and gamma 
radiation. Another study showed that the disparity between the CEM-1-15 and CEM-7-
14 cell lines is mainly related to the difference in the efficacy of the oxidative 
phosphorylation pathway (Berrou et al, 2012). 
As mentioned before, the expression levels of NEIL3 in the GC resistant CEM-1-15 
cells was significantly higher than that in GC sensitive CEM-7-14 cells (Figure 3.12). 
This suggests the possibility that a high level of NEIL3 may be one factor in the 
increased resistance of the CEM-1-15 cells to oxidative stress. NEIL3 acts on oxidised 
purine and pyrimidine bases in both single – and double-stranded DNA releasing them 
in the first step of BER (Liu et al, 2013). To explore this further, similar expression 
studies on a range of DNA repair enzymes would be needed. 
 
4.3 The effect of oxidative stress on hepatoblastoma cells 
In the current study, the impact of oxidative stress on the growth of hepatoblastoma 
cells and on the gene expression levels of NEIL3, hTERT and POT1 was determined. 
HepG2 cells were treated with t-BHP for 72 h and then an MTT assay was carried out to 
estimate the IC50 followed by qTR-PCR to measure the relative expression of NEIL3, 
hTERT and POT1. 
A review of the literature indicates that extensive ROS leads to hepatic cell death 
(Marra et al, 2011). The results of this study confirmed that the viability of the HepG2 
cells was inhibited following treatment with t-BHP and a 50% reduction in the cell 
growth was obtained with 14.55 µM t-BHP (Figure 3.22).  
Furthermore, the influence of the oxidative stress on NEIL3 gene expression was 
investigated. However, the results were difficult to evaluate as opposite trends were 
observed in the level NEIL3 mRNA following exposure of HepG2 cells to 2.5 µM t-
BHP and 5 µM t-BHP, concentrations that were minimally toxic to the cells. At 2.5 µM 
t-BHP, the level of NEIL3 gene expression was significantly greater than in the 
untreated cells (P < 0.01), while at the higher dose, the level of NEIL3 expression was 
significantly less than the controls (P < 0.01) (Figure 3.23). The MTT results suggest 
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that at both concentrations of t-BHP the oxidative DNA base damage could be repaired 
by the high levels of NEIL3 and other DNA glycosylases. Therefore, the decrease in 
NEIL3 mRNA observed at the higher dose may be due to the toxicity of the agent on 
the cells. 
 
4.4 The effect of cisplatin on steroid sensitive, steroid resistant acute lymphoblastic 
leukaemia and hepatoblastoma cells   
Cisplatin was used herein as a control for the MTT and MTS assays. Jordan et al (2000) 
reported that cisplatin inhibits DNA synthesis, transcription and replication through 
DNA cross-links. Subsequently, cisplatin DNA adducts lead to apoptotic cell death. In 
this work, CEM-1-15, CEM-7-14 and HepG2 cell lines were exposed to various 
concentrations of cisplatin for 72 h. The results illustrated a decrease in the growth of 
CEM-1-15, CEM-7-14 and HepG2 cells at each concentration of cisplatin tested. In 
addition, there was on difference in the response of CEM-1-15, CEM-7-14 cells to 
cisplatin (Figures 3.19 and 3.22). 
 
4.5 The effect of doxorubicin on steroid sensitive, steroid resistant acute 
lymphoblastic leukaemia and hepatoblastoma cells    
Doxorubicin belongs to the anthracyclines group of chemotherapeutic drugs (Thorn et 
al, 2011). DOX is commonly used to treat different types of tumours such as sarcoma, 
lymphoma, leukaemia, bladder, liver, lung, thyroid and breast cancer (O'Brien et al, 
2004; Smith et al, 2010; Girotti et al, 2013).  
DOX was chosen for this study to obtain insight on its effect on ALL and 
hepatoblastoma cells, and to correlate this effect with NEIL3. CEM-1-15, CEM-7-14 
and HepG2 cell lines were exposed to various concentrations of DOX for 72 h. The 
statistical analysis showed that the growth of CEM-1-15, CEM-7-14 and HepG2 cells 
declined at each higher concentration of DOX tested. Interestingly, at only one 
concentration (1.56 nM), CEM-1-15 cells showed greater inhibition of growth than 
CEM-7-14 cells (P < 0.05) (Figure 3.20). As it was stated by Minotti et al (2004) DOX 
induces ROS through a pathway of one-electron redox cycling. However, NEIL3 
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belongs to the oxidative DNA glycosylases, which initiate BER to eliminate oxidative 
damaged DNA bases (Liu et al, 2013). Therefore, the influence of 1.56 nM DOX on 
CEM-1-15 cells should be evaluated and it is of great value to explore the effect of this 
dose on oxidative DNA repair genes.  
 
Conclusion 
The results confirmed that NEIL3 is highly expressed in paediatric ALL, osteosarcoma, 
medulloblastoma and hepatoblastoma cells. Thus, NEIL3 could provide novel insights 
for the improved treatment of paediatric cancers. Studying the relation between NEIL3 
and telomerase in paediatric tumour cells illustrated that there was no correlation 
between the expression of NEIL3 and the presence or absence of telomerase. 
Hepatoblastoma cells, steroid sensitive and steroid resistant acute lymphoblastic 
leukaemia (ALL) cells were sensitive to cisplatin, doxorubicin and tert-butyl 
hydroperoxide as a decline in the growth of these cells was observed at each 
concentration of the compounds tested. However, GC resistant ALL cells were also 
more resistant to the cytotoxic effects of t-BHP when compared to the GC sensitive 
ALL cell line. This was associated with a higher expression of NEIL3 in the GC 
resistant cell line. Therefore, high levels of NEIL3 may have a role in decreasing the 
sensitivity of paediatric tumour cells to genotoxic chemotherapeutic drugs.  
 
Future perspectives 
Unpublished work in our laboratory has indicated that siRNA induced knockdown of 
NEIL3 sensitizes colorectal cancer cells to a clinically relevant chemotherapy drug. 
Therefore, based on the results described herein, further research to decrease the levels 
of NEIL3 mRNA (siRNA) or to delete the NEIL3 gene (CRISPR) in paediatric cancer 
cells are warranted. 
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Figure 5.1: qRT-PCR on cDNA of CEM-1-15 cells. qRT-PCR reaction was carried out 
with triplicate aliquots of 5 µl cDNA CEM-1-15 cells, NEIL3, hTERT and POT1 
primers. The reference gene was Gapdh. (A) Amplification curve with Gapdh primers. 
(B) The linear regression curve with Gapdh primers. (C) The melting curve for Gapdh 
primers. (D) Amplification curve with NEIL3 primers. (E) The linear regression curve 
with NEIL3 primers. (F) The melting curve for NEIL3 primers. (G) Amplification curve 
with hTERT primers. (H) The linear regression curve with hTERT primers. (I) The 
melting curve for hTERT primers. (J) Amplification curve with POT1 primers. (K) The 
linear regression curve with POT1 primers (L) The melting curve for POT1 
primers.qRT-PCR was carried out twise on each cell line and these figures represent one 
of the experiments. 
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Figure 5.2: qRT-PCR on cDNA of CEM-7-14 cells. qRT-PCR reaction was carried out 
with triplicate aliquots of 5 µl cDNA CEM-7-14 cells, NEIL3, hTERT and POT1 
primers. The reference gene was Gapdh. (A) Amplification curve with Gapdh primers. 
(B) The linear regression curve with Gapdh primers. (C) The melting curve for Gapdh 
primers. (D) Amplification curve with NEIL3 primers. (E) The linear regression curve 
with NEIL3 primers. (F) The melting curve for NEIL3 primers. (G) Amplification curve 
with hTERT primers. (H) The linear regression curve with hTERT primers. (I) The 
melting curve for hTERT primers. (J) Amplification curve with POT1 primers. (K) The 
linear regression curve with POT1 primers (L) The melting curve for POT1 primers. 
qRT-PCR was carried out twise on each cell line and these figures represent one of the 
experiments. 
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Figure 5.3: qRT-PCR on cDNA of HepG2 cells. qRT-PCR reaction was carried out 
with triplicate aliquots of 5 µl cDNA HepG2 cells, NEIL3, hTERT and POT1 primers. 
The reference gene was Gapdh. (A) Amplification curve with Gapdh primers. (B) The 
linear regression curve with Gapdh primers. (C) The melting curve for Gapdh primers. 
(D) Amplification curve with NEIL3 primers. (E) The linear regression curve with 
NEIL3 primers. (F) The melting curve for NEIL3 primers. (G) Amplification curve with 
hTERT primers. (H) The linear regression curve with hTERT primers (I) The melting 
curve for hTERT primers. (J) Amplification curve with POT1 primers. (K) The linear 
regression curve with POT1 primers (L) The melting curve for POT1 primers. qRT-
PCR was carried out twise on each cell line and these figures represent one of the 
experiments. 
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Figure 5.4: qRT-PCR on cDNA of TC-32 cells. qRT-PCR reaction was carried out with 
triplicate aliquots of 5 µl cDNA TC-32 cells, NEIL3, hTERT and POT1 primers. The 
reference gene was Gapdh. (A) Amplification curve with Gapdh primers. (B) The linear 
regression curve with Gapdh primers. (C) The melting curve for Gapdh primers. (D) 
Amplification curve with NEIL3 primers. (E) The linear regression curve with NEIL3 
primers. (F) The melting curve for NEIL3 primers. (G) Amplification curve with 
hTERT primers. (H) The melting curve for hTERT primers. (I) Amplification curve 
with POT1 primers. (J) The linear regression curve with POT1 primers (K) The melting 
curve for POT1 primers. qRT-PCR was carried out twise on each cell line and these 
figures represent one of the experiments. 
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          hTERT standard curve data                              POT1 standard curve data 
                                        
                                       
                                                                                                                                                                         
  
Figure 5.5: qRT-PCR on cDNA of Saos-2 cells. qRT-PCR reaction was carried out 
with triplicate aliquots of 5 µl cDNA Saos-2 cells, NEIL3, hTERT and POT1 primers. 
The reference gene was Gapdh. (A) Amplification curve with Gapdh primers. (B) The 
linear regression curve with Gapdh primers. (C) The melting curve for Gapdh primers. 
(D) Amplification curve with NEIL3 primers. (E) The linear regression curve with 
NEIL3 primers. (F) The melting curve for NEIL3 primers. (G) Amplification curve with 
hTERT primers. (H) The melting curve for hTERT primers. (I) Amplification curve 
with POT1 primers. (J) The linear regression curve with POT1 primers (K) The melting 
curve for POT1 primers. qRT-PCR was carried out twise on each cell line and these 
figures represent one of the experiments. 
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     Gapdh standard curve data                            NEIL3 standard curve data 
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Figure 5.6: qRT-PCR on cDNA of HOS cells. qRT-PCR reaction was carried out with 
triplicate aliquots of 5 µl cDAN HOS cells, NEIL3, hTERT and POT1 primers. The 
reference gene was Gapdh. (A) Amplification curve with Gapdh primers. (B) The linear 
regression curve with Gapdh primers. (C) The melting curve for Gapdh primers.                  
(D) Amplification curve with NEIL3 primers. (E) The linear regression curve with 
NEIL3 primers. (F) The melting curve for NEIL3 primers. (G) Amplification curve with 
hTERT primers. (H) The melting curve for hTERT primers. (I) Amplification curve 
with POT1 primers. (J) The linear regression curve with POT1 primers (K) The melting 
curve for POT1 primers. qRT-PCR was carried out twise on each cell line and these 
figures represent one of the experiments. 
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Figure 5.7: qRT-PCR on HepG2 cells. qRT-PCR reaction was carried out with 
triplicate aliquots of 5 µl cDAN HepG2 cells, NEIL3, hTERT and POT1 primers. The 
reference gene was Gapdh. (A) Amplification curve with Gapdh primers. (B) The linear 
regression curve with Gapdh primers. (C) The melting curve for Gapdh primers.                   
(D) Amplification curve with NEIL3 primers. (E) The linear regression curve with 
NEIL3 primers. (F) The melting curve for NEIL3 primers. (G) Amplification curve with 
hTERT primers. (H) The linear regression curve with hTERT primers (I) The melting 
curve for hTERT primers. (J) Amplification curve with POT1 primers. (K) The linear 
regression curve with POT1 primers (L) The melting curve for POT1 primers. qRT-
PCR was carried out twise on each cell line and these figures represent one of the 
experiments. 
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Figure 5.8: qRT-PCR on HepG2 cells treated with 2.5 µM t-BHP. qRT-PCR reaction 
was carried out with triplicate aliquots of 5 µl cDAN HepG2 cells, NEIL3, hTERT and 
POT1 primers. The reference gene was Gapdh. (A) Amplification curve with Gapdh 
primers. (B) The linear regression curve with Gapdh primers. (C) The melting curve for 
Gapdh primers. (D) Amplification curve with NEIL3 primers. (E) The linear regression 
curve with NEIL3 primers. (F) The melting curve for NEIL3 primers.                                  
(G) Amplification curve with hTERT primers. (H) The linear regression curve with 
hTERT primers (I) The melting curve for hTERT primers. (J) Amplification curve with 
POT1 primers. (K) The linear regression curve with POT1 primers (L) The melting 
curve for POT1 primers. qRT-PCR was carried out twise on each cell line and these 
figures represent one of the experiments. 
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Figure 5.9: qRT-PCR on HepG2 cells treated with 5 µM t-BHP. qRT-PCR reaction was 
carried out with triplicate aliquots of 5 µl cDAN HepG2 cells, NEIL3, hTERT and 
POT1 primers. The reference gene was Gapdh. (A) Amplification curve with Gapdh 
primers. (B) The linear regression curve with Gapdh primers. (C) The melting curve for 
Gapdh primers. (D) Amplification curve with NEIL3 primers. (E) The linear regression 
curve with NEIL3 primers. (F) The melting curve for NEIL3 primers. (G) Amplification 
curve with hTERT primers. (H) The linear regression curve with hTERT primers (I) 
The melting curve for hTERT primers. (J) Amplification curve with POT1 primers. (K) 
The linear regression curve with POT1 primers (L) The melting curve for POT1 
primers. qRT-PCR was carried out twise on each cell line and these figures represent 
one of the experiments. 
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Table 5.1: Anova: Two-Factor Without 
Replication for NEIL3 and hTERT in CEM-1-15 
cell line  
    
       SUMMARY Count Sum Average Variance 
  NEIL3 6 706 117.6667 25.46667 
  hTERT 6 588 98 4.4 
  
       Column 1 2 212 106 98 
  Column 2 2 224 112 242 
  Column 3 2 209 104.5 180.5 
  Column 4 2 222 111 392 
  Column 5 2 212 106 162 
  Column 6 2 215 107.5 144.5 
  
       
       ANOVA 
      Source of Variation SS df MS F P-value F crit 
Rows 1160.333 1 1160.333 98.89205 0.000176 6.607891 
Columns 90.66667 5 18.13333 1.545455 0.322256 5.050329 
Error 58.66667 5 11.73333 
   
       Total 1309.667 11         
 
 
 
t-Test: Paired Two Sample for Means of NEIL3 and 
hTERT in CEM-1-15 cell line 
     NEIL3 hTERT 
Mean 117.6666667 98 
Variance 25.46666667 4.4 
Observations 6 6 
Pearson Correlation 0.302299611 
 Hypothesized Mean 
Difference 0 
 Df 5 
 t Stat 9.944447971 
 P(T<=t) one-tail 8.77874E-05 
 t Critical one-tail 2.015048373 
 P(T<=t) two-tail 0.000176 
 t Critical two-tail 2.570581836   
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Table 5.2: Anova: Two-Factor Without 
Replication for NEIL3 and POT1 in CEM-1-
15 cell line 
       SUMMARY Count Sum Average Variance 
  NEIL3 6 706 117.6667 25.46667 
  POT1 6 340 56.66667 107.8667 
  
       Column 1 2 182 91 968 
  Column 2 2 194 97 1352 
  Column 3 2 163 81.5 2112.5 
  Column 4 2 176 88 2738 
  Column 5 2 166 83 2048 
  Column 6 2 165 82.5 2244.5 
  
       
       ANOVA 
      Source of Variation SS df MS F P-value F crit 
Rows 11163 1 11163 186.05 0.00037 6.607891 
Columns 366.6667 5 73.33333 1.222222 0.415541 5.050329 
Error 300 5 60 
   
       Total 11829.67 11         
 
 
 
t-Test: Paired Two Sample for Means of NEIL3 and 
POT1 in CEM-1-15 cell line 
     NEIL3 POT1 
Mean 117.6667 56.66667 
Variance 25.46667 107.8667 
Observations 6 6 
Pearson Correlation 0.127198 
 Hypothesized Mean 
Difference 0 
 Df 5 
 t Stat 13.64001 
 P(T<=t) one-tail 1.9E-05 
 t Critical one-tail 2.015048 
 P(T<=t) two-tail 0.00037 
 t Critical two-tail 2.570582   
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Table 5.3: Anova: Two-Factor Without 
Replication for NEIL3 in CEM-1-15 and 
CEM-7-14 cells 
    
       SUMMARY Count Sum Average Variance 
  NEIL3 in CEM-1-15 6 706 117.6667 25.46667 
  NEIL3 in CEM-7-14 6 456 76 72.8 
  
       Column 1 2 200 100 338 
  Column 2 2 193 96.5 1404.5 
  Column 3 2 185 92.5 924.5 
  Column 4 2 212 106 722 
  Column 5 2 185 92.5 1012.5 
  Column 6 2 187 93.5 1012.5 
  
       
       ANOVA 
      Source of Variation SS df MS F P-value F crit 
Rows 5208.333 1 5208.333 126.6207 0.009 6.607891 
Columns 285.6667 5 57.13333 1.388979 0.363617 5.050329 
Error 205.6667 5 41.13333 
   
       Total 5699.667 11         
 
 
t-Test: Paired Two Sample for Means of NEIL3 in CEM-1-15 and 
CEM-7-14 cell line 
   
  
NEIL3 in CEM-1-
15 
NEIL3 in CEM-7-
14  
Mean 117.6666667 76 
Variance 25.46666667 72.8 
Observations 6 6 
Pearson Correlation 0.185796807 
 Hypothesized Mean 
Difference 0 
 Df 5 
 t Stat 11.25258839 
 P(T<=t) one-tail 4.84114E-05 
 t Critical one-tail 2.015048373 
 P(T<=t) two-tail 0.009 
 t Critical two-tail 2.570581836   
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Table 5.4: Anova: Two-Factor Without 
Replication for hTERT in CEM-1-15 and 
CEM-7-14 cells 
    
       SUMMARY Count Sum Average Variance 
  hTERT in CEM-1-15 6 588 98 4.4 
  hTERT in CEM-7-14 6 422 70.33333 35.46667 
  
       Column 1 2 177 88.5 220.5 
  Column 2 2 168 84 578 
  Column 3 2 161 80.5 420.5 
  Column 4 2 175 87.5 180.5 
  Column 5 2 164 82 450 
  Column 6 2 165 82.5 544.5 
  
       
       ANOVA 
      Source of Variation SS df MS F P-value F crit 
Rows 2296.333 1 2296.333 117.5597 0.000116 6.607891 
Columns 101.6667 5 20.33333 1.040956 0.48297 5.050329 
Error 97.66667 5 19.53333 
   
       Total 2495.667 11         
 
 
t-Test: Paired Two Sample for Means of hTERT in CEM-1-15 and 
CEM-7-14 cells 
   
  
hTERT in CEM-1-
15 
hTERT in CEM-7-
14 
Mean 98 70.33333333 
Variance 4.4 35.46666667 
Observations 6 6 
Pearson Correlation 0.032020158 
 Hypothesized Mean 
Difference 0 
 Df 5 
 t Stat 10.84249634 
 P(T<=t) one-tail 5.79214E-05 
 t Critical one-tail 2.015048373 
 P(T<=t) two-tail 0.000116 
 t Critical two-tail 2.570581836   
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Table 5.5: Anova: Two-Factor Without 
Replication for NEIL3 and POT1 in HOS 
cells 
    
       SUMMARY Count Sum Average Variance 
  NEIL3 6 456 76 23.6 
  POT1 6 361 60.16667 0.566667 
  
       Column 1 2 133 66.5 60.5 
  Column 2 2 130 65 50 
  Column 3 2 139 69.5 220.5 
  Column 4 2 144 72 242 
  Column 5 2 135 67.5 112.5 
  Column 6 2 136 68 128 
  
       
       ANOVA 
      Source of Variation SS df MS F P-value F crit 
Rows 752.0833 1 752.0833 61.22795 0.000547 6.607891 
Columns 59.41667 5 11.88333 0.967436 0.514048 5.050329 
Error 61.41667 5 12.28333 
   
       Total 872.9167 11         
 
 
t-Test: Paired Two Sample for Means of NEIL3 and 
POT1 in HOS cells 
     NEIL3 POT1 
Mean 76 60.16667 
Variance 23.6 0.566667 
Observations 6 6 
Pearson Correlation -0.05469 
 Hypothesized Mean 
Difference 0 
 Df 5 
 t Stat 7.824829 
 P(T<=t) one-tail 0.000273 
 t Critical one-tail 2.015048 
 P(T<=t) two-tail 0.000547 
 t Critical two-tail 2.570582   
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Table 5.6: Anova: Two-Factor Without 
Replication for NEIL3 and POT1 in Saos-2 
cells. 
    
       SUMMARY Count Sum Average Variance 
  NEIL3 6 942 157 31.2 
  POT1 6 1033 172.1667 8.966667 
  
       Column 1 2 318 159 162 
  Column 2 2 326 163 242 
  Column 3 2 338 169 50 
  Column 4 2 338 169 98 
  Column 5 2 329 164.5 60.5 
  Column 6 2 326 163 128 
  
       
       ANOVA 
      Source of Variation SS df MS F P-value F crit 
Rows 690.0833 1 690.0833 68.43802 0.000421 6.607891 
Columns 150.4167 5 30.08333 2.983471 0.127731 5.050329 
Error 50.41667 5 10.08333 
   
       Total 890.9167 11         
 
 
t-Test: Paired Two Sample for Means of NEIL3 and 
POT1 in Saos-2 cells. 
     NEIL3 POT1 
Mean 157 172.166667 
Variance 31.2 8.96666667 
Observations 6 6 
Pearson Correlation 0.597871 
 Hypothesized Mean 
Difference 0 
 Df 5 
 t Stat -8.27273 
 P(T<=t) one-tail 0.000211 
 t Critical one-tail 2.015048 
 P(T<=t) two-tail 0.000421 
 t Critical two-tail 2.570582   
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Table 5.7: Anova: Two-Factor Without 
Replication for NEIL3 in Saos-2 and HOS cells 
   
       SUMMARY Count Sum Average Variance 
  NEIL3 in Saos-2 6 942 157 31.2 
  NEIL3 in HOS 6 456 76 23.6 
  
       Column 1 2 222 111 3042 
  Column 2 2 222 111 3362 
  Column 3 2 244 122 3528 
  Column 4 2 245 122.5 3120.5 
  Column 5 2 234 117 3528 
  Column 6 2 231 115.5 3120.5 
  
       
       ANOVA 
      Source of Variation SS Df MS F P-value F crit 
Rows 19683 1 19683 5467.5 0.00046 6.607891 
Columns 256 5 51.2 14.22222 0.005592 5.050329 
Error 18 5 3.6 
   
       Total 19957 11         
 
 
t-Test: Paired Two Sample for Means of NEIL3 in Saos-2 
and HOS  cells 
   
  
NEIL3 in 
Saos-2 
NEIL3 in 
HOS 
Mean 157 76 
Variance 31.2 23.6 
Observations 6 6 
Pearson Correlation 0.877088988 
 Hypothesized Mean 
Difference 0 
 Df 5 
 t Stat 73.94254526 
 P(T<=t) one-tail 4.285E-09 
 t Critical one-tail 2.015048373 
 P(T<=t) two-tail 0.00046 
 t Critical two-tail 2.570581836   
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Table 5.8: Anova: Two-Factor Without 
Replication for POT 1 in Saos-2 and HOS cells 
   
       SUMMARY Count Sum Average Variance 
  POT1 in Saos-2 6 1033 172.1667 8.966667 
  POT1 in HOS 6 361 60.16667 0.566667 
  
       Column 1 2 229 114.5 5724.5 
  Column 2 2 234 117 6498 
  Column 3 2 233 116.5 6612.5 
  Column 4 2 237 118.5 6612.5 
  Column 5 2 230 115 6050 
  Column 6 2 231 115.5 6160.5 
  
       
       ANOVA 
      Source of Variation SS Df MS F P-value F crit 
Rows 37632 1 37632 7236.923 0.00042 6.607891 
Columns 21.66667 5 4.333333 0.833333 0.576848 5.050329 
Error 26 5 5.2 
   
       Total 37679.67 11         
 
 
t-Test: Paired Two Sample for Means of POT1 in Saos-2 and 
HOS cells 
   
  
POT1 in 
Saos-2 POT1 in HOS  
Mean 172.1666667 60.16666667 
Variance 8.966666667 0.566666667 
Observations 6 6 
Pearson Correlation 
-
0.192239555 
 Hypothesized Mean 
Difference 0 
 Df 5 
 t Stat 85.07010684 
 P(T<=t) one-tail 2.1269E-09 
 t Critical one-tail 2.015048373 
 P(T<=t) two-tail 0.00042 
 t Critical two-tail 2.570581836   
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Table 5.9: Anova: Two-Factor Without 
Replication for NEIL3 and POT1 in TC-32 cells 
   
       SUMMARY Count Sum Average Variance 
  NEIL3 6 650 108.3333 102.6667 
  POT1 6 318 53 92 
  
       Column 1 2 145 72.5 1860.5 
  Column 2 2 152 76 1800 
  Column 3 2 187 93.5 1404.5 
  Column 4 2 184 92 1800 
  Column 5 2 149 74.5 1200.5 
  Column 6 2 151 75.5 1200.5 
  
       
       ANOVA 
      Source of Variation SS Df MS F P-value F crit 
Rows 9185.333 1 9185.333 569.3388 0.00024 6.607891 
Columns 892.6667 5 178.5333 11.06612 0.009804 5.050329 
Error 80.66667 5 16.13333 
   
       Total 10158.67 11         
 
t-Test: Paired Two Sample for Means of NEIL3 
and POT1 in TC-32 cells 
     NEIL3 POT1 
Mean 108.3333 53 
Variance 102.6667 92 
Observations 6 6 
Pearson Correlation 0.835502 
 Hypothesized Mean 
Difference 0 
 Df 5 
 t Stat 23.86082 
 P(T<=t) one-tail 1.2E-06 
 t Critical one-tail 2.015048 
 P(T<=t) two-tail 0.00024 
 t Critical two-tail 2.570582   
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Table 5.10: Anova: Two-Factor Without 
Replication for NEIL3 and POT1 in HepG2 cells 
   
       SUMMARY Count Sum Average Variance 
  NEIL3 6 1098 183 9.2 
  POT1 6 526 87.66667 53.86667 
  
       Column 1 2 280 140 4050 
  Column 2 2 285 142.5 4140.5 
  Column 3 2 267 133.5 4512.5 
  Column 4 2 268 134 4232 
  Column 5 2 263 131.5 4900.5 
  Column 6 2 261 130.5 5512.5 
  
       
       ANOVA 
      Source of 
Variation SS Df MS F P-value F crit 
Rows 27265.33 1 27265.33 1649.113 0.00071 6.607891 
Columns 232.6667 5 46.53333 2.814516 0.140312 5.050329 
Error 82.66667 5 16.53333 
   
       Total 27580.67 11         
 
 
t-Test: Paired Two Sample for Means of NEIL3 and 
POT1in HepG2 cells 
 
      NEIL3 POT1 
 Mean 183 87.66666667 
 Variance 9.2 53.86666667 
 Observations 6 6 
 Pearson Correlation 0.67381 
  Hypothesized Mean 
Difference 0 
  Df 5 
  t Stat 40.60927 
  P(T<=t) one-tail 8.54E-08 
  t Critical one-tail 2.015048 
  P(T<=t) two-tail 0.00071 
  t Critical two-tail 2.570582   
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Table 5.11: Anova: Two-Factor Without 
Replication for NEIL3 and hTERT in  HepG2 
cells 
   
       SUMMARY Count Sum Average Variance 
  NEIL3 6 1098 183 9.2 
  hTERT 6 594 99 50.8 
  
       Column 1 2 290 145 3200 
  Column 2 2 295 147.5 3280.5 
  Column 3 2 273 136.5 3960.5 
  Column 4 2 269 134.5 4140.5 
  Column 5 2 281 140.5 3280.5 
  Column 6 2 284 142 3362 
  
       
       ANOVA 
      Source of Variation SS df MS F P-value F crit 
Rows 21168 1 21168 1890 0.00012 6.607891 
Columns 244 5 48.8 4.357143 0.066037 5.050329 
Error 56 5 11.2 
   
       Total 21468 11         
 
 
t-Test: Paired Two Sample for Means of NEIL3 
and hTERT in HepG2 cells 
     NEIL3 hTERT 
Mean 183 99 
Variance 9.2 50.8 
Observations 6 6 
Pearson Correlation 0.869625 
 Hypothesized Mean 
Difference 0 
 Df 5 
 t Stat 43.47413 
 P(T<=t) one-tail 6.08E-08 
 t Critical one-tail 2.015048 
 P(T<=t) two-tail 0.00012 
 t Critical two-tail 2.570582   
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Table 5.12:  Anova: Two-Factor 
Without Replication for NEIL3 in non 
treated cells and NEIL3 in treated 
cells with 5 µM t-BHP in HepG2 cells  
       SUMMARY Count Sum Average Variance 
  NEIL3 (non treated cells) 6 672 112 2 
  NEIL3 (treated cells) 6 544 90.66667 30.26667 
  
       Column 1 2 194 97 338 
  Column 2 2 212 106 128 
  Column 3 2 202 101 242 
  Column 4 2 196 98 338 
  Column 5 2 208 104 162 
  Column 6 2 204 102 200 
  
       
       ANOVA 
      Source of Variation SS df MS F P-value F crit 
Rows 1365.333 1 1365.333 160 0.00005 6.607891 
Columns 118.6667 5 23.73333 2.78125 0.142988 5.050329 
Error 42.66667 5 8.533333 
   
       Total 1526.667 11         
 
t-Test: Paired Two Sample for Means of NEIL3 in non treated and in 
treated cells with 5 µM t-BHP in HepG2 cells  
   
  
NEIL3 (non treated 
cells) 
NEIL3 (treated 
cells) 
Mean 112 90.66667 
Variance 2 30.26667 
Observations 6 6 
Pearson Correlation 0.976823946 
 Hypothesized Mean 
Difference 0 
 Df 5 
 t Stat 12.64911064 
 P(T<=t) one-tail 2.74361E-05 
 t Critical one-tail 2.015048373 
 P(T<=t) two-tail 0.00005 
 t Critical two-tail 2.570581836   
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Table 5.13: Anova: Two-Factor Without 
Replication for hTERT in non treated and in 
treated cells with 2.5 uM t-BHP in HepG2 
cells 
    
       SUMMARY Count Sum Average Variance 
  hTERT in non treated 
cells 6 549.5 91.58333 14.24167 
  hTERT in treated cells  6 635 105.8333 2.166667 
  
       Column 1 2 200 100 50 
  Column 2 2 194 97 200 
  Column 3 2 197.5 98.75 105.125 
  Column 4 2 201 100.5 24.5 
  Column 5 2 197 98.5 180.5 
  Column 6 2 195 97.5 112.5 
  
       
       ANOVA 
      Source of Variation SS df MS F P-value F crit 
Rows 609.1875 1 609.1875 48.01478 0.000961 6.607891 
Columns 18.60417 5 3.720833 0.293268 0.897821 5.050329 
Error 63.4375 5 12.6875 
   
       Total 691.2292 11         
 
 
t-Test: Paired Two Sample for Means of hTERT in non treated and in treated 
cells with 2.5 uM t-BHP in HepG2 cells 
   
  
hTERT in non treated 
cells 
hTERT in treated 
cells  
Mean 91.5833333 105.8333333 
Variance 14.2416667 2.166666667 
Observations 6 6 
Pearson Correlation -0.8070948 
 Hypothesized Mean 
Difference 0 
 Df 5 
 t Stat -6.9292697 
 P(T<=t) one-tail 0.00048029 
 t Critical one-tail 2.01504837 
 P(T<=t) two-tail 0.000961 
 t Critical two-tail 2.57058184   
 
157 
 
Table 5.14: Anova: Two-Factor Without 
Replication for hTERT in non treated and 
treated HepG2 cells with 5 uM t-BHP 
    
       SUMMARY Count Sum Average Variance 
  hTERT in non treated 
cells 6 549.5 91.58333 14.24167 
  hTERT in treated cells 6 749 124.8333 4.566667 
  
       Column 1 2 223 111.5 544.5 
  Column 2 2 210 105 648 
  Column 3 2 216.5 108.25 561.125 
  Column 4 2 223 111.5 420.5 
  Column 5 2 214 107 648 
  Column 6 2 212 106 512 
  
       
       ANOVA 
      Source of Variation SS df MS F P-value F crit 
Rows 3316.688 1 3316.688 951.0215 0.00672 6.607891 
Columns 76.60417 5 15.32083 4.39307 0.065041 5.050329 
Error 17.4375 5 3.4875 
   
       Total 3410.729 11         
 
t-Test: Paired Two Sample for Means of hTERT in non 
treated and treated HepG2 cells with 5 uM t-BHP 
 
   
  
hTERT in non treated 
cells 
hTERT in treated 
cells 
Mean 91.58333333 124.8333333 
Variance 14.24166667 4.566666667 
Observations 6 6 
Pearson Correlation 0.733663711 
 Hypothesized Mean 
Difference 0 
 Df 5 
 t Stat -30.8386366 
 P(T<=t) one-tail 3.36448E-07 
 t Critical one-tail 2.015048373 
 P(T<=t) two-tail 0.00672 
 t Critical two-tail 2.570581836   
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Table 5.15: Anova: Two-Factor Without 
Replication for POT1 in non treated and 
treated HepG2 cells with 2.5 uM t-BHP 
    
       SUMMARY Count Sum Average Variance 
  POT1 (non treated cells) 6 346 57.66667 3.066667 
  POT1 (treated cells) 6 538 89.66667 7.466667 
  
       Column 1 2 146 73 392 
  Column 2 2 149 74.5 612.5 
  Column 3 2 148 74 512 
  Column 4 2 141 70.5 480.5 
  Column 5 2 150 75 648 
  Column 6 2 150 75 450 
  
       
       ANOVA 
      Source of Variation SS df MS F P-value F crit 
Rows 3072 1 3072 667.8261 0.001 6.607891 
Columns 29.66667 5 5.933333 1.289855 0.393412 5.050329 
Error 23 5 4.6 
   
       Total 3124.667 11         
 
t-Test: Paired Two Sample for Means of POT1 in non treated and treated 
HepG2 cells with 2.5 uM t-BHP 
 
    
  
POT1 (non treated 
cells) 
POT1 (treated 
cells) 
 Mean 57.66667 89.66667 
 Variance 3.066667 7.466667 
 Observations 6 6 
 Pearson Correlation 0.13932 
  Hypothesized Mean 
Difference 0 
  Df 5 
  t Stat -25.8423 
  P(T<=t) one-tail 8.1E-07 
  t Critical one-tail 2.015048 
  P(T<=t) two-tail 0.001 
  t Critical two-tail 2.570582   
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Table 5.16: Anova: Two-Factor Without 
Replication for POT1 in HepG2 cells 
treated with 5 uM t-BHP 
    
       SUMMARY Count Sum Average Variance 
  POT1 (non treated cells) 6 346 57.66667 3.066667 
  POT1 ( treated cells) 6 244 40.66667 1.466667 
  
       Column 1 2 100 50 162 
  Column 2 2 99 49.5 112.5 
  Column 3 2 98 49 162 
  Column 4 2 97 48.5 84.5 
  Column 5 2 96 48 162 
  Column 6 2 100 50 200 
  
       
       ANOVA 
      Source of Variation SS df MS F P-value F crit 
Rows 867 1 867 270.9375 0.001 6.607891 
Columns 6.666667 5 1.333333 0.416667 0.820656 5.050329 
Error 16 5 3.2 
   
       Total 889.6667 11         
 
 
t-Test: Paired Two Sample for Means of POT1 in HepG2 cells treated with 
5 uM t-BHP 
 
    
  
POT1 (non treated 
cells) 
POT1 ( treated 
cells) 
 Mean 57.66666667 40.66667 
 Variance 3.066666667 1.466667 
 Observations 6 6 
 Pearson Correlation -0.440086229 
  Hypothesized Mean 
Difference 0 
  Df 5 
  t Stat 16.46017922 
  P(T<=t) one-tail 7.55229E-06 
  t Critical one-tail 2.015048373 
  P(T<=t) two-tail 0.001 
  t Critical two-tail 2.570581836   
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Table 5.17: Anova: Two-Factor Without Replication for ALL cells treated with 
t-BHP 
 
       SUMMARY Count Sum Average Variance 
  Row 1 2 200 100 0 
  Row 2 2 128.3636 64.18182 1927.117 
  Row 3 2 88.07136 44.03568 2160.766 
  Row 4 2 61.37079 30.68539 864.8694 
  Row 5 2 52.58373 26.29186 557.8225 
  Row 6 2 46.28544 23.14272 374.891 
  Row 7 2 33.33516 16.66758 107.6214 
  Row 8 2 28.75682 14.37841 48.54599 
  
       CEM-1-15 8 446.743 55.84287 976.9338 
  CEM-7-14 8 192.0239 24.00299 1009.915 
  
       
       ANOVA 
      Source of Variation SS Df MS F P-value F crit 
Rows 11921.42 7 1703.06 6.001157 0.015305 3.787044 
Columns 4055.113 1 4055.113 14.2892 0.006891 5.591448 
Error 1986.52 7 283.7886 
   
       Total 17963.05 15         
 
t-Test: Paired Two Sample for Means of ALL cells 
treated with t-BHP 
   
  
CEM-1-
15 
CEM-7-
14 
Mean 55.84287 24.00299 
Variance 976.9338 1009.915 
Observations 8 8 
Pearson Correlation 0.714431 
 Hypothesized Mean 
Difference 0 
 Df 7 
 t Stat 3.780106 
 P(T<=t) one-tail 0.003446 
 t Critical one-tail 1.894579 
 P(T<=t) two-tail 0.006891 
 t Critical two-tail 2.364624   
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Table 5.18: Anova: Two-Factor Without Replication for ALL cells treated with cisplatin  
       SUMMARY Count Sum Average Variance 
  Row 1 2 200 100 0 
  Row 2 2 192.6122 96.3061 8.146835 
  Row 3 2 165.5068 82.7534 8.314118 
  Row 4 2 124.7543 62.37713 5.40314 
  Row 5 2 99.23012 49.61506 32.91925 
  Row 6 2 66.76327 33.38163 176.1725 
  Row 7 2 50.2919 25.14595 58.70611 
  Row 8 2 40.73386 20.36693 6.315354 
  
       CEM-1-15 8 492.2478 61.53097 860.6168 
  CEM-7-14 8 447.6446 55.95558 1172.713 
         
       ANOVA 
      Source of 
Variation SS Df MS F P-value F crit 
Rows 14061.67 7 2008.81 81.92663 3.5E-06 
3.78704
4 
Columns 124.34 1 124.34 5.071039 
0.05903
3 
5.59144
8 
Error 171.6374 7 24.51962 
   
       Total 14357.65 15     
 
 
 
Table 5.19: Anova: Two-Factor Without Replication for ALL cells treated with doxorubicin 
       
SUMMARY Count Sum Average 
Varian
ce 
  Row 1 2 200 100 0 
  Row 2 2 144.1856 72.0928 378.3 
  
Row 3 2 92.31662 46.15831 
6.3435
8 
  
Row 4 2 83.83277 41.91638 
2.1095
1 
  
Row 5 2 68.98179 34.49089 
24.100
83 
  
Row 6 2 67.6233 33.81165 
15.591
93 
  
Row 7 2 61.65203 30.82601 
3.5108
76 
  
Row 8 2 56.41923 28.20961 
2.6398
35 
  
       CEM-1-15 8 381.7358 47.71698 525.46
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98 
CEM-7-14 8 393.2755 49.15944 
790.49
5 
  
              ANOVA 
      Source of Variation SS df MS F P-value F crit 
Rows 
8787.479
39 7 1255.354 
20.711
81 
0.00035
7 
3.78704
4 
Columns 
8.322704
28 1 8.322704 
0.1373
14 
0.72192
5 
5.59144
8 
Error 
424.2738
93 7 60.61056 
   
       
Total 
9220.075
99 15         
 
 
 
 
 
 
 
 
 
 
 
